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ABSTRACT
This Ph.D. dissertation examined the effects of bacterial DNA on immune
surveillance in ovine lymph nodes (LN). The first study identified long-term changes
in lymph nodes following exposure to plasmid DNA. Treated lymph nodes were
heavier and had larger medullary areas. Furthermore, medullary cord thickness and
medullary sinus width as well as germinal center size and number were increased in
plasmid treated lymph nodes.
To determine whether bacterial DNA altered cell trafficking through lymph
nodes, the efferent lymphatic of the prescapular LN of sheep was cannulated and
cells were collected. Intradermal injection of as little as 4 Jlg of plasmid DNA
expressing the green fluorescent protein of jellyfish (eGFP) caused a marked
increase in the cell trafficking through the prescapular lymph node. A dose-
dependent facet existed for this response, as the increase in cell trafficking response
persisted longer with 40 J.Lg or 400 Jlg of plasmid-eGFP than with 4 Jlg. This
increased cell trafficking was independent of green fluorescent protein expression as
both pCAN1-eGFP and pCAN1 induced similar responses.
Increased cell traffic induced by bacterial DNA was further characterized by
determining whether bacterial DNA form was critical for this response. Treatment
with intact plasmid (circular) DNA induced the greatest increase in cell traffic. In
contrast, when plasmid DNA was digested with restriction enzymes into linear
fragments of DNA, then cell trafficking was not significantly increased.
Numerous studies have shown that immunostimulatory guanosine-cytosine
(CpG) motifs activate cells in vitro and can improve protective immune responses in
vivo. Therefore we tested the hypothesis that the presence of immunostimulatory
CpG motifs within plasmids was responsible for altering cell trafficking. It was shown
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that plasmids wHh added immunostimulatory CpG sequences affected cell trafficking
in a dose-dependent manner. The injection of 40 Ilg of pBISIA-88 caused an
increase in cell trafficking while injecting 400 Ilg pBISIA-88 failed to increase cell
flow above control levels.
Analysis of cell populations collected in efferent lymph gives insight into
treatment effects on immune surveillance. This is well-studied following treatment
with antigen and in general, antigen induces a selective movement of cells into
lymph that occurs 24 hours post-treatment. In contrast, plasmid DNA induced a
rapid, non-selective movement of lymphocytes through the lymph node, suggesting
that bacterial DNA and antigen may affect cell trafficking by different mechanisms
and thereby have distinct effects on immune surveillance.
Short-term effects of bacterial DNA on lymph node architecture and cellular
composition were also investigated to determine whether an increase in cell
trafficking was associated with structural changes within the lymph node. While it
was shown that bacterial DNA induced changes within a lymph node, including an
increased number of germinal centers and an increased frequency of CD72+CD21 +
B cells, these changes were not correlated to increased cell trafficking.
In summary, bacterial DNA altered immune surveillance in sheep lymph
. nodes by changing cell traffic and lymph node architecture and composition. Many
of these responses differed from responses observed by others following antigen
treatment. The present observations suggest that bacterial DNA can function as an
important signal to modulate immune surveillance and host responses to infections
by pathogens.
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CHAPTER 1
LITERATURE REVIEW
1.1 Introduction
For centuries it has been known that protective immunity can develop
following an exposure to an infectious agent. Early clinical studies showed that the
injection of attenuated or killed pathogens could prevent disease in individuals
subsequently exposed to the same organism. Pasteur coined the term vaccines to
describe the immunization procedure with agents (antigens) that could promote
protection against disease (Silverstein, 1989). Since then, the development of
vaccines has grown and the administration of either killed or modified-live vaccines
is used routinely for the immunoprophylaxis of both veterinary and human diseases.
Plasmid-based vaccines are a recent technology developed for the induction
of disease protection. The ability to insert gene sequences that encode for almost
any known protein potentially makes DNA vaccines an ideal method for
. immunoprophylaxis. Methods to improve DNA vaccine efficacy, including improved
DNA vaccine adjuvanticity by the addition of immunostimulatory guanosine-cytosine
(CpG) motifs, the coexpression of immunomodulatory proteins such as cytokines,
and the coadministration of antigen to bolster immune responses, are presently
being studied. Currently, DNA vaccines are not being implemented in human or
animal vaccination programs. The infancy of DNA vaccine technology, its inability to
outperform conventional vaccines and a potential lack of acceptance by the public,
are barriers that may impede DNA vaccine use. To overcome these problems, DNA
vaccines are currently undergoing intensive research to improve vaccine efficacy. A
major finding is that small sequences of DNA with a central CpG motif flanked by
two purine and pyrimidine nucleotides can markedly influence both innate and
adaptive immune responses. It has become evident that plasmid (bacterial) DNA,
and in particular these CpG rich DNA sequences, can activate the cells involved in
the induction of an immune response. These cells, namely B cells, natural killer
cells, dendritic cells and macrophages,· respond to CpG stimulation in vitro with
enhanced proliferative responses, decreased apoptosis, cell maturation and the
secretion of a plethora of cytokines and chemokines (Krieg et al., 1995; Ballas et al.,
1996; Yi et al., 1998, Takeshita et al., 2000). Plasmids with added immuno-
stimulatory CpG sequences can induce strong humoral and cell-mediated immunity
in vivo, as well as protect animals against challenge with various microorganisms
(Klinman et al., 1999; Weighardt et al., 2000).
To date, little research has examined the effects of either plasmid DNA or
immunostimulatory DNA sequences that contain CpG motifs (oligodeoxyribonucelotide;
CON) on immune surveillance. The recirculation of lymphocytes through secondary
lymphoid tissues plays a critical role in the induction of an adaptive immune response by
providing a mechanism for antigen presenting cells to screen the T and B cell antigen
. receptor repertoire. This screen of the receptor repertoire enhances the level of
immunosurveillance performed by the adaptive immune system. Therefore, I
hypothesized that one mechanism by which immunostimulatory CpG motifs can enhance
adaptive immune responses is by altering cell trafficking.
In this work, which used the ovine lymph node model, immunosurveillance was
monitored by analyzing the dynamics of cell migration through a lymph node and then
determining whether these changes in cell trafficking were associated with morphological
changes within the lymph node. The following sections contain a review of the literature
2
on: DNA vaccines, immunostimulatory CpG motifs, lymph node structure and cell
trafficking to provide a background and rationale for the research conducted.
1.1.1 Similarities and Differences Between Eukaryotic and Prokaryotic DNA
Eukaryotic and prokaryotic DNA are similar, yet in some respects differ in physical
properties and chemical composition. For a comprehensive review on eukaryotic and
prokaryotic DNA, see Alberts et al. (1994). Briefly, both prokaryotic and eukaryotic DNA
contain the four nucleotides of adenine, guanine, cytosine and thymine, covalently
bonded by phosphodiester linkages that join the 5' carbon of a deoxyribose sugar of a
nucleotide to the 3' carbon of another. Strands of DNA are held together by hydrogen
bonds and form an a. helix with one turn every 3.4 nm. The molecular packaging differs
between prokaryotic and eukaryotic DNA. Prokaryotic DNA is circular and located within
the cytoplasm, while eukaryotic DNA is wrapped around protein scaffolds (nucleosomes)
to form chromosomes located within the nucleus. The eukaryotic genome is 1000-10000
times larger than prokaryotic, which necessitates it needs to be tightly wrapped into
chromosomes. The location of DNA within a nucleus in higher organisms offers
protection from cytoplasmic metabolites and permits a special form of regulation for DNA
replication. Unlike prokaryotic DNA that undergoes both transcription and translation
simultaneously, eukaryotic DNA is transcribed within the nucleus, with translation and
. post-translation modifications occurring within the cytoplasm.
There are also significant differences between eukaryotic and prokaryotic DNA at
the molecular level. Firstly, prediction of nucleotide frequencies by 'nearest neighbor
analysis' indicates that the base pair arrangement in eukaryotic DNA is non-random, as
base pair frequencies found in eukaryotes do not correspond with predicted frequencies.
Swartz et al. (1962), demonstrated that the CpG frequency in eukaryotic DNA was one-
third the predicted frequency calculated from base pair composition. Secondly, the
majority of vertebrate DNA is methylated while the methylation of invertebrate DNA is
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limited or nonexistent (Bird, 1987). Methylation of eukaryotic DNA occurs by transferring
a methyl group from s-adenosyl-methionine to cytosine to form 5-methylcytosine
(Hergersberg, 1991).
Approximately 1% of eukaryotic DNA is unmethylated and is located in discrete
sites such as 'CpG islands' and areas of regulation that include promoters (Bird et al.,
1985). This lack of methylation and an increased frequency of CpG motifs in 'CpG
islands' and the under-representation of CpG motifs in the majority of eukaryotic genomic
DNA have sparked theories endeavoring to explain the CpG discrepancies present in
vertebrate DNA. A popular theory suggests that cytosine is prone to deamination and
that deamination of 5'-methylcytosine leads to the formation of thymine. This newly
formed thymine causes a base pair mismatch leading to excisional repair of the
nucleotide and loss of the original cytosine residue. The consequence is an overall
reduction in CpG frequency within the genome (Bird et a/., 1985).
Lack of methylation of cytosine residues in areas of DNA regulation such as
promoter regions may ensure that only selected regions of DNA are transcribed. It is
speculated that methylated nucleotides can either prevent protein-DNA interaction or
alter chromatin structure. The presence of methylated bases in large areas of genomic
DNA, would prevent polymerases from randomly binding to DNA regulatory proteins and
. transcribing gene products (Hergersberg, 1991).
1.1.2 Characteristics of Plasmids Used in DNA Vaccines
A circular plasmid is the primary construct used in DNA-based immunization.
Most plasmids contain an origin of replication, antibiotic resistance gene, a multiple
cloning site, a promoter/enhancer region and a messenger RNA (mRNA) polyadenylation
(poly [A)) sequence. The insertion of intron sequences into a plasmid for improved gene
expression is optional.
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1.1.2.1 Origin of Replication
An origin of replication (ORI) is needed within a plasmid to produce large copy
numbers of plasmid in bacteria. The colicinogenic factor E1 (CoL E1) exists in E.coli as
an autonomous replicating circular plasmid. In an experiment by Clewell (1972), bacteria
containing CoL E1 plasmid were grown in media treated with chloramphenicol. DNA
analysis indicated that bacterial chromosomal DNA did not increase in content indicating
a cessation of host cell DNA synthesis. In contrast the CoL E1 plasmid continued to
replicate long after bacterial chromosomal DNA synthesis had ceased (Clewell, 1972).
Plasmid numbers increased by 125-fold and the self-replicating plasmids were virtually
unaffected by antibiotics. The ability of CoL E1 to replicate autonomously makes it a
good candidate for use within the ORI. Indeed, a portion of CoL E1 is used as the ORI in
many commercially available plasmids.
1.1.2.2 Antibiotic Resistance
To produce large quantities of a plasmid, bacteria containing the plasmid must be
grown in culture and be 'positively selected' from contaminating bacteria. This can be
accomplished by inserting an antibiotic resistance gene into the plasmid. The plasmid
will express the protein for antibiotic resistance and therefore all bacteria containing that
protein will survive and propagate in culture supplemented with the specific antibiotic. In
contrast, bacteria lacking the plasmid cannot produce its antibiotic resistance protein and
will die in culture. Antibiotic resistance genes used in plasmid isolation express proteins
that interfere with the activities of a specific antibiotic, including ampicillin, kanamycin,
neomycin, and chloramphenicol.
1.1.2.3 Promoter/Enhancer Regions
To generate high-level expression of an inserted gene product, viral promoters!
enhancers are often added to plasmids upstream from the inserted gene. The three
main promoters/enhancers used in plasmids are, the early simian virus (SV40) promoter,
5
the Rous sarcoma virus long terminal repeats (RSV LTR), and the immediate-early
promoter of human cytomegalovirus (HCMV IE1).
The early SV 40 promoter was one of the first promoters to demonstrate
enhanced protein expression in cell culture. Moreau et al. (1981) showed that removal of
a 72-base pair repeat within the SV 40 promoter caused a marked decrease in gene
expression. In comparison, the addition of this sequence to other viral promoters caused
a significant increase in reporter gene expression.
The RSV LTR are conserved sequences involved in the initiation of transcription
and include sequences found in TATA boxes. Plasmids with the RSV LTR promoter can
express high levels of protein: compared to plasmid lacking the promoter, plasmids with
the RSV LTR promoter displayed a three and ten-fold increase in gene expression in
mouse kidney cells and HELA cells, respectively (Gorman et al., 1982).
The IE1 promoter/enhancer from HCMV also has strong promoter activity in vitro.
Boshart et al. (1985) compared gene expression in plasmids encoding HCMV IE1 or
other viral promoters. Northern blot analysis indicated that a plasmid with HCMV IE1 had
a three- to five-fold increase in gene expression compared to one with the SV 40
promoter. Similarly, plasmids with the HCMV IE1 had the greatest level of gene
expression when compared to RSV LTR and other viral promoters that included those
. from hepatitis B virus, herpesvirus saimiri and murine cytomegalovirus (Boshart et al.,
1985). The HCMV IE1 promoter contains four copies of which three repeating CCCGCC
base pair sequences provides a binding site for SP1 transcription factor (Boshart et a/.,
1985). This multiple repeating binding site may explain the enhanced gene expression
with plasmids encoding HCMV IE1.
To enhance gene expression in selected tissue, tissue specific promoters and
enhancers can be added to plasmid DNA. It is believed that targeting a plasmid to the
desired tissue should ensure that genes are expressed only within that tissue. This is
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particularly important in cancer therapy, as targeting plasmids expressing cytotoxic gene
products to cancer cells could reduce systemic toxicity. The addition, for example, of a
prostate specific antigen (PSA) tissue promoter and enhancer to plasmids that express
p53, preferentially killed transfected prostate cancer cells while sarcoma cells exposed to
the same plasmid survived (Lee et al., 2000). The use of tissue-specific promoters and
enhancers may also help improve DNA vaccine efficacy. Plasmids designed to
specifically express antigen in immunologically active cells such as dendritic cells may
therefore improve the induction of a desired immune response.
1.1.2.4 Polyadenylation Tails
To produce large quantities of expressed protein, a constant supply of mRNA
must be produced and maintained within the cell. To maintain high levels of mRNA by
enhancing mRNA stability within cells, poly [A] tails are added to the 3' end of the gene
transcript. Pfarr et al. (1986) demonstrated that the poly [A] tail of mRNA improves
protein production and that poly [A] tails of different species have different levels of
activity. Plasmids with or without the bovine growth hormone poly [A] sequence (BGH
poly [AD were compared and it was observed that protein expression was 60 fold higher
in cells transfected with plasmids containing BGH poly [A] than cells transfected with
plasmid lacking BGH poly [A] sequence. Cells transfected with a BGH poly [A]-
. containing plasmid also had a three-fold increase in protein expression when compared
to cells transfected with plasmid containing human collagen poly [A] (Pfarr et al., 1986).
1.1.2.5 Intron A
The largest intron from HCMV, intron A, has been added to plasmids to improve
protein production. Intron A has five binding sites for strong nuclear factor 1 (NF1)
regulator genes and it is believed that these binding sites help improve plasmid
transcription. Chapman et al. (1991) showed that cells transfected with plasmids
containing intron A demonstrated a 980/0 increase in gene expression compared to cells
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transfected with plasmid that lacked intron A. To determine if the NF1 site within intron A
is essential for enhanced gene expression, three bases within the NF1 site were mutated
and the modification of these three bases was found to cause a marked reduction in
protein expression (Chapman et al., 1991).
1.1.3 Immune Stimulatory Properties of Bacterial DNA
The immunostimulatory effects of bacterial DNA were first discovered in the mid-
1980s by several Japanese research groups. Tokunaga et al. (1984) digested
Mycobacterium bovis and found that the streptomycin sulfate (SM) precipitated fraction
displayed anti-tumor activity in vitro. This SM fraction was further purified into several
sub-fractions and the MY-1 sub-fraction was found to be immunologically active. The
composition of MY-1 fraction is: 700/0 DNA, 280/0 RNA, 1.30/0 protein, 0.2% saccharides,
and 0.1 % lipid. Multiple injections of the MY-1 fraction caused tumor regression in
guinea pigs. To determine which component of MY-1 induced immune stimulation,
Tokunaga et al. (1984) digested the fraction with DNase and RNase enzymes. They
demonstrated anti-tumor activities in RNase treated samples while, in contrast, the anti-
tumor activity was abolished following DNase treatment. This clearly demonstrated that
DNA was the active component of MY-1.
To characterize its activity further, Shimada et al. (1985) examined the effects of
. MY-1 in mice. They showed that mice injected with MY-1 demonstrated a marked
reduction in both tumor size and metastases. Also illustrated was a 100% survival rate in
mice treated with repeated injections of high concentration of MY-1 into subcutaneous
tumors and the numbers of tumors at distant sites were reduced after subcutaneous
injections of MY-1. Interestingly, the researchers showed that the MY-1 activity was not
due to direct cytotoxicity, as incubation of the fraction with both normal cells and various
tumor cells caused no increase in cell death in either group.
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To determine which sequences of bacterial DNA were immunostimulatory,
Tokunaga et al. (1992) digested the DNA and then examined the effects of digested DNA
on natural killer (NK) cell activity in vivo. They showed that only oligomers greater than
15 bases were active and that these immunostimulatory sequences were palindromes
that centered on a CpG motif. These initial experiments demonstrated the ability of
bacterial DNA, rather than other biologically active bacterial components, to stimulate
cells and that activity of bacterial DNA was likely related to the presence of short DNA
sequences containing CpG motifs.
1.2 Introduction to DNA Vaccines
The development of DNA vaccines was a consequence of work directed at
improving post-natal gene therapy. Early gene therapy research was aimed at removing
cells from tissue, transfecting these cells with viral vectors and then re-implanting them
into the host (Friedmann, 1989). It was during this period that the seminal experiment by
Wolff et al. (1990), demonstrated the uptake of naked DNA and the expression of
encoded genes in vivo. The researchers injected DNA vectors expressing different
reporter genes into skeletal muscle of mice. It was shown that the level of gene
expression in muscle fibers was strong and comparable to gene expression in fibroblasts,
with protein expression within muscle persisting for at least two months.
The definitive experiment, proving that injection of plasmid vectors was a suitable
method for inducing immunity, was performed by Ulmer et al. (1993). Mice injected
intramuscularly (im) with plasmid encoding influenza A nuclear protein developed
protective immunity against an aerosolized viral challenge. The plasmid treatment
generated both antigen-specific cell-mediated (CMI) and humoral immune responses,
with the CMI response providing disease protection. These initial experiments
demonstrated that injected plasmid DNA could indeed express encoded genes at a level
sufficient to induce protective immunity.
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1.2.1 Potential Benefits of DNA Vaccination
DNA vaccines offer several distinct advantages over current killed and attenuated
(modified live) vaccines. These benefits include the development of strong humoral and
cell-mediated responses. The ability to immunize against multiple pathogens will be
discussed in the following section. It is noteworthy that, although DNA vaccination is a
potential weapon in the arsenal for disease prevention, currently no DNA vaccine has
out-performed any conventional vaccine (Manickan et al., 1997). Although there are
many examples of DNA vaccines inducing strong humoral and eMI responses as well as
generating protective immunity, it will be shown that there are also examples of DNA
vaccine failure.
1.2.1.1 Antigen-specific Humoral and Cell-Mediated Responses
DNA vaccines can induce high antibody titers that persist for long periods of time.
Using a vector encoding influenza A nuclear protein, Ulmer et al. (1993) injected 100 Jlg
of plasmid into the quadriceps muscles of mice at birth and at three and six weeks of
age. Enzyme linked immunosorbent assay (ELISA) for nuclear protein (NP)
demonstrated a three-log increase in serum antibody titer at the fifth week of age. To
determine whether anti-NP antibodies were protective, the researchers took serum
antibodies from plasmid DNA treated mice and passively immunized naive mice exposed
to live virus. A reduction in virus load was not detected in mice following viral challenge
suggesting that antibodies generated after plasmid injection were ineffective at controlling
virus growth. In contrast, the transfer of serum antibodies from mice exposed to whole
virus to naive mice resulted in a marked reduction in virus load following challenge. The
likely explanation for this observation is that neutralizing antibodies were specific to viral
proteins other than the internal structural NP.
In further studies to determine whether plasmid-based vaccines can generate
protective antibodies, mice were injected with a plasmid expressing a strain-specific
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hemagglutinin A (HA) protein. In these mice, antibody titers remained elevated for at
least 1.5 years and after several 1 Jlg injections of DNA encoding HA, all mice survived
viral challenge (Deck et al., 1997). This study, however, did not determine if a CMI
developed after injection and therefore it cannot be assumed that protection arose from
humoral immunity alone.
Similar to viral infections or vaccination with live attenuated vaccines, DNA
vaccines can generate antigen-specific CMI in vivo. Protective cell-mediated immunity
was highlighted in a vaccine study in mice conducted by Ulmer et al. (1993). To
determine whether protective immunity was caused by production of antigen-specific
cytotoxic T lymphocytes (CTl), spleen T cells were isolated from DNA-immunized mice
and stimulated with Il-2. These cells were then incubated with either virally-infected
autologous cells or cells loaded with MHC-restricted NP peptides. There was marked
lysis of spleen cells with both treatments, indicating that CTl responses occurred and
were indeed antigen-specific.
The experiments by Deck et al. (1997) and Ulmer et al. (1993) indicated that DNA
based vaccines have the ability to generate long-term protection in mice. Although DNA
vaccines can induce protective immunity against certain pathogens, DNA vaccines have
not been able to induce sustained immune responses and protection against all
pathogens as initially anticipated. As an example, injection of a DNA vaccine against
rotavirus in mice, was ineffective in disease protection. Choi et al. (1998), showed that
the intradermal injection of plasmids encoding either the viral protein (VP) 4 or VP7 of
rotavirus produced moderate serum IgG antibody titers and low levels of neutralizing
fecal IgA antibodies. Neither plasmid treatment, however, reduced viral shedding during
the 7-day challenge period.
Immune responses induced by DNA vaccines can also vary substantially among
different species. DNA vaccines expressing the gene for the sporozoite protein of
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Plasmodium falciparum were injected into inbred and outbred strains of mice and into 20
humans (Le et al., 2000). All treated mice developed robust antibody responses as early
as 10 days post-treatment. In comparison, the human volunteers failed to develop
detectable antibody titers over a 12-month period. These two examples illustrate the
inability of some antigens to elicit adequate protective immune responses, and the
variability of immune responses generated to DNA vaccines between two different
species.
1.2.1.2 Immunization Against Multiple Antigens
Another potential advantage of using DNA vaccines to protect against disease is
the relative ease of combining plasmids that express various antigens into a single
vaccine formulation. Using such a vaccine, a clinician could immunize individuals against
multiple pathogens with one injection. A detailed study by Braun et al. (1998) examined
the effects of combining different DNA vaccines on antibody production. Mice were given
a single intradermal injection of individual plasmids expressing glycoprotein B (gB) and 0
(gO) of bovine herpesvirus-1 (BHV-1), the hemagglutinin/neuraminidase of bovine
parainfluenza-3 virus (PI3) or the hemagglutinin of human influenza virus (HINF).
Antibody levels generated by these mice peaked between Day 70 and Day 95 post-
vaccination and were primarily IgG1 isotype, with the exception that immunization with
plasmid expressing HINF generated IgG2a antibodies. To determine if the addition of a
second plasmid would alter antibody titers, mice were injected simultaneously with two
different plasmids. The data demonstrated that a slight decrease in total antibody
production levels occurred suggesting that co-administration of plasmid has little adverse
effect on total antibody production. In addition, the co-administration of different vectors
did not change the isotype of antibodies produced. There was one exception, however,
where the mixing of pl~smidsexpressing HINF and gO modified the predominantly IgG2a
antibody response to a predominantly IgG1 response in treated mice (Braun et al., 1998).
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Co-administration of plasmids encoding different antigens therefore was shown to elicit
strong antibody responses. Unfortunately, this study did not determine if antibody
responses were protective.
Neonates of domestic species and human babies are highly susceptible to
infectious agents and often succumb to disease. It would therefore be beneficial to
vaccinate newborns early in life and render them less susceptible to infection. The
presence of maternal antibodies and the perception that neonates are susceptible to
antigen-specific immunotolerance have created obstacles to the development of vaccines
for the neonate. DNA vaccines appear able to surmount these problems and induce both
antigen-specific humoral and CMI. A study by van Drunen Littel-van den Hurl< et al.
(1999) showed that lambs can overcome the presence of maternal antibodies and
develop immune responses after DNA vaccination. Ewes, between 75 to 95 days
gestation, were vaccinated with either a plasmid expressing gD (pSLlAgD) or a null
plasmid control. The newborn lambs were then vaccinated with pSLlAgD at three days
of age and antibody levels were evaluated. All lambs were shown to be immunologically
competent, as lambs from ewes treated with the null plasmid generated modest levels of
gD specific antibody titers. The lymphocytes of lambs from pSLlAgD immunized ewes
also generated strong antigen-specific T cell proliferative responses in vitro. This
investigation indicated that the presence of maternal antibody did not prevent the
development of a CMI response (van Drunen Little-van den Hurk et al., 1999).
Not all DNA vaccines will generate protective immunity in neonates in the
presence of maternal antibodies. As an example, neonatal mice from hyper-immune
dams were injected with plasmids that express HA and NP of influenza virus. The
neonates failed to generate HA specific antibodies but could develop high levels of NP
specific antibodies. Strong CTL responses were induced by both antigens, however
mice with low levels of HA antibodies succumbed to virus challenge. It was suggested
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that the dev~lopment of protective antibody was essential for survival and the presence
of maternal antibodies specific for HA antigen lead to vaccine failure (Pertmer at al.,
2001 ).
1.2.2 Enhancement of Immune Responses to DNA Vaccines
For an extensive review on methods to enhance efficacy of DNA vaccination see
Gurunathan at al. (2000). Ultimately, an effective vaccine should stimulate long-term
immunity and memory that provides disease protection. Unfortunately, DNA vaccines
have not been the 'magic bullet' as many scientists hoped and there are many examples
of vaccine failure after inoculation (Richardson at al., 1997; Choi at al., 1998; Le at al.,
2000). Various approaches to improve vaccine efficacy have therefore been undertaken.
These include the addition of viral promoters and intron sequences to vectors (section
2.2.3 and 2.2.5), the addition of CpG immunostimulatory sequences to plasmids (section
2.10.2), the expression of cytokines and co-stimulatory molecules, vaccine boosting,
enhanced delivery to MHC, and gene manipulation.
1.2.2.1 Plasmid Encoding Cytokines and Co-stimulatory Molecules
Plasmid-based vaccines encoding cytokines or antigen presenting cell co-
stimulatory surface molecules can be used to improve immune responses. This can be
accomplished by either co-administrating two or more plasmids, or pre-immunization with
. plasmids used to improve adjuvanticity. Leachman at al. (2000) demonstrated that pre-
injection of plasmid DNA expressing granulocyte-macrophage colony stimulating factor
(GM-CSF), improved immune responses to subsequent DNA vaccination against rabbit
papillomavirus. Immunization with the plasmid-expressing antigen alone caused a 50%
reduction in skin lesions of rabbits challenged with virus. In comparison, pre-treatment
with a GM-CSF expressing plasmid followed by injection of the plasmid encoding viral
antigen prevented the formation of skin lesions in 67% of the challenged animals.
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Furthermore, there was a delay in the onset of skin lesions and a 99% reduction in the
total volume of papillomas in the pre-treatment group.
In experiments by Tripp et al. (2000), mice were treated with plasmids expressing
CD40 ligand and G protein of respiratory syncytial virus (RSV). These mice were then
challenged with RSV and their immune functions assessed. In vitro assays on
pulmonary T lymphocytes demonstrated an approximate two to four-fold increase in the
production of Th1 cytokines (ll-2 and INF-y) and a 300/0 increase in nitrous oxide levels.
There were also improved CTl responses, a seven-fold increase in antigen-specific
antibody titers and a 50% increase in virus clearance.
1.2.2.2 Boosting with Protein or Live Virus
Although DNA vaccines can generate both antigen-specific antibody and CTl
responses in vivo, these responses often do not provide disease protection (Choi et al.,
1998; le et al., 2000). Immune responses can be enhanced by boosting DNA-
immunized animals with either protein or live virus. Monkeys inoculated with DNA
vectors expressing HIV-1 envelope protein developed modest levels of neutralizing
antibody and weak in vitro CTl responses. In comparison, if DNA-primed monkeys were
subsequently given HIV-1 glycoprotein, then there was a substantial increase in both
humoral and CMI responses. These monkeys had developed protective CTl responses
and were protected against challenge with SIV/HIV chimeric virus (letvin et al., 1997).
Another approach to enhancing DNA vaccines is to combine DNA vaccination
with live virus vector immunization. Mice were immunized with a DNA vaccine
expressing malarial circumsporozite protein and then inoculated with vaccinia virus
expressing the same protein. Mice receiving the DNA vaccine developed poor to
moderate non-protective antibody responses. In contrast, the majority of mice boosted
with either virus expressing antigen or the original DNA vaccine were protected from
protozoal challenge, with a survival rate reaching 690/0 (Sedegah et al., 1998).
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1.2.2.3 Manipulation of Genetic Sequences and Type of Antigen Expressed
The immunogenicity of antigens within DNA vaccines may be enhanced by
genetically altering the expressed gene. Replacement of several codon sequences of
g120 from wild type HIV-1 with sequences from different highly expressed human genes
resulted in a significant increase in the in vitro expression of the mutated (sp 120) when
compared to wild type g120 (Andre et al., 1998). Intramuscular injection of plasmid with
sp120 gene induced a five and six-fold increase in CTL and antibody levels, respectively.
The selection of the proper antigen for use in DNA vaccines is critical for the
development of protective immunity in animals. If non-protective antigens are expressed
in DNA vaccines, this could lead to vaccine failure and the subsequent death of
challenge animals. As an example, plasmids expressing structural proteins of Japanese
encephalitis virus resulted in disease protection against virally challenged mice. These
mice developed antibody profiles that vary from Ig2a alone to a more balanced
IgG1/1gG2a ratio. In contrast, if these were immunized with plasmid expressing non-
structural proteins, mice succumbed to the disease (Chen et al., 1999a). This example
highlights the importance of encoding protective antigens in DNA vaccines.
1.2.2.4 Improved Antigen Targeting and Enhanced Delivery to MHC
Immune responses can be improved by designing vaccine delivery systems that
. target antigens to either target lymph nodes (LN) or antigen-presenting cells (APC).
These DNA vaccines are developed as fusion proteins that express antigen and targeting
molecules. For example, DNA vaccines encoding L-selectin can target the high
endothelial venules (HEV) of LN while expression of cytotoxic T lymphocyte antigen 4
(CTLA-4) targets antigen to APC. When these modified vectors were injected into mice
and serum antibody levels were measured, the researchers demonstrated a 75 and 100-
fold increase in antigen-specific antibody production in mice treated with L-selectin and
CTLA-4 vaccines, respectively (Boyle et al., 1998).
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Similarly, targeting antigens to cell organelles involved in antigen processing can
enhance immune responses. Proteosomes are involved in the digestion of cytoplasmic
proteins and it has been hypothesized that targeting DNA vaccine antigens to these
structures will facilitate protein digestion and result in improved antigen-presentation by
MHC. Since ubiquitin directs intracellular proteins to proteosomes, Wu & Kipps (1997)
constructed a plasmid expressing an ubiquitin-~-galactosidase chimera and injected it
into mice. They measured gene expression in vitro and the in vivo production of antigen-
specific antibodies and CTL. Treatment with proteosome inhibitors caused a 1500k
increase in ~-galactosidase expression, confirming that the chimeric protein was indeed
targeted to proteosomes for degradation. Antigen-specific CTL activity was 60% greater
in mice treated with plasmid expressing the chimeric protein compared to mice
immunized with plasmid expressing ~-galactosidase alone. It is noteworthy that antigen-
specific antibodies were not detected in mice immunized with plasmid expressing
chimeric protein but were detected in mice treated with the plasmid expressing ~­
galactosidase. The researchers hypothesized that rapid intracellular degradation of
antigen caused a reduced amount of peptide available for the induction of an antibody
response. This method of antigen targeting therefore may be of value for inducing CMI
but not humoral immunity.
1.2.3 Delivery Systems for DNA Vaccination
Various methods to enhance DNA vaccine uptake and improve the induction of
an immune response have been developed. These methods include the direct
intracellular delivery of plasmid DNA (gene gun) and the use of various lipid formulations
and microbial carriers to improve mucosal delivery. These techniques will be discussed
in the following sections.
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1.2.3.1 Gene Gun
The direct transfer of plasmid DNA to cells can potentially enhance cell
transfection and facilitate the induction of immune responses. To achieve this goal, DNA
can be delivered intracellularly by ballistic delivery (gene gun) of plasmid annealed to
gold particles. Delivery of plasmids into cells should reduce the amount of plasmid lost to
enzymatic degradation by tissue DNases and thereby increase the amount of plasmid
available to induce immunological products. For instance, the gene gun delivery of a
plasmid expressing a malarial antigen produced better immunity in mice than
intramuscular (im) injection. Ballistic delivery of plasmid was associated with a six-fold
increase in antibody production after three treatments and promoted a switch from a
predominately IgG1 immune response to a more balanced IgG1/lgG2a antibody
response. Furthermore there was a 30% increase in survival following challenge of the
gene gun-immunized mice when compared to im immunized mice (Leitner et al., 1997).
Gene gun vaccination has also been used to induce strong immune responses in
domestic animals. Ballistic delivery of pLSIAtgD plasmid increased IFN-y secretion from
collected peripheral blood mononuclear cells, increased neutralizing antibody titers and
produced strong proliferative responses. After challenge with BHV-1, vaccinated cattle
had increased levels of nasal and serum neutralizing antibodies as well as decreased
.viral shedding relative to controls (Braun et al., 1999). Unfortunately, a direct comparison
between gene gun and other DNA vaccine delivery methods was not addressed in this
study.
1.2.3.1 Encapsulation of Plasmid DNA
Encapsulation of DNA within polymers or Iiposomes can improve vaccine delivery
to mucosal surfaces (Jones et al., 1997; Klavinskis et al., 1997). The environment within
the gut or respiratory tract can limit the efficacy of inducing immune responses following
DNA vaccination. The low pH of the stomach, abundant pancreatic enzymes within the
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intestine, and the presence of cilia within the trachea can lead to either the rapid
breakdown or clearance of plasmids. One method to overcome some of these 'hazards'
is to encapsulate the vaccine prior to delivery. Plasmid encapsulated in poly D L-Iactide-
coglycolide microspheres was given orally to mice: relative to intraperitoneal injected
controls, the oral delivery of 50 Ilg of encapsulated plasmid caused an approximate 3-, 4-
and 7-fold increase in serum IgA, IgM and IgG antibody levels, respectively. A 5 to 20-
fold increase in IgA levels was also present in stool samples after treatment. Intradermal
injection of microparticle DNA complexes similarly induced markedly enhanced antibody
response compared to naked DNA (Jones et al., 1997).
Encapsulation of plasmid in liposomes provides another method to help
ameliorate plasmid uptake and vaccine efficiency. The ability to design Iiposomes that
vary in composition, size and number of lipid bi-Iayers makes Iiposomes an ideal delivery
system (Swenson et al., 1988). In mice, when gene expression in nasal epithelium was
compared between plasmid DNA-lipid complexes and naked DNA, a 30-fold increase in
gene expression was shown in the DNA-lipid treatment group versus naked controls,
indicating that Iiposomes do indeed enhance plasmid uptake (Klavinskis et al., 1997).
The administration of Iiposome-DNA complexes to animals, however, does not
consistently improve the induction of antigen-specific immune responses. As an
. example, injection of Iiposomes encapsulating plasmid expressing Schistosoma
japonicum into mice, failed to produce antigen-specific antibodies. In comparison,
injection with unencapsulated plasmid resulted in strong antibody responses that lasted
for eight weeks (Zhang et al., 2000). The researchers did not measure CTL and neither
treatment reduced parasite egg shedding.
1.2.3.3 Use of Microorganisms to Deliver DNA
Delivery of DNA vaccines can be enhanced with use of attenuated
microorganisms to carry plasmid DNA into cells. Using its natural route of entry into
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cells, the microbe should enhance plasmid uptake. Bacteria that carry plasmid can be
delivered to the gut, enter through M cells and be picked up by APC that reside in
Peyer's patches. In this manner a vaccine can be delivered in a relatively specific
fashion to immunocompetent cells. Mice were orally immunized with a strain of
attenuated salmonella, containing a plasmid that expressed a glycoprotein of L.
monocytogenes. After a single oral immunization, all mice developed strong CTl and
proliferative responses and had elevated levels of antigen-specific antibody. In a
challenge study, 60% of the mice survived following immunization with the attenuated
salmonella vector as compared to null vector controls (Darji et al., 1997). This suggests
that microbial delivery may be an effective method to develop mucosal immunity.
Alphaviruses are single stranded RNA viruses whose mechanism of intracellular
replication has the potential to produce vast quantities of mRNA. Exploiting this
phenomenon, Hariharan et al. (1998) engineered a new plasmid expressing gB of herpes
simplex virus-1 (HSV-1) and compared the alphavirus modified plasmid to a conventional
DNA vaccine containing a HCMV promoter. A single treatment with 10 ng of the modified
plasmid produced responses that were equivalent to immunization with 10 /-1g of
conventional DNA vaccine. Alphavirus DNA vectors are, therefore, potent and effective
inducers of immune responses.
As our understanding of the potential uses for DNA vaccines expands, methods
to further optimize vaccination efficacy are needed. Improvement in plasmid construct,
the types of antigens expressed and vaccine formulation can enhance immune
responses following DNA vaccination.
1.2.4 Routes of Plasmid Delivery
Plasmid delivery has been achieved by a variety of routes to elicit long lasting and
often protective immunity. These routes of delivery include intramuscular (im),
subcutaneous (sc), intravenous (iv), intraperitoneal (ip), intradermal (id), and topical. To
20
obtain mucosal immunity, routes of delivery include oral, intranasal, vaginal, and ano-
rectal. Each of these delivery routes has been investigated in the effort to improve
immune responses either systemically or at mucosal surfaces.
1.2.4.1 Intramuscular Delivery
Original reports regarding gene expression in tissue after DNA vaccination (Wolff
et al., 1990) and disease protection (Ulmer et al., 1993) were made after plasmid was
injected into the quadriceps muscles of mice. These experiments demonstrated that
DNA immunization was possible and that im injection was a potential route of delivery.
Davis et al. (1994) showed that pre-injection with hypertonic sucrose induced muscle
inflammation and low levels of muscle necrosis and that pre-treatment with irritants, five
to 10 days prior to DNA injection, caused a 10-fold increase in gene expression and
antibody production. They proposed that regenerating muscle acquires more plasmid
than normal muscle and thereby generates greater levels of expression.
There is great potential for implementing DNA vaccines in the livestock industry.
The method of vaccine delivery is an important consideration for food-producing animals
and certain delivery methods such as im injection might not be acceptable in the future.
As an example, im injection of DNA vaccines can potentially cause significant muscle
necrosis at the injection site and damage could reduce meat quality at slaughter.
. Therefore, other methods of vaccine delivery that do not compromise vaccine efficiency
should be developed for livestock.
1.2.4.2 Subcutaneous, Intravenous and Intraperitoneal Delivery
Other methods of vaccine delivery have been explored due to limited success of
im injection. The efficacy of plasmid-based vaccination for the induction of immune
responses against varicella zoster was tested by injecting mice im and sc with a plasmid
expressing glycoprotein E. Both methods of delivery induced strong and comparable
antibody responses that peaked at week 4 and remained elevated up to 12 weeks post-
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treatment (Hasan et al., 2000). This study proved that sc and im routes of delivery were
equally effective for the induction of an immune response.
Intravenous delivery of DNA vaccines is another approach that can be used to
induce immune responses. The iv injection of plasmid expressing HA of influenza
induced antigen-specific antibodies and protection during a mouse challenge study with
influenza virus (Fynan et al., 1993). This study demonstrated markedly elevated levels of
serum IgG antibodies and a small increase in IgA levels post-plasmid treatment. The
DNA vaccine induced protective immunity, as 95% of virus challenged animals survived.
Intraperitoneal injection of plasmid DNA may be the least effective delivery
method to induce protective immunity. In both mice and chickens, ip injection of plasmid
expressing influenza HA protein failed to induce protection against influenza viral
challenge and all challenged animals succumbed to illness following plasmid injection. In
comparison, 95% of the animals given plasmid by either im and iv routes survived (Fynan
et al., 1993). It is noteworthy that ip delivery of plasmid can produce a strong antibody
response if the plasmid is administered with microspheres (see section 2.8.1).
1.2.4.3 Topical and Intradermal Delivery
Delivery of DNA vaccines to the skin offers several advantages over parenteral
delivery methods. Ease of application, the potential release of immune stimulating-
. cytokines from epithelial cells and the presence of antigen presentir')g cells such as
Langerhans cells are all potential advantages of dermal delivery.
Expression of plasmid-encoded genes in vivo has been documented after topical
application of naked plasmid DNA. In mice, Fan et al. (1999) demonstrated that gene
expression could be detected after exposure to naked plasmid DNA. Interestingly,
detectable gene expression was limited to hair follicles. The researchers showed that a
small percentage of cells surrounding hair follicles were able to take up DNA and express
the encoded gene. They speculated that plasmid DNA may enter the skin through
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epithelial cells located within pilosebaceous units and proposed that hair follicles in the
anagen phase may incorporate more DNA than resting follicles.
Intradermal delivery is an excellent method of plasmid administration as large
quantities of DNA can be delivered into a relatively small area that includes large
numbers of APC, keratinocytes and dermal macrophages. One of the initial studies
demonstrating that intradermal vaccination induced a good level of protection against
viral infection was undertaken by Fynan et al. (1993); however, the level of protection
was not as effective as im injection. With further developments, it has become apparent
that id delivery induces immune responses more effectively than delivery by im injection.
Raz et al. (1994) showed that, in mice, id injection of plasmid expressing influenza HA
antigen induced greater antibody and CTL responses than im injection of the same
amount of plasmid. The id injection cross-protected mice from challenge with a viral
strain that differed from the virus antigen used in the DNA vaccine. Unfortunately, a
challenge study in mice comparing levels of protection following im and id infection was
not completed. Therefore, it remains to be determined which form of delivery induces
optimal protection.
Similar observations have been made when comparing id and im DNA
vaccinations in cattle. In·calves, intradermal injection of plasmid expressing the secreted
form of BHV-1 glycoprotein D (tgD) induced higher neutralizing antibody titers when
compared to im injection. The intradermal injection of the DNA vaccine also improved
clinical scores of calves challenged with BHV-1. These calves were less febrile, had
better weight gain and less viral shedding than controls (van Drunen Littel-van den Hurk
et al., 1998). Unfortunately, no comparable challenge studies have been done in im
vaccinated calves. Therefore, while a direct comparison between the efficacy of
different delivery methods has not been performed, id vaccinated calves did develop
higher antibody titers with fewer injections than im injected calves.
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1.2.5 Mucosal Immunity
The development of a strong mucosal immune system can be an important
component in host defense. Major pathogens that cause morbidity and mortality in both
man and domestic livestock invade the body at mucosal surfaces. As many parenteral
vaccines are relatively ineffective at inducing immune responses at mucosal surfaces, it
is essential that vaccines be designed to specifically bolster mucosal immunity. Through
a common immune system that links the various mucosal surfaces, delivery of vaccines
at one mucosal site should induce immune responses at distant mucosal sites. In
attempts to develop mucosal immunity, DNA vaccines have been delivered to respiratory,
gut and vaginal mucosa.
1.2.5.1 Oral and Intranasal Delivery
As previously mentioned, the development of immunity following oral delivery of
DNA vaccines was first described by Jones et al. (1997) (see section 2.6.2). This study
demonstrated that oral delivery of DNA vaccines could generate antigen-specific
antibody responses at distant mucosal sites.
Recently, strong systemic and mucosal responses were observed following a
single oral vaccination of fetal sheep. Gerdts et al. (2000) demonstrated that delivery of
naked DNA into the oral cavity of fetal sheep induced both antigen-specific eMI and
. humoral responses in vivo. It remains to be determined if oral immunization of the fetus
can be applied to other species, particularly humans.
Successful intranasal vaccination with naked DNA was first achieved in mice.
IntranasaJ vaccination against influenza virus induced moderate protection with 76%
survival rate after viral challenge (Fynan et al., 1993). Since then, researchers have tried
to improve mucosal immunity by increasing IgA antibody levels at mucosal surfaces.
Using liposome-DNA complexes, both systemic and mucosal immune responses were
induced after intranasal administration. In mice, there was a 50% to 800/0 increase in
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eTl activity in cells isolated from the spleen and iliac IN as well as 2 and 60-fold
increases in serum IgA and IgG antibody titers, respectively. Four and eight-fold
increases in IgA and IgG antibody levels were also detected in vaginal secretions
(Klavinskis et al., 1997). These results indicate that intranasal vaccination can induce
immunity at various mucosal sites throughout the common mucosal immune system.
Although immunization at nasal mucosal surfaces should elicit immune responses
at all mucosal surfaces, this does not always occur following DNA vaccination. Intranasal
treatment of mice with lipid complexes of plasmid DNA expressing various membrane
proteins of Chlamydia trachomatis failed to induce protective immunity. Immunization
with plasmids induced modest antibody and eTl responses, but failed to reduce vaginal
shedding of the microbe or improve fertility in challenged mice (Pal et al., 1999).
1.2.5.2 Genital and Ana-rectal Delivery
The application of plasmid DNA vaccines to the vaginal and rectal mucosa is
potentially convenient method for immunization. Topical application of plasmid DNA to
vaginal mucosa and subsequent gene expression was described in mice by Wang et al.
(1997). To test the adequacy of antigen-specific mucosal immunity, IgA levels were
measured in vaginal swabs. This analysis demonstrated an increase in both the amount
of IgA secreted and the level of neutralizing antibody present after DNA vaccination.
Delivery of plasmid DNA via the genital tract may offer not only a convenient route
for vaccine delivery in domestic animals, but may also induce effective mucosal
immunity. To evaluate and compare the efficacy of vaginal plasmid DNA delivery, the
plasmid pSLlA-tgD was injected either id or intravaginally (ivn) by gene gun delivery in
cattle. Though not significantly different, ivn injected cattle had lower clinical scores than
id vaccinated animals following BHV-1 challenge. Furthermore, there was a substantially
greater increase in serum antibody titers after ivn injection than that observed for either id
injected cattle or non-immunized cattle (loehr et al., 2000).
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Ano-rectal delivery is another potential route for the development of mucosal
immunity. Using a gene gun to inoculate the ano-rectal mucosa with VP6 antigen of
rotavirus, Chen at al. (1999b) detected a two-fold increase in the level of antigen-specific
IgG antibody in serum and a moderate increase in intestinal IgA levels. DNA
immunization also induced modest levels of protection, with reduced viral shedding, in
challenged mice.
As previously indicated, the delivery of DNA to one mucosal surface does not
consistently induce immunity at distant mucosal sites. For example, the delivery of
plasmid expressing papillomavirus antigen to the rectal mucosa failed to induce either
serum antibodies or neutralizing antibodies at the vaginal mucosa. In contrast, vaginal
delivery of the same plasmid produced high serum antibody titers and moderate levels of
neutralizing antibodies in vaginal secretions (Schreckenberger at al., 2000).
Although there are examples of vaccine failure, in general the delivery of DNA
vaccines to mucosal surfaces often generates protective and relatively long-lasting
immunity. The delivery of DNA vaccines to mucosal surfaces may have other limitations.
Delivery of intranasal vaccines to cattle can be particularly challenging: the necessity for
restraint of the head or the expulsion of vaccine in nasal secretions may make this route
of delivery impractical. Furthermore, the delivery of DNA vaccines to vaginal or rectal
.mucosa may require further development of specialized delivery systems.
DNA vaccination has been hailed as the third generation of vaccines (Butts at al.,
1998), with the potential to revolutionize conventional vaccine technology. Although DNA
vaccination hold great promise for providing immunoprophylaxis against infectious
diseases, its efficacy at inducing protective immunity remains inconsistent. I have
highlighted several examples of vaccine failure that may be related to either the type of
antigen expressed or to the route or method of delivery. Thus, further work is needed to
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optimize individual DNA vaccines to ensure consistent induction of protective immunity.
1.2.6 DNA Vaccine Induced Antigen Presentation
For DNA vaccines to induce an immune response, proteins encoded within the
plasmid must be expressed, processed and presented to immunologically competent
cells. Frequently, the quantity of protein produced after DNA vaccination is miniscule
(Gurunathan et al., 2000); therefore, an efficient method for antigen processing and
presentation is needed to ensure the induction of strong and protective immune
response. Three possible pathways by which antigen presentation can occur following
DNA vaccination have been proposed and these are discussed below.
1.2.6.1 Dendritic Cell Activation
One hypothesis is that dendritic cells (DC) take up plasmid and present
endogenously expressed antigen in an MHC-restricted fashion. Evidence for DC as the
primary antigen-presenting cell has been generated through several separate
experiments. In a study by Casares et al. (1997), plasmid DNA encoding antigen was
injected im into mice and then the draining LN was removed. The LN cells were isolated
and then sorted by flow cytometry, into individual cell populations. Purified DC were then
cultured with T cell hybridoma cells and this caused significant T cells activation. In
comparison, cultures of LN B cells and keratinocytes isolated from the DNA injection site
with the same T cells did not induce T cell activation. These data suggested that DC
rather than B cells or keratinocytes presented antigen following plasmid injection.
To further identify the. cell types involved in antigen-presentation after vaccination,
Condon et al. (1996) injected into mice a plasmid expressing the gene for green
fluorescent protein (GFP) of jellyfish. Using differential interference contrast microscopy,
it was shown that cells with a dendritic morphology expressed the protein, but it was not
conclusively demonstrated that the cells expressing GFP were indeed DC. Cells such as
fibroblasts can take up plasmid and express protein and these cells often display a
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dendritic-like morphology (Wolff et a/., 1990). It is likely, however, that the majority of
GFP expression was produced by dendritic cells with a potentially smaller portion of
protein expression in stromal fibroblasts.
1.2.6.2 The Role of Non-Professional Antigen Presenting Cells
As previously described, DNA vaccines injected im are expressed in myocytes
(Wolff et a/., 1990; Davis et a/., 1994) may induce protective immunity (Ulmer et a/.,
1993). It is difficult to determine, however, the mechanism by which an antigen
expressed in a somatic cell can induce an immune response in vivo. Unlike APC, muscle
cells and other somatic cells appear to lack the co-stimulatory proteins that function as
important second signals during the generation of an adaptive immune responses. It is
therefore thought, based on evidence from several experiments that antigen presentation
is unlikely to occur via somatic cells.
Chimeric crossbred mice lacking MHC-1 expression on APC, were used to
demonstrate that myocytes could present antigen when co-stimulatory proteins were
expressed on their surface. The myocytes of F1 hybrid mice were co-administered with
plasmids encoding the co-stimulatory CDB6 protein and an antigen and myocytes
expressing CDB6 were able to present antigen (Agadjanyan et a/., 1999). It is
noteworthy that expression of CDB6 was verified by immunohistochemistry and myocytes
. lacking COB6 expression failed to induce an immune response, thus demonstrating the
requirement for co-stimulatory molecules.
To further evaluate the role of muscle cells as potential antigen presenters, two
groups of mice were injected im with plasmid DNA and the resulting immune responses
evaluated. The injection site was excised from the first group of mice within one minute
post-inoculation, while the injection site of the second group remained intact. 80th
groups of mice developed similar humoral responses. This observation suggests that
antigen expression in muscle cells was not essential for the induction of a humoral
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immune response. In contrast, removal of the overlying skin 24 hours following id
plasmid injection abrogated antibody responses. The authors hypothesized that cells
. residing in the skin were responsible for the induction of antibodies (Torres et al., 1997).
They suggested that either direct transfection of Langerhans cells or the activation of
keratinocytes with the subsequent enhancement of Langerhans cell function resulted in
the induction of an immune response.
Interestingly, unique co-stimulatory molecules have been detected on non-
professional antigen presenting cells. Cells such as keratinocytes, synovial fibroblasts
and enterocytes express proteins that can function in lymphocyte activation. Stimulation
of CD6 which is expressed on both immature and mature cells in mice and on breast
carcinoma cell lines, by CD6 ligand can lead to T cell activation. CD6 ligand is an
inducible protein that has been detected on skin epithelium. Therefore, it has been
suggested that skin could assist in T cell activation along with appropriate professional
antigen presenting cells (Wee et al., 1994). Co-stimulatory molecules are also
constitutively expressed on keratinocytes surfaces. CD24 (nectadrin), for instance, can
be detected on cultured human keratinocytes grown in minimal media. Nectadrin is
believed to be homologous to a heat-stable antigen, an antigen that delivers a co-
stimulatory signal to T cells leading to T cell activation. It is possible therefore, that
.nectadrin could also playa role in T cell activation. Further studies are needed however,
to determine the function of nectadrin in vivo (Redondo et al., 1998).
1.2.6.3 Transfer of Antigen to Antigen-Presenting Cells
The phenomenon of antigen transfer from one cell to another could explain the
initial observations that CTL and humoral responses develop after im injections with DNA
vaccines. Transfected somatic cells could be the source of expressed antigen that is
then acquired by APC to induce an immune response. This idea was delineated by
Ulmer et al. (1996). Using F1 hybrid mice, from parents with different MHC-restricted
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haplotypes, it was shown that somatic cells transferred antigen to professional APC.
Myoblasts from F1 hybrid mice that were expressing antigen and were restricted to one
of the parents (HD) were injected into the other parent (HK). The recipient mouse could
generate an effective CTL indicating that antigen expressed on MHC-I of myoblasts was
passed to APC as CTL responses were restricted to the MHC haplotype of antigen-
presenting cells not that of myoblasts.
1.3 Introduction to Immunostimulatory Oligodeoxyribonucleic Acids
As previously discussed, work in the 1980's demonstrated that bacterial DNA
displayed immunostimulatory properties both in vitro and in vivo. It became apparent that
palindromes with CpG central motifs were important in immune stimulation. Sequences
causing activation in mice included: AACGTT, AGCGCT, ATCGAT, CGATCG, CGTACG,
CGCGCG, GCGCGC and TCGCGA (Yamamoto et al., 1994; Krieg, 1999). DNA
sequences lacking a central C or G nucleotide did not stimulate immune responses in
vitro. Since the 1980's, work has progressed to characterize the immune modulating
properties of these short sequences of DNA and it has been shown that CpG motifs
flanked by two purines upstream and two pyrimidines downstream were indeed
immunostimulatory. This section will focus on the effects of oligodeoxyribonucleic acids
(ODN) in the context of CpG hexamers on isolated cell preparations and the in vivo
. enhancement of immune induction.
1.3.1 In Vitro Immunostimulation
A variety of cell types including lymphocytes (Krieg et al., 1995), NK cells (tho et
al., 1999), macrophages (Stacey et al., 1996) and DC (Sparwasser et al., 1998) can be
activated by immunostimulatory CpG motifs. The cellular responses to GpG motifs
include secretion of cytokines and chemokines, enhanced cell proliferation, increased
expression of activation markers and costimulatory molecules and enhanced production
of oxygen reactive species within cells. Morphologically, cells such as dendritic cells
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have an activated appearance with the presence of extended veil-like structures and
numerous intracytoplasmic bodies. The effect of immunostimulatory CpG motifs on
lymphocytes, macrophages and dendritic cells is discussed below.
1.3.1.1 B cells
The seminal experiment demonstrating direct B cell activation by
immunostimulatory CpG motifs was performed by Krieg et al. (1995). B cells were
isolated from mouse spleens and were incubated with DNA sequences containing
defined CpG motifs. Optimal B cell activation was seen in OON containing CpG
preceded by two purines and followed by two pyrimidines. Nuclease-resistant
phosphorothioate OON could activate B cells at lower concentrations than
phosphodiesterate OON, suggesting that OON with phosphodiester linkages are
degraded by DNase. Increased expression of activation markers and increased cytokine
production can also occur in B cells following treatment. Spleen cells isolated from mice
previously injected with OON, produced a six-fold increase in IgM antibody titers along
with an approximately 50% increase in the level of MHC-II expression on B cells. There
was also increased expression of the B cell activation markers B7-2 and Bla-1, but the
actual level of expression was not stated. Klinman et al. (1996) verified the previous
work by Krieg et al. (1995) and confirmed that OON treatment induced B cells to secrete
. more IL-6 and IL-12 and produce more IgM antibody.
Immunostimulatory oligodeoxyribonucleic acid (ISOON) also inhibits apoptosis in
B cells. The addition of ISOON to WEHI 231 B cells, for example, caused an approximate
two-log reduction in apoptosis post-treatment. It is believed that ISOON may both down-
regulate and up-regulate different proto-oncogenes. Specifically, ISOON can prevent c-
myc down-regulation and can promote the up-regulation of bel2 and bel-xl. The
interactions between these oncogene products are not fully understood, however they be
important regulators of either transcription or DNA replication (Yi et al., 1996).
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1.3.1.2 T Cells
Unlike B cells, quiescent T cells cannot be stimulated to proliferate in culture by
treatment with ISOON. Activated T cells, expressing the C071 proliferation marker,
however, displayed increased cell proliferation after ISOON treatment (Bauer et al.,
1999). In contrast to the apparent unresponsiveness of quiescent T cells to ISOON
treatment, activated T cells readily secrete cytokines following treatment. For example,
C04 T cells harvested from mouse spleens displayed a 1.5 and 2-fold increase in IFN-y
and IL-6 cytokine production respectively, after treatment with ISOON when compared to
unstimulated cells (Klinman et al., 1996). In a second study using antigen-sensitized
mice, it was demonstrated that C04 T cells isolated from spleens and then incubated
with ISOON produced 3D-fold more in IFN-y secretion than C04 T cells isolated from
na"ive mice (Broide et al., 1998).
Immunostimulatory OON can also indirectly reduce the secretion of certain
cytokines from T cells. In an eosinophil hypersensitivity model, Broide et al. (1998)
demonstrated an 830/0,76%, and 47% reductions in T cell secretion of IL-5, IL-3 and GM-
CSF, respectively, following ISOON treatment. These cytokines are involved in
eosinophil production and the researchers suggested that a reduction in eosinophil
numbers following ISOON treatment was likely caused by deviation from a Th2 to Th1
. type immune response. From this experiment, it was difficult to determine whether T cell
activation was caused by a direct ISOON stimulation or by activation of resident dendritic
cells followed by the release of mediators that activate T cells. In this experiment, cells
isolated from the spleen were incubated with ISOON prior to T cell purification, thus
allowing time for the release of cytokines from dendritic cells. It is possible, that ISOON
activates T cells both directly and indirectly through the stimulation of local antigen
presenting cells.
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1.3.1.3 Natural Killer Cells
Natural killer cells may also be activated by ISOON. Treatment of isolated human
NK cells with ISOON caused a 4-fold increase in IFN-y production, independent of TNF-u
or IL-12 production. The addition of either IL-12 or IL-2 notably enhanced cytokine
production with a further one to eight-fold increase in IFN-y secretion (Iho et al., 1999).
Similar results by Klinman et al. (1996) demonstrated a five-fold increase in the number
of NK cells secreting IFN-y following ISOON treatment. Immunostimulatory OON also
enhances activation of NK cells resulting in the expression of activation markers.
Exposure of highly purified human NK cells to ISOON caused an increase in C069 and
HLA-ABC expression (Iho et al., 1999).
Adding ISOON to cultured NK cells increased NK lytic activity in vitro. Incubation
of ISOON with NK cells, from Band T cell depleted spleen cultures, caused a 60%
increase in NK cell-induced cell death (Ballas et al., 1996). Interestingly, cell
preparations of highly purified NK cells did not respond to ISOON and the researchers
suggested that increased NK cell killing is dependent on ISOON activation of accessory
cells. Using neutralizing antibodies, Ballas et al. (1996) demonstrated that NK cell killing
depended on the presence of IL-12, TNF-u and IFN-~ and IFN-y, four cytokines known to
be secreted by either macrophages or dendritic cells. The authors believed that release
of these cytokines by either macrophages or dendritic cells could be responsible for NK
cell activation.
It is difficult to explain the discrepancy between findings of Iho et al.,(1999) and
Ballas et al. (1996). Iho and colleagues used different techniques for isolating NK cells
than did Ballas et al. and thereby used a more purified population of NK cells in their
experiment. This suggests that NK cells may be directly affected by ISOON, however,
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the presence of minute numbers of dendritic cells or macrophages releasing cytokines to
activate NK cells can not be excluded.
1.3.1.4 Macrophages and Monocytes
Macrophages play an integral role in the induction of immunity as they link the
innate and acquired immune system. In view of the numerous effects of ISODN on
lymphocytes, it was perhaps reasonable to assume that ISODN would affect macrophage
activity and, in fact, macrophages are activated directly by ISODN to secrete various pro-
inflammatory cytokines (Krieg &Wagner, 2000). Incubation of ISODN with mouse
macrophages (Stacey et al., 1996), human monocytes (Roman et al., 1997) and isolated
peritoneal macrophages from SCID mice (Sparwasser et al., 1997) demonstrated low to
substantial elevations in TNF-u secretion. Stimulated peritoneal macrophages had a 30-
fold increase in the secretion of TNF-u when compared to unstimulated controls and
LPS- treated peritoneal macrophages (Sparwasser et al., 1997). Similarly, ISODN
treatment induced the production of IL-1, IL-6 and GM-CSF by mouse macrophages
(Sparwasser et al., 1998). To examine the extent of ISODN induction of other cytokines,
the mRNA levels for various cytokines expressed by monocytes were measured. The
mRNA levels of IFN-y, IL-12 and IL-18 were all increased after treatment with ISODN,
signifying induction of gene expression (Roman et al., 1997).
1.3.1.5 Dendritic Cells
Similar to macrophages, DCs link the innate and acquired immune systems and
are activated by ISODN. Direct exposure of DCs to ISODN results in DC maturation and
improved antigen presentation (Sparwasser et al., 1998; Hartmann et al., 1999; Krieg &
Wagner, 2000). Dendritic cells, isolated from human blood and treated with ISODN
displayed enhanced expression of the activation markers MHC-II, ICAM-1, 87-2 (C086)
and C040. Immunostimulatory OON treatment of DC also increased the life span of OCs
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in culture (Hartmann et al., 1999). Dendritic cell activation by ISODN has also been
observed in mice. Following ISODN treatment there is a moderate up regulation of MHC-
II, 87-2 (C086) and CD40 as well as elevated secretion of IL-12, IL-6 and IFN-y
(Sparwasser et al., 1998). The hallmark of DC maturation is the ability to present antigen
and activate T cells. Indeed, pre-treatment of OCs with ISODN and incubation with
harvested T cells caused a substantial increase in the mixed leukocyte reaction of
cultured T cells, signifying T cell activation (Sparwasser at al., 1998). Finally, changes in
cell morphology were observed following ISOON treatment. Morphologically,OCs
treated with ISOON appeared more mature with increased intracytoplasmic bodies, multi-
vesicular structures and sheet-like veiled processes that extended from the cell
(Sparwasser at al., 1998; Hartmann et al., 1999).
Direct activation of OCs is fundamental to the integration of innate and acquired
immune systems. The ability of ISODN to activate DC is very convincing but refutable.
In the experiments of Sparwasser et al. (1998) and Hartmann at al. (1999), OCs were
isolated from a mixed cell population and were enriched to approximately 95-99% purity.
It is theoretically possible therefore, that a small percentage of other cells (monocytes or
lymphocytes) activated by ISODN were responsible for dendritic cell activation, although
it is highly unlikely.
. 1.3.2 In Vivo Effects of Immunostimulatory Oligodeoxyribonucleic Acids
In vitro testing has provided insight into the potential mechanisms and pathways
by which ISOON may activate the immune system. In vitro data suggest that ISOON
should enhance humoral and cell-mediated responses in vivo. Indeed, ISOON present
as tandem repeats in a plasmid, co-administered with protein antigen, or in plasmids
expressing an antigen did improve these immune responses. An early study by Sato et
al. (1996) examined the effects on antibody responses of two different plasmid
constructs, one encoding kanamycin resistance, and the other ampicillin resistance. The
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plasmids expressing ampicillin resistance demonstrated a 9-fold improvement in antigen-
specific antibody titers and it was believed that the presence of two additionallSOON
repeats within the ampicillin gene were responsible for enhanced activity. To clarify this,
ISOON sequences were added to the other plasmid expressing kanamycin resistance.
The addition of a single ISOON sequence elevated antibody titers by 17-fold and caused
a 5-fold increase in IFN-y production relative to non-modified plasmids (Sato et al., 1996).
Roman et al. (1997) characterized the immunomodulatory effects in mice of free
ISOON and of ISOON incorporated in plasmid. The addition of a single ISOON sequence
to plasmid caused low to moderate improvement in IgG2a antibody titers as compared to
mice treated with either alum and plasmid or with plasmid alone. Co-administration of
free ISOON with a plasmid vaccine resulted in a marked 17-fold increase in IgG2a
antibody production. Cytokine profiles also change in mice after treatment with plasmids
containing ISOON, as the IL-4:IFN-y ratio decreased from 17:1 in control groups to 2.5:1
in plasmid treated groups. Antibody responses and cytokine secretion profiles suggested
that both free ISOON and ISOON inserted within plasmids reduced predominantly Th2
type immune response to a more balance Th1 and Th2 type of response.
The co-administration of ISOON and protein antigen can also improve immune
responses in vivo. Oavis et al. (1998) injected ISOON with hepatitis B surface antigen
(HBSAg) into mice and showed an approximate10-fold increase in antibody titers as
compared to mice treated with the HBSAg vaccine formulated with alum. Similarly, mice
treated with HBSAg, alum and ISOON responded with an approximately 1DO-fold
increase in antibody titers when compared to mice injected with HBSAg and alum.
Interestingly, a more balanced immune response developed in mice with ISOON versus
mice treated with alum alone. Alum treatment generated a predominantly IgG1, Th-2
type immune response, while ISOON combined with alum generated a relatively equal
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IgG1/lgG2a.antibody ratio. The combined treatment of ISOON and alum caused a 35-
fold increase in total antibody titers when compared to alum treatment alone.
lmmunostimulatory OON combined with alum also improved CTl responses in cells
isolated from spleen. Treatment of isolated splenocytes with ISOON and alum induced
an approximately 40% increase in CTl activity, while the CTl activity in spleen cells
following treatment with alum alone was virtually nil.
In conclusion, ISOON either as a free form or inserted into plasmids, induce a
variety of cellular responses in vitro and enhanced acquired immune responses in vivo.
Thus, ISODN are being investigated as a potential adjuvant for vaccines.
1.3.3 Immunoneutralizing Oligodeoxyribonucleic Acids
The characterization of ISOON has implied that immune neutralizing-OON
(INOON) may be also present in prokaryotic and eukaryotic DNA and indeed it has been
demonstrated that the addition of either eukaryotic or prokaryotic DNA to cells can
reduce or eliminate immune activation. Unmethylated mammalian DNA when added to
mouse 8 cells will not elicit cell activation or enhance proliferative responses (Sun et a/.,
1997). It is believed that the lack of immune stimulation by mammalian DNA is not
entirely dependent on the state of methylation but related to some structural component
of the DNA. This idea is supported by the observation that the addition of non-CpG OON
. reduces immune activation induced by ISOON. In a macrophage cell line, Sparwasser et
al. (1998) demonstrated that non-CpG OON compete with ISOON and block intracellular
processing. This interference with DNA processing may result in a lack of activity and it
seems reasonable that within biological systems, direct competition between non-CpG
ODN and CpG OON might hamper cell stimulation.
Krieg et al. (1998) provided the definitive proof that INOON are indeed present
within biological systems. In mouse cells, these researchers showed that DNA from
different serotypes of adenovirus could prevent immune stimulation. Adenovirus
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serotype 2 caused a 4 to 5 fold reduction in IFN-a. and IL-6 secretion when compared to
cells treated with adenovirus serotype 12. Although both serotypes have approximately
the same number of CpG motifs, the sequences with CpG motifs vary. To elucidate
further the inhibitory effects of INODN on cytokine production, they inserted ODN from
adenovirus serotype 2 into known ISODN sequences. The introduction of these
neutralizing CpG motifs into the ISODN caused a 500/0 reduction in cytokine production
and cells that were treated with synthetic INODN produced very little cytokine.
1.3.4 Cellular Mechanisms by which Plasmid DNA and CON Activate Cells
The cellular mechanisms by which ISODN or plasmid DNA activates cells to
induce immune modulation are beginning to be understood. Recent experiments have
helped elucidate some of the events and possible mechanisms involved in immune
activation and these are discussed below.
1.3.4.1 Cellular Uptake
Leukocyte surface proteins readily bind large segments of foreign DNA in a
ligand-receptor-mediated fashion and this binding and subsequent internalization of DNA
can be abrogated by proteolytic digestion of these proteins. The scavenger receptor
expressed on macrophages and NK cells is one possible surface protein that may be
involved in DNA binding (Kimura et al., 1994). Using a competitive binding assay for
. DNA uptake, Kimura et al. (1994) demonstrated that large fragments of DNA are actively
taken up by cells and this uptake can be improved by flanking DNA sequences with
polyguanine tails. The authors suggested that NK cells and macrophages might use the
scavenger receptors to bind and internalize large fragments of DNA.
An inducible protein, Mac-1, located on granulocytes, macrophages and NK cells
has been shown to readily bind ODN. Binding of ODN to Mac 1 occurs in a saturable
manner and can be readily blocked by monoclonal antibodies. Treatment of
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granulocytes with TNF-a increases Mac-1 expression on the cell's surface and improves
OON induced cell activation (Benimetskaya et al., 1997).
Oligodeoxyribonucleotides can be bound by and internalized into a variety of cells
such as myeloid cells, fibroblasts and carcinoma cell lines, in a manner that is
temperature dependent and saturable. In one study it was shown that OON bind to a
surface protein that varies from 79-90 KO in size and is then transported into the cell by
receptor-mediated endocytosis. Additionally, another study using protein annealing
agents and inhibitors of endocytosis verified that OON bound to surface proteins prior to
internalization and internalization occurred via endocytosis. Labeling studies revealed
that approximately 1.2 x 106 receptors on the surface of a cell can bind to bacterial ONA.
Plasmid DNA blocks uptake of OON, suggesting that plasmid ONA and OON may bind to
the same protein for cellular transport (Yakubov et al., 1989).
Initially it was suggested that ISOON-induced cell activation required only surface
binding and not internalization. Free OON and OON coupled to sepharose beads
induced similar immune responses. The internalization of sepharose beads was not
deemed possible and the authors believed that immune stimulation was induced by the
binding of ISOON to surface receptors (Liang et al., 1996). This theory was disputed by
Manzel & Macfarlane, (1999) who suggested that sepharose beads were indeed
. internalized and when ISOON were coupled to particles that truly could not be
internalized, then cell activation did not occur.
Oligodeoxynucleotides may also be internalized by non-receptor-mediated
processes. In HL60 cell lines, OON were internalized at concentrations exceeding the
binding capacity of the receptor. Stein and Cheng (1993) suggested therefore that
uptake of OON occurs by fluid-phase pinocytosis and showed that hepatoma HEP 62
and HEP 2215 cell lines internalize OON by both fluid-phase endocytosis and absorptive
endocytosis.
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The method of OON internalization may therefore depend on the cell type and
internalization can either be a receptor-mediated process or a non-specific form of uptake
such as fluid-phase pinocytosis or absorptive endocytosis. It is evident that internalizing
OON through different methods helps ensure that neither OON nor bacterial DNA escape
contact with cells involved with immunosurveillance.
1.3.4.2 Pathways of Cell Activation by Oligodeoxyribonucleic Acids
The mechanisms by which ISOON cause cell activation are currently being
explored and it is believed that OON must be internalized to cause immune stimulation.
Once taken up by cells, OON are translocated to endosomes for acidification, an
essential step in cell activation by ISOON. Co-administration of ISOON and known
inhibitors of endosomal acidification, such as anti-malarial agents, blocked cell activation
(Hacker at al., 1998; Macfarlane & Manzel, 1998).
Following acidification in endosomes, ISOON enter the cytoplasm and
possibly the nucleus, with a small proportion of ISOON being released from the cell
(Tonkinson & Stein, 1994). Immunostimulatory OON bind to a receptor within the
cytoplasm prior to cell activation. This internal receptor has not been conclusively
identified but the Toll like receptor-9 (TLR-9) is considered the most likely candidate
(Hemmi at al., 2000; Krieg & Wagner, 2000). Within minutes after internalization,
. TLR-9 links ISOON to the myeloid differentiation marker 88 (My088) and tumor
necrosis factor receptor-associated factor 6 (TRAF6) and leads to subsequent
activation of the ER1 JNK1 and P38 stress kinases (Hacker at a/., 2000). Binding of
ISOON to My088 is essential for cell activation, as mice deficient in My088 fail to
respond to ISOON treatment (Hacker at al., 2000; Krieg & Wagner, 2000).
The activation of JNK1 and P38 kinases causes phosphorylation of the c-
JUN and ATF2 and this leads to activation of the transcriptional factor, activating
protein-1. Activating protein-1 is involved in the integration of other signal pathways
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that are either directly or indirectly involved with the expression of cytokines such as
IL-6, TNF-a and IFN-y (Hacker et al., 1998). In addition to activating the JNK1 and
P38 pathways, ISOON can induce expression of NFKB and increase the production
of cytokines through oxygen dependent processes. Using a mouse B cell line, Yi et
al. (1998) demonstrated an approximately 300/0 increase in the production of
intracellular oxygen following ISOON treatment. Adding an anti-oxidant to pre-
stimulated B cells followed by treatment with ISOON caused a marked reduction in
IL-6 production.
In conclusion, the mechanisms by which ISOON induce cell activation include the
internalization and translocation of ISOON to endosomes for acidification, transport of
ISOON to the cytoplasm leading to activation of protein kinases and oxygen reactive
species that are important in gene transcription and cytokine release. It is apparent that
signaling pathways involved in cell activation are complex and could allow for the
integration of different signals induced by different ligands (Krieg & Wagner, 2000).
1.3.5 Innate Immunity
A review of innate immunity was made by Medzhitov and Janeway (1997).
For decades, most immunologists focused their attention on studying lymphocyte
function and the development of acquired immunity. They have generated vast
. amounts of information on both the molecular and cellular events that arise during
the induction of humoral and cell-mediated immunity. During their endeavors,
however, they have generally neglected to evaluate the importance of cells
associated with the innate immune system on the induction of acquired immunity.
Indeed, it has now become apparent that the innate immune system controls events
involved with both the initiation and type of immune response that arises after
exposure to a pathogen.
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The innate immune system is phylogenetically older than the acquired immune
system as it is found in all multicellular organisms and uses receptors encoded in
germline ONA (Fearon & Locksley, 1996). The conservation of these receptors suggests
that the innate immune system recognized and eliminated pathogens prior to the
development of the adaptive immune system. To protect against foreign invaders, cells
of the innate immune system have developed receptors that recognize structures that are
unique to microorganisms and essential for the microbial survival. These receptors also
have perfect self-nonself discrimination, a hallmark of innate immunity (Medzhitov &
Janeway, 1997). The molecular structures found in microorganisms are known as
pathogen-associated molecular patterns (PAMP) and are recognized by either soluble
proteins or cell surface receptors known as pattern recognition receptors (PRR) (Table
1.1 ).
As discussed previously (see section 1.31), ISOON can induce the release of
cytokines and chemokines (Krieg et al., 1995; Klinman et al., 1996; Iho et al., 1999;
Takeshita et al. t 2000), increase expression of costimulatory molecules (Sparwasser et
al., 1998; Hartmann et al., 1999) and enhance effector functions (Ballas et al., 1996) of
previously untreated cells. The CpG motifs present within ISOON are responsible for
many of these cellular responses by directly activating cells associated with innate
. immunity. CpG motifs are therefore considered to be PAMP that bind to PRR of different
cell populations (Krieg & Wagner, 2000).
1.3.5.1 Disease Protection by ISODN Activation of Innate Immunity
Immunostimulatory CON can induce cell activation in vitro and enhance
humoral and cell-mediated immunity in vivo. Since the activation of cells in vitro
suggested that CpG motifs were PAMP and activators of innate immunity, CpG
motifs should protect against infectious disease in an antigen-independent manner.
Recent studies have shown that ISOON, in the absence of conventional vaccines or
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Table 1.1 Selected Ligands and Receptor Involved in Innate Immunity.
Receptor Site of Expression Ligand Function
85 Humoral - liver 1) Polysaccharides 1) Activate complement
2) Enhance P<I>,
SAP Humoral - liver 1) Microbe cell wall 1) Enhance P<I>,
polysaccharides 2) Stabilized EC matrix
2) EC matrix proteins proteins
LBP Humoral - liver 1) LPS transfer to 1) Enhance sensitizing
CD14 and lipoproteins of cells to LPS
Mannose Macrophages Multiple carbohydrates 1) Targeting to cells
Receptor Dendritic cells expressing MHC-II
Endothelial cells
Scavenger Macrophages 1) Bacterial and yeast 1) Clearance of LPS
Receptors Endothelial cell cell walls and microbes
HEV 2) Bacterial DNA 2) Cell activation
LPS Receptor Macrophages 1)LPS 1) Microbe clearance
(CD14) Monocytes 2) Other microbial cell 2) Enhance LPS
PMN wall components sensitivity
3) Induce inflammatory
cytokine release
Complement Macrophages 1)LPS 1) Activates B cells
Receptors Monocytes 2) Complement 2) LPS clearance
B cells 3) Fibrinogen 3) Complement
Dendritic cells cleavage
Toll Receptor Macrophages 1)LPS 1) Cytokine production
Monocytes 2) Bacterial DNA 2) Cell activation
Dendritic cells
The table modified from Fearon & Locksley, (1996) and Krieg & Wagner, (2000)
Abbreviations: CRP C-reactive protein; SAP serum amyloid protein; LPS lipo-
polysaccharide; LPB LPS binding protein; P<I> phagocytosis; EC extracellular; HEV
high endothelial venules; PMN polymorphonuclear leukocyte.
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DNA vaccines, can enhance the ability of mice to survive challenge with a variety of
pathogens. Mice were injected with 50 Jlg of ISOON ip and challenged with Listeria
monocytogenes over a period of 14 days post-injection. All mice treated with OON
containing CpG motifs survived challenge, while mice treated with GpC OON
succumbed to disease. The experiment was then extended for a four-month period
and mice were injected with ISOON containing CpG motifs every 14 days. Similar to
the observations of the first experiment, only mice receiving ISOON with CpG motifs
survived challenge. Protection was relatively short-lived however, as animals died
from bacterial challenge one month following the last ISOON injection (Klinman et
al., 1999). The authors believed that protection was mediated by increased
secretion of IL-6 and IFN-y by various cell types and that CpG motifs lowered the
threshold necessary to induce cell activation.
In another study, it was shown that OON with CpG motifs protect mice against
infectious peritonitis. Using the colon ascendens stent peritonitis model, Weighardt et al.
(2000) demonstrated that mice treated with OON containing CpG motifs had improved
survivability and a diminished bacterial load in the peritoneal cavity when compared to
GpC OON controls. They showed enhanced systemic levels of IL-10 and IL-18 had a 4-
fold increase in the number of neutrophils present within the abdominal cavity. There
. was also increased expression of cell receptors such as Mac-1 and FCRy on neutrophils
as well as enhanced effector function that included both increased phagocytosis of
bacteria and increased respiratory burst activity. The authors believe that the rapidity of
response and improved activation of neutrophils by ISOON with CpG motifs indicate that
CpG motifs may directly activate an innate rather than acquired immune response.
These examples show that CpG motifs may indeed offer a degree of protection against
various bacterial diseases.
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Although the use of either bacterial DNA or ISODN for protection against
infectious disease has potential clinical application, there are some limitations to this type
of treatment. Firstly, treatment with bacterial DNA or ISODN is only effective when
administered prior to challenge with the microorganism. As an example, Elkins et al.
(1999), demonstrated that protection against bacterial challenge occurred when either
bacterial DNA or ISODN were given to mice 3-14 days prior to exposure with Listeria
monocytogenes. If mice were both treated with bacterial DNA or ISODN and exposed to
bacteria on the same day, the mice succumbed to disease. Secondly, bacterial DNA or
ISODN treatment was only protective against challenge with intracellular organisms: mice
infected with Y. enterocolitica failed to survive the challenge (Elkins et al., 1999).
1.3.6 Safety Issues
Identifying potential health hazards throughout the development of new
biotechnologies is of utmost importance. The use of plasmid DNA and ISODN in people
and animals is of no exception, with the potential development of at least seven types of
adverse reactions as well as perhaps those yet unforeseen. Firstly, plasmid DNA could
randomly integrate into the host genome and lead to the inadvertent activation of proto-
oncogenes, inactivation of tumor suppresser genes or inactivation of genes involved in
regulation of cell processes. Secondly, DNA vaccines might alter the 'appearance' of the
. host cell and thereby initiate an autoimmune state within the host. Thirdly, plasmid
vaccines might induce antigen tolerance or disease enhancement within the vaccine
recipient. Fourthly, immunostimulation and the release of cytokines might cause local or
systemic inflammatory responses. Fifthly, deviation of immune responses and a
subsequent inability to respond appropriately to infection could occur. Sixthly, long-term
exposure to antigen may be detrimental or lead to disease, and finally, plasmid used in
animals might be transferred to people following meat consumption. Each of these
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potential risks will be further discussed in detail with an attempt to evaluate real or
perceived risk of exposure to either plasmid DNA or ODN.
1.3.6.1 Integration of Plasmid into the Host Genome
Plasmid DNA can persist in tissue for many months post-vaccination. In general,
intact plasmid or plasmid fragments are thought to be localized epichromosomally and do
not covalently integrate into the host's genome. Plasmid DNA was injected iv into mice
and tissue samples were subsequently collected at various time points. Tissue
assessment for plasmid remnants by polymerase chain reaction (PCR) amplification,
indicated that the majority of plasmid DNA underwent degradation within minutes of
injection, but fragments of DNA remained present within muscle for up to six months.
The amount of DNA present within the nucleus was exceedingly small at roughly 0.012
copies of plasmid per genome (Lew et al., 1995). It was not determined, however,
whether the plasmid fragments were incorporated into the host genome.
To prove conclusively that plasmid DNA does not incorporate into the host's
genome, it must be demonstrated that neither contamination with other plasmids has
occurred nor has foreign DNA annealed to the host's genome. Using PCR to detect
plasmid DNA can be problematic, as contaminating DNA will inadvertently be amplified to
give a false positive result. To prevent false positives from arising, Nichols et al. (1995)
. used stringent isolation techniques and single sided PCR to analyze for plasmid content
after treatment. The researchers analyzed muscle tissue at 1, 2, 3, 6, 12 and 18 weeks
following im injection and confirmed that plasmid DNA did not incorporate into the host
genome but remained epichromosomal. They estimated that approximately 7.5 copies of
plasmid per 1 J.l.g of genomic DNA was present in tissue after DNA vaccination. Using
risk analysis to define a 'worst case scenario', the researchers assumed that if all 7.5
copies of plasmid incorporated into genomic DNA, the incorporation frequency of plasmid
would still be 1000-fold lower than the natural rate of spontaneous mutation within the
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genome. This analysis suggests that if plasmid DNA does incorporate into the genomic
DNA, the effects would likely be inconsequential.
A single study exists, however, demonstrating that foreign DNA could incorporate
into the host genome. Schubbert et al. (1997) delivered phage DNA orally and then
detected the presence of the phage DNA within the genomic DNA of splenic B cells, T
cells, and macrophages and in gut epithelium of treated mice. To prove that the DNA
was indeed of phage origin, they cloned DNA segments from mouse tissue containing
phage DNA and then hybridized it to native mouse genomic DNA. They found that one
cloned DNA segment hybridized to the mouse IgE gene while two other cloned segments
hybridized to distant but unidentified sites of the mouse genome. The hybridization of
plasmid to the IgE gene could lead to either impaired antibody function or malignant
transformation of IgE producing B cells, both having potential clinical ramifications.
1.3.6.2 Auto-immune Potential of DNA Vaccines
The potential for evoking auto-immunity by DNA vaccination poses a concern and
could limit the use of DNA vaccines in a clinical setting. The ability to generate
antibodies to bacterial DNA has been known for several decades. Healthy people and
patients with systemic lupus erythematosus (SLE) were tested for antibody binding to
mammalian and prokaryotic DNA. Serum from healthy people bound strongly to DNA
. from Gram-positive organisms but did not bind to calf thymus DNA. In comparison,
serum from SLE patients bound to calf thymus DNA as well as to DNA from Gram
positive and Gram negative organisms (Karounos et al., 1988).
Although the development of cross-reactive antibodies to mammalian DNA after
bacterial DNA injection is possible, definitive proof for the induction of autoantibodies by
bacterial DNA has not been demonstrated. To address this issue, Gilkeson et al.
(1993;1996) injected bacterial DNA into both BALB/c and New Zealand black/white
(NZB/NZW) mice and demonstrated the development of immune mediated
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glomerulonephritis. Mice treated with bacterial DNA administered with bovine serum
albumin (BSA) in Freund's adjuvant, had high anti-DNA antibody titers and enhanced
proliferation of glomerular tufts with increased deposition of IgM, IgG and C3 of
complement within the mesangium. Unfortunately, treatment of mice with bacterial DNA
alone was not included and therefore it is difficult to determine from this study if bacterial
DNA alone can induce the production of autoantibodies.
Another study demonstrated that injection of DNA produced antibodies that cross-
reacted with mammalian DNA. Deoxyribonucleic add from E. coli was injected into mice
and serum was collected. Antibodies in the collected serum bound to calf thymus DNA
with approximately 50% of the efficacy of antibody binding to E. coli DNA. This
observation supported the conclusion that the antibodies were cross-reactive (Gilkeson
et al., 1998).
To determine if changes in cytokine profiles occur in mice following injection with
bacterial DNA, NZB/NZW mice were injected with DNA from E. coli. It was shown that a
substantial change in the ratio of cells secreting IFN-yand IL-4 occurred in isolated
spleen cells. Gilkeson et al. (1998) demonstrated a 10 to 25-fold increase in the ratio of
IFN-y: IL-4 secreting cells, suggesting that bacterial DNA induced a Th1-like immune
state of activation and thereby could reduce the potential to develop SLE. It is believed
that SLE manifest as a predominantly Th2 immune response with elevated levels of IL-4.
The presence of bacterial DNA within vertebrates may induce a cell-mediated
form of auto-immunity. The transfer of activated antigen-specific T cells from mice
susceptible to experimental allergic encephalomyelitis (EAE) to normal mice can induce
disease within the recipient. Thymocytes from EAE mice were primed with antigen and
exposed to either ISODN or a non-stimulating form of ODN and then injected into
untreated mice. Mice receiving ISODN treated T cells developed moderate to severe
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EAE, while mice receiving T cells treated with non-stimulating ODN remained
asymptomatic. The authors speculated that activation of T cells by ISODN resulted in the
induction of IL-12 and a subsequent increase in IFN-y levels. It is believed that exposure
to bacterial DNA during an infection could perhaps inadvertently lead to a Th1 type
autoimmune state (Segal et al., 1997).
1.3.6.3 Potential for Immunological Tolerance
The development of immunological tolerance can be potentially life-threatening, in
particular if an individual is unable to recognize a pathogen as foreign and mount an
appropriate protective immune response. The development of immunological tolerance,
however, is unlikely to occur in adults. As previously described, administration of low
doses of plasmid expressing antigen can generate long-term immunity and protect
against disease (Ulmer et al., 1993; Deck et al., 1997). Vaccination with DNA in the
neonate has also induced both strong humoral and CMI (Butts et al., 1998). There
remains, however, the potential to induce immunological tolerance in the neonate after
vaccination (Silverstein & Segal, 1975) and indeed it has been documented that mice can
become tolerant to antigen following DNA vaccination (Mor et al., 1996). Mice between
two and five days of age failed to generate antigen-specific antibodies or CTL responses
and failed to secrete IL-4 and IFN-y from splenocytes following an injection of plasmid
. DNA expressing the circumsporozite protein (CSP) of Plasmodium yoelii. No
improvement in immune responses was detected after a vaccine boost at six week of age
either. Interestingly, neonates exposed to antigen co-administered with the DNA vaccine
developed strong humoral and CMI indicating that delivery of plasmid with protein may
prevent the development of immune tolerance.
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1.3.6.4 Enhancement of Disease
A potential risk of DNA vaccination is the failure to develop protective immunity
and to enhance the progression of disease. This was demonstrated in a feline
immunodeficiency virus (FIV) vaccine study, in which cats were injected with DNA
expressing different envelope proteins and then exposed to virus. Cats immunized with
the DNA vaccine developed poor antibody titers and demonstrated markedly elevated
virus titers that began one week earlier than control groups and remained elevated for
the duration of the experiment (4 weeks). There was a direct correlation between
vaccine induced antibody titers and elevated virus titers, as increased antibody levels
paralleled the increase in viral loads (Richardson et al., 1997). Unfortunately,
immunization with viral protein alone was not performed in this experiment, as this was a
necessary control to determine whether an inappropriate vaccine antigen had been
selected for protection against disease. It is possible that DNA vaccines expressing a
different viral antigen may have been successful in disease prevention. From the
experiment, however, the data convincingly shows that viral multiplication was
accelerated following the injection of plasmids expressing viral antigens and that DNA
vaccines may inadvertently enhance some diseases.
1.3.6.5 Development ofUnintentional Local and Systemic Inflammation
From previous discussions, it is apparent that the adjuvanticity of ISODN is partly
dependent on the production and release of cytokines. It has been suggested that a fine
balance between adjuvanticity and toxicity is always present and the absolute safety of
the adjuvant is never guaranteed (Gupta et al., 1993). Therefore, the potential exists for
an ISODN adjuvant to cause both local and systemic adverse responses. Administration
of bacterial DNA or ISODN into joints (Deng et al., 1999) or lower airways (Schwartz et
al., 1997) in mice caused a severe inflammatory reaction. Comparing calf thymus DNA
to bacterial DNA or ISODN, Schwartz et al. (1997) demonstrated a 4-fold increase in the
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numbers of neutrophils, production of macrophage inhibitory protein-2 and a 2-fold
increase in TNF-a levels within lung lavages from animals treated with bacterial DNA or
ISODN. Similarly, Deng et al. (1999) showed that the inflammatory lesions produced by
intra-articular injections of bacterial DNA or ISODN were dependent upon the presence
of macrophages and elevated expression of TNF-a.
To ensure that the inflammation was due to treatment with either bacterial DNA or
ISODN and not LPS contamination, mice were either given LPS and used as controls
(Schwartz et al., 1997) or a specialized mouse strain (C3H/Hej) that is unresponsive to
LPS was used in certain experiments (Deng et al., 1999). In these studies, it was shown
that inflammation was indeed caused by exposure to bacterial DNA or ISODN and not by
LPS. Treatment with quantities of LPS that equaled the amount of LPS present in
bacterial DNA preparations did not induce detectable inflammation within the airways
(Schwartz et al., 1997).
Most DNA vaccine studies demonstrated minimal tissue damage following im
injection. In a single study, however, injection of plasmid DNA into mice either previously
exposed to virus or vaccinated with DNA expressing a viral antigen, caused severe
myositis that persisted for at least 4-days post-exposure. The inflammatory lesions were
dependent on the presence of CTL and on the immune status of the mice prior to
treatment. The authors speculated that inflammation may have been caused by
expression of virus antigen within muscle cells (Yokoyama et al., 1997).
Adverse systemic effects after ISODN treatment have been documented as well.
Intraperitoneal injection of ISODN in mice can cause substantial elevations of TNF-a in
blood. In ~-D-galactosamine (~-GaIN) sensitized mice for example, treatment with 2.5-5
nmol (15-30 J.lg) of ISODN can induce massive liver cell apoptosis and it is believed to be
related to elevated levels of serum TNF-a (Sparwasser et al., 1997). It is noteworthy that
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the amount of ISOON used in the experiment is well within ranges used in other mouse
experiments (Klinman et al., 1997; Oavis et al., 1998; Lipford et al., 2000). It is likely that
sensitization to ~-GaIN caused mice to release more TNF- a. systemically and thereby
cause liver injury. It is evident from the study, however, that massive release of TNF-a.
into circulation following ISOON treatment is detrimental and an undesirable side effect.
Studies have recently been performed to evaluate the long-term effects of
multiple ISOON injections in mice. Evidence demonstrated convincingly that ISOON
does not cause unwanted side effects following multiple treatments (Klinman et al.,
1999). In this experiment, previously untreated mice were injected weekly with 50 /-1g of
ISOON ip over a four-month duration. All mice survived and none of them displayed
either clinical signs of illness, or developed inflammatory lesions within sampled tissue.
The lack of mortality and tissue injury following ISOON injection differs from observations
seen by Sparwasser et al. (1997). It is evident therefore, that the immune status of the
animal prior to ISOON treatments, as seen in the experiment by Sparwasser et al.
(1997), can greatly influence the development of adverse reactions.
1.3.6.6 Long-term Expression of Antigen
Although long-term expression of antigen in tissue has obvious advantages, it
may pose a potential hazard as well. It has been suggested that the development of
antibodies specific for one strain of influenza virus may reduce the capacity of the
immune system to protect against a different strain. Newman et a/. (1993) vaccinated
people with two different influenza vaccines and showed that robust antibody responses
were strain specific. Only one group of vaccinated recipients however, developed strong
cross-reactive antibodies (Newman et al., 1993). The researchers suggested that prior
exposure to a wild strain of influenza and the persistence of viral antigen prevented the
development of cross-reactive antibodies in one of the vaccinated groups. This concern
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may be unwarranted as DNA vaccines can induce a strong cell-mediated response that
cross protects against different viral strains (Ulmer at al., 1993).
Persistent long-term exposure to foreign DNA within cells might also be
potentially hazardous. Several chronic diseases have been associated with the presence
of foreign viral RNA within tissues. For example, a study examining muscle biopsies
from patients with chronic fatigue syndrome demonstrated that 500/0 of all affected
patients had fragments of enterovirus RNA present within cells (Gow at al., 1991). It is
difficult to compare this investigation with DNA vaccine studies as the quantity of RNA
present in cells was not determined. The long-term effects of plasmid DNA incorporated
into cells are unknown. It is possible that the long-term presence of plasmid in cells is
hazardous, but it will take decades to determine this, as the use of DNA vaccines in
clinical trials has just begun.
1.3.6.7 Transfer of Foreign DNA Through Meat Consumption
Use of DNA vaccines in food producing animals raises safety concerns distinct
from the use of DNA vaccines in people. The presence of foreign DNA in meat after im
injection and the subsequent ingestion of treated meat might lead to the inadvertent
transfer of plasmid DNA to people. To address this concern, Babiuk at al. (1998) injected
calves im with plasmid and then excised the injection site three weeks later. The excised
. muscle was fed to rats and various rat tissues were examined for plasmid remnants by
peR amplification. Fragments of plasmid were not detected in any tissue suggesting that
transfer of foreign DNA to the consumers will likely not occur. Furthermore, methods of
vaccine delivery such as id injection and ballistic (gene gun) delivery can greatly reduce
the amount of plasmid used for DNA vaccination and thereby further reduce any potential
for the transfer of plasmid from livestock to people.
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1.3.7 Oligodeoxyribonucleotides and the T-helper Paradigm
Understanding the categorization of T helper cells is important for determining the
effects of DNA vaccines and ISOON on T cell activation. For a review on T helper
subclasses see Romagnani (2000). Briefly, T helper cells were initially characterized into
type 1 and type 2 T helper cells according to the type of cytokines produced and their
influence on the types of antibodies produced by B cells. T helper 1 cells (Th1 ) produce
predominately IFN-y, IL-2, TNF-a, supported B cell production of opsoninising antibodies
(lgG2a) and the development of CTL responses. T helper 2 cells (Th2) produce IL-4, IL-
5, IL-6, IL-9, IL-10, IL-13 and support antibody responses associated with IgG1 and IgE
production. This T helper cell classification has been expanded to include type 0 helper
cells that express both Th1 and Th2 cytokines and type 3 helper cells that express high
levels of TGF-~. The type of T helper response that develops is affected by cross
regulation between various cytokines. The production of IFN-y for example, greatly
inhibits proliferation of Th2 cells while IL-4 inhibits Th1 proliferation. Furthermore, certain
cytokines such as IFN-y and IL-4 are exclusively produced in Th1 and Th2 type immune
responses, respectively.
In vitro and in vivo experiments suggest that ISOON shift T helper cells towards a
Th1 bias. Using C04 T cells from mice, Zimmermann et al. (1998) demonstrated that
unstimulated T cells secrete IL-4: IFN-y at a ratio of approximately 10:1. If these cells
were treated with either a moderate or high concentration of ISOON, the IL-4:IFN-y ratio
changed to approximately 1:24 and 1:60 respectively. Furthermore, ISOON treatment
caused a greater reduction in the IL-4:IFN-y ratio than treatment with anti-IL-4 alone. To
determine if ISOON caused a bias in Th2 and Th1 cell activation in vivo, the researchers
examined changes in the immune function of BALB/C mice following challenge with
Leishmania major. Mice treated with ISOON survived challenge while untreated mice
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died eight weeks later. Examination of isolated T cells from both experimental groups
revealed that untreated mice produced high amounts of IL-4 and no IFN-y. In contrast,
ISOON treated mice did not produce IL-4 but produced large amounts of IFN-y. Treated
mice also had reduced production of IgG1 and increased production of IgG2a and IgG2b
antibodies. Zimmermann et al. (1998) also examined the levels of ILR12B2 (IL-12
receptor) mRNA expression. The ILR12B2 expression was increased in Th1 cells and
abolished in Th2 cells, and it was demonstrated that ISOON treated mice strongly
expressed ILR12b2 while expression of the mRNA was undetectable in untreated mice.
These results indeed verified that in mice treated with ISOON, there was a clear shift in T
helper cell development with a Th1 bias.
1.3.8 Conclusion for the DNA Vaccination Section
Plasmid ONA and ISOON have demonstrated remarkable biological activity in
vitro and in vivo. The potential use of antigen-encoding plasmids for vaccines and
ISOON as adjuvants may revolutionize immunoprophylaxis and gene therapy in the
future. Currently, we are beginning to achieve a greater understanding of mechanisms
involved in bacterial ONA immune stimulation. As research continues in the area of ONA
immunization and immunostimulation, improvements in immune protection should occur,
hastening the implementation of ONA vaccines and ISOON into clinical trials.
. 1.4 Introduction to Lymph Nodes
Lymphoid tissues are structures that play an integral role in immune
surveillance and lymphocyte development. These exist either as diffusely dispersed
tissue as seen in the alimentary and respiratory tracts or as discrete localized
structures such as thymus, spleen and lymph nodes (LN). As LN act as points of
immune surveillance, the induction of immune responses and are pivotal in
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lymphocyte movement between blood and lymph, this section will examine the
structure-function relationships of LN.
1.4.1 The General Structure of Lymph Nodes
A detailed review of LN morphology is given by Junqueira (1986). Briefly, LN
are encapsulated structures containing a subcapsular sinus, cortex and medulla.
The cortex consists of both a superficial and a deep (paracortex) compartment. The
medulla is composed of cords and sinuses. Lymph nodes are also highly
vascularized and well innervated with arteries and nerves entering the LN and the
vein exiting the hilar region of the LN. Lymph enters the LN via the afferent
lymphatics connecting to the capsular surface of the LN and lymph exits through
valved efferent lymphatics at the hilum. The internal framework of the LN is
composed of a fine trabecular meshwork of reticular fibers that acts as scaffolding to
maintain structural integrity (Wheater, 1987).
1.4.1.1 Cortex
The cortex is one of two major regions of the LN and is subdivided into
superficial cortex and the deeper paracortex. Between the superficial cortex and the
capsule lies the subcapsular sinus. The spherical lymphoid follicles (primary
follicles) of the superficial cortex contain small dark staining non-reactive B cells
. admixed with few dendritic cells (van der Valk & Meijer, 1987). The paracortex is
predominantly composed of T cells and small numbers of dendritic cells. This region
also contains specialized high endothelial venules (HEV), structures associated with
lymphocyte migration from the blood to LN.
1.4.1.1.1 Primary Follicle and Germinal Centers
Germinal centers (GC), also known as secondary follicles, arise from primary
follicles following stimulation with antigen. Stimulation with foreign antigen is a
prerequisite for GC development, as GC are not detected in germ free animals (Kim
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& Watson, 1971} Surrounding the GC is the mantle zone, composed of cell
populations found in primary follicles. Monoclonal antibody studies in man verified
that the cells within the mantle zone are small B cells that express slgM, IgO, C023,
C039 and C044 antigens (Maclennan et al., 1992; lagresle et al., 1993) and
produce alkaline phosphatase (van der Valk & Meijer, 1987).
1.4.1.1.2 Lymphoid Cells
lymphoid cells of the GC are categorized into centroblasts, centrocytes and
Iymphoblasts. Centroblasts are actively dividing cells and appear as large round
cells, with sparse basophilic cytoplasm and express little to no surface
immunoglobulin (slg) (Maclennan et al., 1991). Nuclei are vesicular with prominent
nucleoli and mitotic figures are abundant (Maclennan etal., 1991). Centrocytes
may be either small or medium sized and develop from centroblasts (Nieuwenhuis &
Opstelten, 1984). Medium sized centrocytes have large nuclei with fine stippled
chromatin, while the nuclei of small centrocytes have condensed chromatin and
clefts. The cytoplasm in both cell types is sparse (Nieuwenhuis & Opstelten, 1984).
B Iymphoblasts, less common than either centroblasts or centrocytes, have medium
sized nuclei with in indistinct nucleoli and scant to moderate amounts of dark
basophilic cytoplasm (van der Valk & Meijer, 1987). Other lymphoid cells occurring
. with lower frequency within GC include NK cells, T cells and plasma cells
(Namikawa et al., 1987; Janossy et aI., 1989; Seva et al., 1998).
1.4.1.1.3 T Cells
Although T cells are a major population of IN, only smaller numbers of T
cells have been identified within GC. In a well-differentiated GC, T cells are located
in areas adjacent to the mantle zone (Nieuwenhuis & Opstelten, 1984; Imai &
Yamakawa, 1996). In mice, these T lymphocytes are predominately C04 T cells
and these cells are believed to assist in germinal center development (Secord et al.,
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1996). The C04 T cells out-number other T cells, such as C08 T cells, by 12:1
(Rouse et a/., 1982).
1.4.1.1.4 Tingible-Body Macrophage
Tingible-body macrophages (TBM) are macrophages with a starry-sky
appearance and are present within active GC, appearing several days after antigen
exposure. Initially these macrophages were considered to be scavengers of
apoptotic cells as they could be identified engulfing dead lymphocytes within either
reactive or involuting tissues (Fadok et a/., 1992). It is becoming apparent, however,
that TBM may also regulate GC development. /n vitro studies with hybridoma cells
demonstrate that these macrophages reduce production of IL-2 by B cells. The
authors suggest that TBM may also playa role in the down-regulation GC growth
(Smith et a/., 1998). Interestingly, the number of macrophages present within GC
parallels GC growth, as the number of macrophages remains in relatively constant
proportion to the increasing number of B cells during the enlargement of GC.
1.4.1.1.5 Follicular Dendritic Cells
Dendritic cells are categorized into Band T lymphocyte-associated cells.
The B cell-associated follicular dendritic cells (FOC) are found within follicles, while T
cell-associated dendritic cells are located in non-follicular areas. Initially, Chen et al.
. (1978) coined the term FOC to describe specific cells located in GC that trap antigen
complexes. Tew et ala (1982) further defined them as cells located within follicles
that lacked Thy-1 antigen and slgM and express C3 and Fe receptors. Presently,
FOC are categorized by the following: 1) their location within a GC, 2) fulfilling rather
stringent immunohistochemical and ultrastructural criteria, 3) their ability to trap and
retain antigen for prolonged periods and 4) association with B cells. Accordingly,
seven subtypes of FOCs have been identified and the undifferentiated and
differentiated forms of these cells are located within the dark and light zones of GC
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respectively (Imai & Yamakawa, 1996). Follicular dendritic cells have a plethora of
functions within GC. They function as part of GC scaffolding and are tightly
associated with the reticular fibers and cytoskeleton proteins of reticular cells
(Gloghini & Carbone, 1990; Ogata et al., 1996). Antigen trapped on FOC is
presented to B cells as immune complex coated bodies (iccosomes) and FOC help
activate B cells to transform into plasma cells (van Rooijen, 1990). Follicular
dendritic cells can also prevent induction of apoptosis in B-Iymphocytes. Using
isolated tonsillar lymphocytes and dendritic cells, Lindhout et al. (1993)
demonstrated that cells forming FOC-B cell clusters survive in culture for long
periods while B cells not associated with FOC rapidly undergo apoptosis. This was a
T cell independent process, as T cells were not detected within these clusters.
1.4.1.1.6 The Anatomical Structure and Development of Germinal Center
Germinal centers are the site of clonal expansion and differentiation of B
lymphocytes (Kroese et al., 1987; Liu et al., 1989). Germinal center development
has been extensively studied in human tonsillar tissue and based on light
microscopy of hematoxylin and eosin stained LN sections, the GC have been
divided into four relatively distinct anatomical regions (van der Valk & Meijer, 1987).
These are the dark, basal light, apical light and outer zones. The area that lies
closest to the medulla is the dark zone and this region is surrounded by a pale area
composed of two zones, the basal light and the apical light, respectively.
Surrounding the entire GC is the outer zone and this zone is the most peripheral
area of a GC. The mantle zone surrounds the outer zone but is not considered part
of the GC.
1.4.1.1.7 Dark Zone
The dark zone is the main site of GC cell proliferation and contains numerous
centroblasts that express various activation markers. Using immunofluoresence in
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human tonsillar tissue, Hardie et al. (1993) demonstrated that the dark zone contains
the highest population of cells undergoing mitosis and expressing markers for B
lymphocyte activation. Within the dark zone, there is a rapid transformation of
centroblasts into centrocytes. The cell cycle for centroblasts lasts approximately
seven hours and therefore, within a 24-hour period the de novo production of
centrocytes can be substantial. In the dark zone, re-arrangement of IgV genes
occurs within centroblasts through somatic mutations (Maclennan et al., 1992).
This takes place within the first few days following antigenic stimulation with a
mutation rate that exceeds pre B-cells by approximately1 0 fold (Berek, 1992).
Unlike other zones, TBM and FOe numbers are low within the dark zone suggesting
that interactions with B cells are minimal. Indeed, few FOC-B cell clusters are found
within this area (Kasajima et al., 1986; Imai et al., 1998).
1.4.1.1.8 Basal Light Zone
The basal light zone lies adjacent to the dark zone, contains both
centroblasts and centrocytes and the highest number of apoptotic cells of all zones
in a GC. The expression of cell markers, high cell turn over rate and presence of
FOC suggests that the basal light zone is an important area for the regulation of B
cell maturation. The importance of expression of cell markers on centrocytes is
. highlighted by Liu et al. (1989). Studies on isolated human tonsillar B cells showed
that GC centrocytes not expressing C039 or IgO died rapidly by apoptosis. In
contrast cells expressing these molecules survived for longer periods. The authors
suggested that this form of regulation would ensure that only centrocytes with high
antigen affinity would survive to give rise to memory B-cells. Interaction with FOC in
the basal light zone is likely an important regulatory event to ensure only antigen-
specific stimulated B-Iymphocytes expand and differentiate. Indeed, within this
zone, FOC are well organized with numerous intercellular connections and they
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express activation markers including cell adhesion molecules (Imai & Yamakawa,
1996). This is further exemplified by the numerous tight FOC-B lymphocyte clusters
found in this zone.
1.4.1.1.9 Apical Light Zone
The apical light zone contains mainly medium sized centrocytes that display
little mitotic activity and undergo little apoptosis. In this area, it is believed that
centrocytes differentiate into memory B-cells and plasma cells, enabled by free
antigen or antigen presented as iccosomes (van Rooijen, 1990). Follicular dendritic
cells are in the highest concentration in the apical light zone, and these cells are
activated as demonstrated by the enhanced expression of activation markers.
Nematode challenged mice demonstrated marked increases in the expression of the
complement receptor (FC,RII) receptor on FOCs located within this area (Maeda et
al., 1992). Similar to the basal light zone, this zone has many tight FOC-B cell
clusters and these are likely important for FOC and B cell communication. Major
isotype class switching also occurs within the apical light zone. The small numbers
of T cells which have been identified in this zone may facilitate this by expressing
C040-ligand and secreting IL-4 and IL-10, key elements required for class switching
(Liu & Arpin, 1997).
1.4.1.1.10 Outer Zone
A heterogeneous population of cells varying from centroblasts, centrocytes
and plasma cells is found in the outer zone (Imai et al., 1998). Occasional T cells,
mainly C04 T cells, are identified at the dark zone-mantle interface (Rouse et al.,
1982). Interestingly, in contrast to the tight FOC-B cell clusters detected within the
basal and apical light zones, the FOC in the most basal area of the outer zone do
not form tight clusters with B cells (Imai &Yamakawa, 1996). The reason for this
61
altered FDC-B cell relationship within the outer zone compartment remains
unknown.
1.4.1.2 Paracortex
The paracortex is the cortical area surrounding follicles that extends to the
medulla. It is composed of loosely arranged cells and consists of predominately T
cells with rare interdigitating dendritic cells (IDC) (Junqueira, 1986; Wheater, 1987)
and an occasional B-cell (Seva et al., 1998). Specialized high endothelial venules
(HEV) are present and facilitate the migration of lymphocytes from blood to LN
parenchyma.
1.4.1.2.1 T Cells
The majority of T lymphocytes within the paracortex are small cells with dark
staining nuclei and scant cytoplasm. Present in fewer numbers are larger T-
immunoblasts that resemble centroblasts found in the GC dark zone (van der Valk &
Meijer, 1987). All subpopulations of T cells have been identified in the paracortex.
While located throughout the region, the most numerous, the CD4 T cells,
preferentially aggregate around the GC. CD4 T cells are believed to interact directly
with B cells at the follicular periphery and assist in B cell differentiation (Liu & Arpin,
1997) as well as in GC development (Garside et al., 1998). CD4 T cells also form
. aggregates in tissue similar to FDC-B lymphocyte cluster. Comprised of both newly
activated and memory T lymphocytes (Janossy et al., 1989; Seva et al., 1998), these
aggregates may facilitate communication between cells and assist in the clonal
expansion of T cells. Randomly scattered throughout the paracortex are CD8 T
cells, which represent the second largest subpopulation of T cells in the LN. In the
LN of the adult ruminant, for example, CD4 T cells out-number CD8 T lymphocytes
by approximately 2 fold (Seva et al., 1998).
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Rarely found within the paracortex are y8TCR T cells. Using immuno-
histochemistry and morphometric analysis, Seva et a/. (1998) found only occasional
clusters of y8 T cells within the paracortex. These cells were detected at a frequency
of 1 cell per 1500 mm2 of total LN area, which represents approximately 9% of the
total T cell population.
1.4.1.2.2 Interdigitating Dendritic Cells
A population of cells, known as interdigitating dendritic cells (IDC), forms a
network of intercellular connections within the paracortex. These cells are similar to
FDC in GC (Imai et a/., 1998) and have been shown to present antigen and induce
activation of paracortical CD4 T lymphocytes. Ingulli et a/. (1997) demonstrated with
confocal microscopy, that within the paracortex, labeled CD4 T cells cluster around
IDC. This aggregation occurs only after antigen stimulation, indicating that both CD4
T cells and IDC were activated and developed a cognate immune interaction.
1.4.1.2.3 Minor Cell Populations within the Paracortex
B cells are found in small numbers within the paracortex.
Immunohistochemistry was used to show that B cells migrate from HEV to follicles
(Blaschke et a/., 1995). It is believed that B cells represent migratory cells and do
not permanently reside within the paracortex.
1.4.1.3 Medulla
The medulla is situated between the paracortex and hilum and contains two
prominent structures; the medullary cords and the medullary sinuses. Medullary
cords are packed with cells and extend as linear rays towards the hilum. Medullary
sinuses are spaces that separate medUllary cords, extend to the hilum and
communicate with efferent lymphatic vessels.
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1.4.1.3.1 Medullary Cords
Medullary cords are composed predominantly of B cells and plasma cells
with smaller numbers of T cells, macrophages, mast cells and granulocytes
(Junqueira, 1986; Wheater, 1987; Welsch et al., 1997). Within the cords of most
species a 'plasma cell reaction' occurs, producing newly formed plasma cells,
memory B-Iymphocytes and increasing antibody production (van der Valk & Meijer,
1987). Straus (1981) used immunohistochemistry and histological criteria to create
a rough classification system describing the variety of lymphocytes found in
medullary cords. The author characterized four cell types present in cords after
antigen exposure and suggested that some cell types may represent various stages
of cell progression. Typical lymphocytes were small and round, with a thin rim of
scant cytoplasm. Protoplasm cells are precursors to plasma cells and are either
small, with small eccentric nuclei or large blast-like cells with large nuclei. Mature
plasma cells are characterized by intense antibody staining, eccentric nuclei and
reduced nuclear to cytoplasm ratio. The majority of immunoglobulins produced by B
lymphocytes within medullary cords are IgG isotypes. This observation was further
highlighted by Sato et al. (1990). FollOWing oral gavage with live anaerobic bacteria,
. numerous IgG producing cells with little production of IgA and IgM were detected in
medullary cords of LN draining the forestomachs.
Macrophages within medullary cords of LN are closely associated with both
Band T cells and may function in lymphocyte cell recruitment or facilitate
lymphocyte movement within the medulla. Medullary macrophages for example,
express a sialoadhesion molecule that enables them to associate with lymphocytes.
The binding affinity of these macrophages to lymphocytes is much stronger than
lymphocyte binding to other macrophages such as peritoneal macrophages and in
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some cases stronger than lymphocyte binding to antigen presenting dendritic cells
(van den Berg et al., 1992).
Mast cells and eosinophils found in medullary cords generally occur grouped
together or in association with plasma cells. The presence of mast cells has been
associated with lymphocyte activation in man and may explain their relationship with
plasma cells (Battezzati & Donini, 1973). Mast cells may also ingest lipid that
passes through the sinuses, as heparin that is present in mast cell granules is
considered a lipid clearing factor and may be responsible for lipid uptake (Welsch et
al., 1997). Eosinophils are likely attracted to these same areas where mast cells are
present by mast cells releasing eosinophil chemotatic factor (Cotran et al., 1999).
1.4.1.3.2 Medullary Sinuses
Medullary sinuses are channels that carry lymph from the cortex to the hilum.
These are not merely empty spaces but contain various cell types that include
lymphocytes and macrophages. Macrophages within this area are similar to
macrophages present in medullary cords and display many of the same
morphological features and have the same enzyme activities (van der Valk & Meijer,
1987). As omnivorous phagocytes, they display undulating membranes and cellular
projections and contain numerous Iysosomes and phagosomes. These cells do not
.normally present antigen and do not constitutively express la antigen in mice
(Fossum & Ford, 1985).
1.4.1.4 Lymph Node Framework
Lymph nodes maintain their three-dimensional structural integrity using
complex arrangements of extracellular proteins to form reticular fibers (Castanos-
Velez et al., 1995). Reticular fibers interconnect to form an intricate network for
cellular communications that varies between LN compartments. Ushiki et al. (1995),
demonstrated that reticular fibers extend in a perpendicular fashion from the capsule
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to hilum and the thickness of reticular fiber bundles varied at different LN locations.
For example, reticular fibers surrounding primary follicles or germinal centers located
within the paracortex, were more compressed than those within the medullary cords.
The reticular fibers are enclosed by fibroblastic reticular cells (FRC) with the
basal lamella of the reticular cell often investing the fiber (Ushiki et al., 1995).
Initially, reticular fibers were thought to be composed of Type III collagen (Fossum &
Ford,1985). Recently, however, researchers have demonstrated that Type I and IV
collagen are also present and the proportions of collagen found within the fibers vary
between LN compartments (Castanos-Velez et al., 1995). Fibroblastic reticular cells
contain other proteins, including myofilaments, enabling the LN to expand and
contract after stimulation (Tykocinski et al., 1983).
1.4.1.5 Lymph Node Vasculature
Lymph node vasculature is divided into two groups: blood vessels and
lymphatic vessels. These groups will be discussed in the following sections.
1.4.1.5.1 Blood Vessels
Blood vessels supply the LN with nutrients and oxygen and remove
metabolic waste products. Blood to the LN arrives via one or two arteries that enter
the LN 'at the hilum (Herman et al., 1972; Anderson & Anderson, 1975). A complex
. vasculature system exists within the LN and the LN contains numerous
arteriovenous connections and innervated venous sphincters. After the arteries
enter the LN they continue longitudinally either branching to form cortical capillaries
or entering the medulla to form a capillary network. Follicles and GC within the
cortex have different microcirculatory blood flow patterns. Follicles are supplied by
small arterioles that enter the follicle directly while GC receives blood from plexuses
of arterioles and capillaries arising from branches of longitudinal arteries. Blood
from venous plexuses drains to larger vessels by a centripetal drainage pattern.
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Venous blood is then returned into a single vein to exit the LN at the hilum (Herman
et al., 1972; Anderson & Anderson, 1975). Arteriovenous communications are seen
throughout the cortex and medulla. These structures are innervated by
unmyelinated fibers and as a result blood flow is influenced by sympathetic
stimulation.
1.4.1.5.1.1 High Endothelial Venules
High endothelial venules (HEV), also known as post-capillary venules, are
highly specialized structures involved in the emigration of lymphocytes from
circulation into the LN. They are located predominately within the paracortex with a
few present as 'fine' vessels below the subcapsular sinus (Sainte-Marie & Peng,
1996). Histologically, HEV are distinct from other vessels found in LN and other
tissues. Unusually tall columnar endothelial cells, with abundant cytoplasm and a
prominent nucleus are characteristic features of HEV. The pleomorphic capability of
the cells enables them to flatten and elongate, thereby, resembling squamous cells
(Sainte-Marie, 1966). The endothelial cell morphology of HEV appears to be
influenced by the local tissue environment. Occlusion of afferent lymphatic vessels
for example, will change HEV from tall columnar endothelial cells into flat elongated
cells that have a reduced metabolic activity and morphologically resemble normal
endothelium (Hendriks et al., 1987).
Lymphocytes can readily bind to HEV and be extracted from blood. It has
been suggested that approximately 85-90% of all lymphocytes found in efferent
lymph are blood lymphocytes that have entered the LN (Young, 1999). Anderson &
Anderson (1976) used serial sections of rat LN to show that approximately 760/0 of
lymphocytes found in deep paracortical vessels were in contact with HEV. These
lymphocytes had microvillous projections that attached to 'pits' randomly located on
endothelial surfaces. Furthermore, numerous lymphocytes were identified migrating
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across HEV at cell junctions, with a small number of lymphocytes being engulfed by
endothelial cells. Approximately 25% of all lymphocytes that flow through a resting
LN pass through the HEV into LN parenchyma (Girard & Springer, 1995).
The method by which lymphocytes bind and cross HEV involves four stages;
tethering, triggering, strong activation and migration (Anderson & Shaw, 1993).
Briefly, tethering is the loose attachment of lymphocytes to endothelial cells and
likely involves the interaction between L-selectins of lymphocytes binding to
proteoglycans on endothelial cell surfaces. Triggering involves the binding of
several ligands between lymphocytes and endothelium causing the rapid adhesion
of these and other protein receptors. Once triggered, the binding allows for strong
activation and strong adherence between lymphocytes and endothelium causing the
adherence of tumbling lymphocytes. Finally, the lymphocyte migrates across the
endothelium, predominantly through intercellular spaces.
On the luminal surface of HEV endothelium is a negatively charged
glycocalyx. The glycocalyx is rich in sialic carbohydrates and O-sulfated
proteoglycans (Van Damme et al., 1994) which may play an important role in the
immobilization of pro-adhesion molecules. These molecules, which may regulate
lymphocyte trafficking include various cytokines and chemokines (Table 1.2).
. Interestingly, venules displaying the same morphological features as HEV in rodents
and man have not been identified in ruminants (Harp et al., 1990). The post-
capillary venules in sheep are lined by low to medium sized endothelial cells, but are
functionally similar to HEV found in other species. Using fluorescent-labeled cells,
Harp et al. (1990) demonstrated similar efficacy in lymphocyte migration across HEV
in mice and across post-capillary venules in sheep.
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Table 1.2. Chemokine ligands and chemokine receptors associated with lymphocyte
migration.
Biological Activity Chemokine Chemokine Ligands
Receptor
Migration of na·ive T-cells to CCR7
lymph nodes and Peyer's
patches
SLC,ELC
Migration of na"ive T-cells
within lymphoid tissue
Migration of memory T-cells
to lymph nodes
Migration of memory T-cells
to gut
Migration of memory T-cells
to sites of inflammation
Migration of Th1 effector T-
cells
Migration of Th2 effector T-
cells
Migration of B-cells
CXCR4 SDF-1a
CCR7 SLC,ELC
CCR9 TECK
CCR2 MCP-1,3,4
CCR5 RANTES, MIP-1 a,1 ~
CCR2 MCP-1,3,4
CCR5 RANTES, MIP-1a,1~
CXCR3 IP-10, Mig, 1-TAC
CCR3 Eotaxin-1,2, RANTES,MCP-2,3,
HCC
CCR4 TARC, MDC-1
CXCR4 SDF-1a
CCR7 SLC
CXCR4 SDF-1a
CXCR5 BLC
Table modified from von Andrian & MacKay, (2000).
Abbreviations: SLC secondary lymphoid tissue chemokine; ELC Epstein-Barr-virus-
induced gene 1 ligand chemokine; SDF-1 a stroma-derived factor-1 a, TECK thymus-
expressed chemokine; MCP monocyte chemoattractant protein; RANTES regulated
on activation normal T-cell expressed and secreted; MIP macrophage inflammatory
protein protein; HCC human C-C chemokine; IP-10 inducible protein of 10 kd; Mig
monokine induced by INF-y; 1-TAC interferon inducible T cell a-chemoattractant;
TARC thymus-and activation-regulated chemokine; MDC-1 macrophage-derived
chemokine-1; BLC B-Iymphocyte chemoattractant.
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1.4.1.5.2 Lymphatic Vessels
Extranodal vessels transporting lymph are categorized into either afferent or
efferent lymphatics. Afferent lymphatic vessels collect extracellular fluid and cells
from tissue and transport the lymph to the LN. Efferent lymphatics, in contrast,
collect lymph from LN and through connections with other lymphatic vessels return
lymph to the thoracic duct. Lymphatic vessels are valved with the orientation of
valves in the direction of lymph flow (Wheater, 1987). Lymphatic vessels are lined
with a flat endothelium similar to that found in blood vessels. Borron & Hay (1994)
demonstrated that lymphatic endothelium has similar morphology, metabolic activity,
surface marker expression and capacity to bind lymphocytes as does vascular
endothelium. Besides these similarities between vascular and lymphatic
endothelium, it is postulated that endothelium of efferent vessels may also regulate
cell migration. This was first proposed by Binns & Licence (1988), using
lymphocytes from suckling pigs and fetal lambs. Lymphocytes collected from pigs
were injected iv into sheep and these lymphocytes exited the LN through efferent
lymphatics. Conversely, sheep lymphocytes administered iv to pigs left the LN
through HEV. These results indicate that signals required for lymphocyte migration
through a LN is recipient dependent and may be controlled by both the vascular
endothelium of HEV and lymphatic endothelium.
1.4.1.6 Innervation of Lymphoid Tissue
Adrenergic receptors and noradrenergic nerve fibers have been identified in
LN. Noradrenergic fibers and a2 and t3 adrenergic receptors are found in high
concentration in medullary cords and within the paracortex (Felten et a/., 1985;
Fernandez-Lopez et a/., 1994a; Fernandez-Lopez & Pazos, 1994). Felten et a/.
(1985) demonstrated that nerve fibers innervating blood vessels terminate as
plexuses within LN parenchyma and suggested that nerve stimulation could alter
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both blood flow to various compartments and influence lymphocyte function by
flooding the microenvironment with catecholamines. Parasympathetic fibers have
, not been found in LN; however, the occasional presence of acetylcholinesterases
along nerve fibers may indicate muscarinic innervation (Felten et al., 1985).
1.4.1.7 Effects of ISODN on Lymph Node Cellularity
As previously described, bacterial DNA (1.2 section) and ISOON (section
1.3) can stimulate cells and play an integral role in both the development and
maintenance of a variety of immune responses. It is intuitive that with the induction
of an immune response, structural changes in the draining LN should occur as well.
Until recently, such effects of ejther bacterial DNA or ISOON on the draining LN
have not been examined and only one study, in mice reported relatively short-term
changes in the draining LN after ISOON treatment. Injection of 5 nmol (30 ug) of
ISOON into the footpad of mice cause an increase in cell numbers isolated from a
draining LN. It was observed that cell numbers began to rise within the first 24 hours
following treatment, with the number peaking by the tenth day post-treatment. A
maximal 88-fold increase in cell number was demonstrated, with substantial yet
varied increases in lymphocytes, dendritic cells and granulocytes throughout the
experiment (Lipford et al., 2000). This study unfortunately, did not describe
. morphologic changes within the lymph node after treatment, so the effects of ISOON
on cortical and medullary structures are unknown.
1.4.1.8 Conclusion for the Lymph Node Section
Lymph nodes are relatively complex structures that contain diverse cell
populations important for immune function. The structure of LN allows for optimal cellular
interactions and ensures proper processing of foreign antigen. As LN are dynamic
tissues capable of major structural change after stimulation, exposing a LN to plasmid
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DNA should enable us to determine the capacity of DNA to induce either short or long-
term changes in LN structure.
1.5 Introduction to Cell Trafficking
Lymph is an extracellular fluid categorized on composition and location.
Interstitial fluid (ICF), also known as tissue lymph, occupies intercellular spaces and
is in direct contact with the extracellular matrix. Interstitial fluid contains few cells
and low protein concentrations (Battezzati & Donini, 1973). Lymph is divided into
three groups; peripheral, intermediate and central lymph. Peripheral lymph (afferent
lymph) is located between the tissue and the draining LN. Intermediate lymph
(efferent lymph) is fluid that has crossed lymphoid tissue but has not yet reached the
main lymphatic trunks; and central lymph is lymph found in the main lymphatic trunk
prior to reaching the venous circulation (Battezzati & Donini, 1973).
1.5.1 Non-Cellular Lymph
Lymph consists of both cellular and non-cellular components. The non-
cellular component of lymph contains all protein fractions found in blood (Battezzati
& Donini, 1973), but generally in lower concentrations (Schmid-Schonbein, 1990). In
sheep for instance, the protein content of lymph from the mediastinal LN was 60% of
that found in blood (Spencer & Hall, 1984). Interestingly, not all proteins have
. reduced levels in lymph when compared to blood. Spencer & Hall (1984)
demonstrated that IgA levels were markedly elevated in lymph collected from the
thoracic duct compared to IgA levels in blood. Lymph can contain biologically active
molecules such as cytokines as well. In people, Yawalkar at at. (1998)
demonstrated that following ultraviolet light exposure, afferent lymph had increased
concentrations of IL-6 and IL-8. Similarly, treatment of sheep with antigen causes a
significant rise in IL-2 levels within efferent lymph (Bujdoso at a/., 1990).
Concentrations of electrolytes and other small molecules in lymph differ from blood.
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Calcium, phosphorous and potassium levels for example, are slightly lower in lymph,
while nitrogen and glucose have comparable values (Battezzati & Donini, 1973).
Lipids are also present in lymph and the amount of lipid present is dependant on
diet. In people for instance, it was shown that consumption of a meal will cause a
substantial rise in the cholesterol and triglyceride content of intestinal lymph
(Battezzati & Donini, 1973).
1.5.2 Cellular Lymph
Cell populations found in lymph vary considerably between the different
compartments (Young, 1999). For the purpose of this discussion, only afferent and
efferent lymph will be discussed in detail.
1.5.2.1 Afferent Lymph
Afferent lymph is composed of erythrocytes, granulocytes (Battezzati &
Donini, 1973), lymphocytes (Hall & Morris, 1965; Hall, 1967; Smith et al., 1970b) and
dendritic cells (Bujdoso et al., 1989). Afferent lymph flow rates are approximately 1
x 106 cells/hour/vessel and in general the lymph contains 85-95% lymphocytes and
10-15% macrophages and dendritic-like cells (Issekutz etal., 1981; Young, 1999).
The majority of lymphocytes are T cells, representing 80% of the entire lymphocyte
population. The subpopulations of T cells correspond to 40-550/0 CD4 T cells, 13-
. 15% CD8 r cells and 11-30% y8TCR T cells. These T cells can express high levels
of activation markers as well: for instance, the proportion of CD4 and CD8 cells
expressing IL2a. receptor (CD25), L selectin and MHCII are 36%, 670/0, 89% and
19% ,75%,80°1'0 respectively (Haig et al., 1999). B cells represent the remaining 15-
20% of lymphocyte populations found in afferent lymph (Haig et al., 1999; Young,
1999).
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The number of cells that traffic through an afferent vessel varies considerably
and is dependent on local tissue reactions. In sheep, Smith et 81. (1970a)
demonstrated that resting afferent lymph from the lower leg flowed at approximately
9 x 106 cells/hour and contained 80-900/0 small lymphocytes, 2-50/0 Iymphoblasts and
5-100/0 macrophage and macrophage-like cells with few granulocytes. After
treatment with killed influenza virus and Freund's incomplete adjuvant, there was a
marked change in cell number and phenotype. Within the first 24-48 hours, 70-90%
of afferent cells were granulocytes. After 96 hours, however, the majority of cells
were small lymphocytes, Iymphoblasts and plasma cells with few numbers of
macrophages. These cell populations remained relatively constant for the duration
of the experiment. It is noteworthy, that as a granuloma developed at the injection
site, there was a gradual increase in cell flow. A peak flow of 60 x 106 cells/hour
occurred between Day 20 and Day 40-post treatment.
An experiment by Cahill et 81. (1976) highlights the effect of short-term
antigen exposure on cell traffic. Unlike the previous experiment, Cahill's group
injected sheep with killed influenza virus in the absence of Freund's incomplete
adjuvant. They demonstrated a rapid but brief increase in afferent cell flow that
returned to pre-stimulation levels by Day 4. Smith et 81. (1970a) reported similar
. findings, that treatment with Freund's adjuvant and killed virus induced a rapid influx
of neutrophils two hours following treatment and a decline in neutrophil number that
then occurred within the first 18 hours after treatment. Interestingly, the number of
small lymphocytes remained constant throughout the experiment with a slight but
transient increase in macrophage numbers. Unfortunately, neither experiment
examined changes in the various lymphocyte subpopulations after treatment.
A more recent study examined the effects of a parasite-induced, acute
dermatitis on lymphocyte populations of afferent lymph. A 4-fold increase in both
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CD 4 and yoTCR T cells was seen in afferent lymph 30 hours post-treatment. 80th
lymphocyte populations appeared to be activated, with strong expression of the IL-2
receptor (CD25). It is noteworthy that not all cell populations were affected by the
treatment as CDB T cells, CD45R 8 cells and CD1+ dendritic cells remained
relatively unchanged (Nash et al., 1996).
Not all treatment modalities will cause changes in cell populations of afferent
lymph, even in the presence of enhanced cell flow. For example, short-term
treatment of skin with ultraviolet light can cause a three-fold increase in cell flow in
people. Analysis of the collected cells, however, indicated that there was no
appreciable change in the frequency of cell populations. The CD4 and CDB T cells
and the CD1 a dendritic cells remained at constant levels over the 7-day trial
(Yawalkar et a/., 199B).
From the above described experiments, it is evident that cell flow and cell
populations in afferent lymph can vary greatly. Differences in the treatment regimes,
including type of antigen, duration of exposure and route of administration, result in
markedly different responses. It is difficult, therefore, to make accurate predictions
of the changes that may occur in afferent lymph following a specific treatment. In
general, however, treatment with an antigen causes increased cell trafficking with
. variable changes in the numbers for individual cell populations.
1.5.2.2 Efferent Lymph
There are significant differences between the population of cells seen in
efferent and afferent lymph as efferent lymph is almost entirely composed of
lymphocytes. Lymphocytes in efferent lymph consist of approximately 750/0 T cells
and 25%) 8 cells. The CD4, CDB and yo T cells represent approximately 40-430/0,
14-15°1'0 and 0-10% of total cell populations in efferent lymph, respectively (Haig et
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a/., 1999; Young, 1999). The T cells present in efferent lymph also have a reduced
expression of activation markers relative to T cells in afferent lymph. The CD4 and
CD8 T cells expressing IL-2u receptor (CD25), L selectin and MHCII are 50/0, 350/0,
30% and 10/0, 64% and 380/0 respectively (Haig at a/., 1999).
1.5.2.2.1 Kinetics of Cell Flow in Efferent Lymph
The movement of lymphocytes through an antigen stimulated LN ;s well
studied. The magnitude and duration of cell flow and changes in phenotype of cells
emigrating from LN are quite variable and vary with the antigen administered. In
general, efferent lymph has a cell flow rate of approximately 30 x 106 cells/hour/gram
of LN and changes occur in three distinct phases following antigen administration
(Young, 1999).
A remarkable drop in cell flow in efferent lymph after antigen exposure
characterizes Phase 1. Using cannulated efferent lymphatic vessels in sheep, Cahill
at a/. (1976) demonstrated that the magnitude and duration of cell flow 'shut down'
not only differed between antigens but also differed between mitogens as well.
Injection with bacteriophage for instance, resulted in a nearly acelluar lymph that
lasted for approximately 12 hours post-treatment. In contrast, injection of horse red
blood cells caused a drop in cell output that was less than 10% of pre-stimulation
values. A similar disparity in cell flow 'shut down' was demonstrated after treatment
with two B-cell mitogens. Administration of lipopolysaccharide (LPS) caused an
almost complete cessation in cell traffic that lasted for 18 hours. In contrast,
injection of pokeweed mitogen (PWM) had little effect. In all treatments, the
numbers of cells in efferent lymph were near pre-treatment levels by the 6th day
post-treatment
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The apparent shutdown in cell traffic seen in Phase 1 is probably not due to
reduced cell movement from the blood to LN, but rather, to an enhanced retention of
cells within the LN. Using radiolabelled cells, researchers determined that
emigration of cells from blood to LN was equal in both antigen treated and untreated
LN. There was however, a marked reduction in cell numbers leaving the LN within
efferent lymph of the antigen treated LN (Cahill et al., 1976; Issekutz et al., 1981).
In general, Phase 2 is characterized by a large increase in cell flow that
reaches maximal levels within 24 hours after treatment (Young, 1999). The duration
and magnitude of this response, however, is greatly dependent on the type of
antigen administered and the duration of antigenic exposure. For instance, infusion
of allogeneic lymphocytes in sheep caused a 7-fold (35 x 107 cells/hour) increase in
cell flow that peaked approximately 50 hours post-treatment and returned to pre-
stimulation values by Day 6 (Cahill et al., 1976). In comparison, Pedersen et al.
(1975) demonstrated a 7-fold rise (35 x 107 cell/hour) in cell flow following renal
allograft transplantation, with cell flow being maximal 80 hours post-treatment and
remaining markedly elevated for more than 10 days. These two experiments
illustrate the importance of antigen form and administration on cell flow. The long
duration of cell flow in the experiment by Pedersen et 81. (1975) is likely caused by
the prolonged presence of antigen and the later onset of maximal flow may indicate
that foreign renal tissue is not as effective as foreign lymphocytes at inducing events
leading to increases in cell trafficking.
Efferent cell flow is markedly affected by treatment with mitogens as well. In
sheep, Cahill et al. (1976) demonstrated that LPS induced increased cell flow to a
maximum of 25 x 107 cell/hour 48 hours following treatment and flow rates then
returned to pre-stimulation levels by Day 6. In contrast, PWM caused a maximal rise
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in cell flow 24 hours post-treatment that was equivalent to the cell flow rate observed
following treatment with LPS. Cell flow continued to rise and was greatest by the
third day. Unlike LPS treated animals, cell flow in PWM treated sheep did not return
to baseline levels by the 6th day.
In phase 2, the increased numbers of lymphocytes in efferent lymph is
caused by an increased recruitment of lymphocytes from blood. In sheep, Hay &
Hobbs, (1977) demonstrated that stimulation of LN with allogeneic lymphocytes
could cause a four-fold increase in blood flow. A four-fold increase in blood flow
corresponded to a relatively equivalent four-fold rise in the numbers of efferent
lymphocytes. The researchers also determined that in a stimulated LN, 25% of all
lymphocytes that flow through the LN exited in efferent lymph, while the remaining
750/0 of lymphocytes stayed within blood.
Generally, phase 3 is characterized by the appearance of blast cells and
activated lymphocytes and lasts for 2-3 days prior to returning to baseline levels
(Young, 1999). Similar to the first two phases, Phase 3 is affected by the type of
antigen treatment. Injection of allogeneic lymphocytes for instance, caused an
elevation of the proportion of blast cells beginning on Day 5 post-treatment and
subsiding by Day 7. The blast cells represented approximately 200/0 of all efferent
lymphocytes (Hay & Hobbs, 1977). This differs greatly from transplantation of skin
graphs, where the presence of blast cells in lymph begins on Day 5, peaks at Day 15
and returns to pre-treatment levels at Day 21 (Hall, 1967).
The increased number of blast cells in lymph usually preceded an increased
release of activated cells as well. Salmonella antigen was injected subcutaneously
in sheep and efferent lymph cells were collected. Twenty-four hours post-injection,
there was an increase in blast cells and 48 hours after injection there was a
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significant increase in activated lymphocytes producing antibody. Using a plaque-
forming assay, the researcher demonstrated an approximate 20-fold increase in
antibody production that continued throughout the trial (Hay et al., 1972).
1.5.2.2.2 Cell Phenotypes within Efferent Lymph
Cell populations found in efferent lymph can be greatly affected by antigen
treatment. As an example, Haig et al. (1996) treated sheep with orfvirus and
measured the phenotypes of lymphocytes in efferent lymph. They demonstrated a
biphasic response that was characterized by increased numbers of memory CD4 T
cells with fewer numbers of memory COB T cells. Na'ive CD4 and COB T cells were
lower in number as compared to their memory counterparts and y8 T cells were
rarely present. In contrast, lymph collected from sheep treated with Toxoplasma
gondii demonstrated an initial increase in both CD4 and COB T cells in the early
stages of infection; however, as the infection progressed, COB T cells became the
dominant T cell population (Innes et al., 1995).
The effect of antigen treatment on B cell populations was demonstrated by
Gohin et al. (1997). Efferent lymph collected from sheep after administration of
Salmonella abortusovis demonstrated an increase in both Band T cells in the early
stages following treatment. At the peak response, however, T cell populations
diminished while B cells increased markedly with all Iymphoblasts being activated B
cells (Gohin et al., 1997).
1.5.3 Lymphocyte Recirculation
The recirculation of lymphocytes between different immune compartments is
an important component of the immune system. Usually small lymphocytes migrate
from blood to the LN and back to lymph, allowing for continual immunological
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surveillance (Gupta et al., 1998). Lymphocyte recirculation, therefore, is a selective
process that affects both 8 and T cells and can be tissue specific.
Good examples of tissue specific lymphocyte recirculation were
demonstrated by Abernethy etal. (1991) and Mackay etal. (1996). The former
group collected intestinal lymphocytes from efferent lymph, labeled them with a
fluorochrome marker and then injected cells back into venous blood. The
researchers demonstrated a 4-5-fold increase in labeled cells collected in both
afferent and efferent intestinal lymph as compared to prescapular afferent lymph.
The latter group, using two fluorochromes, further demonstrated tissue specific
recirculation. Cells collected from intestinal efferent lymph were labeled with a green
marker, while cells collected from prescapular efferent lymph were labeled with a red
marker. Cells were then returned to the venous circulation and recollected from both
intestinal and prescapular lymph. Mackay et al. (1996) demonstrated a two fold
enrichment in green cells collected from intestine and in red cells collected from skin.
These observations revealed tissue-specific homing of lymphocyte populations.
Interestingly, not all lymphocytes will recirculate. Two distinct populations of
8 cells have been identified in sheep based on expression of CD11 band CD21. The
CD11b+ 8 cells are found only in blood and the marginal zone of the spleen. CD21+
8 cells are found in blood and the primary follicles of spleen, Peyer's patches and
LN. When peripheral blood 8 cells were labeled and reinjected back into circulation,
only CD21+ 8 cells were collected from efferent lymph, and CD11b+ 8 cells were
absent in lymph at all times after injection (Gupta et al., 1998).
Lymphocyte subpopulations emigrate from blood to efferent lymph at
different rates and in different frequencies. The resting LN for instance, will extract
CD4 and y8 T cells at the same rate, and this rate is significantly faster than the rate
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at which COB T cells or B cells are extracted. Phenotype analysis indicated that the
resting LN preferentially extracts more CD4 T cells than other lymphocyte
subpopulations. For example, CD4 T cells represent approximately 70% migrating
lymphocytes, while low numbers of COB T cells and B cells and rare y8 T cells make
up the remaining lymphocytes (Witherden et al., 1990). These findings are similar to
Abernethy et al. (1991), with approximately 62-720/0 of CD4 T cells and 5-120/0 COB
T cells being extracted from blood into efferent lymph over a 4B-hour collection
period. Unfortunately, this experiment did not measure extraction rate of y8 T cells.
Lymphocytes can migrate to both inflamed and healthy tissue. Cells
collected from afferent vessels draining a subcutaneous granuloma were labeled
with 1111n-oxime and returned to blood. The numbers of labeled lymphocytes
migrating back to the granuloma were 4-5 times greater than the numbers of cell
recirculating through efferent lymph (Issekutz et al., 19BO).
1.5.4 Non-Antigenic and Non-Mitogenic Mediators
Biologically active compounds other than antigen or mitogens can influence
cell movement in efferent lymph. These compounds vary from large protein
complexes including complement to small molecules such as cyclic nucleotides and
cytokines. Interestingly, not all of these compounds will cause a 'shut down' in cell
traffic followed by a period of increased cell flow that occurs after antigen treatment.
This section will examine how different compounds influence cell trafficking,
highlighting the differences in cell trafficking responses follOWing treatment.
Complement can induce a pause in the migration of cells into the efferent
lymph post-treatment. Infusion of complement or complement activating factors,
including immune complexes, cobra venom factor and inulin, into afferent lymph
caused a rapid and short-lived reduction in cell output. Of interest, a complete
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disappearance of B cells in efferent lymph was noted, while the level of T cells
remained relatively constant. This observation supports the conclusion that a non-
random selection of lymphocyte populations occurred post-treatment (McConnell &
Hopkins, 1981).
Mediators of inflammation and non-inflammatory vasoactive compounds can
also change cell trafficking after injection. These mediators have distinct effects on
the kinetics and magnitude of cell flow. Prostaglandins (PG) for example, cause a
reduction in cell flow. Hopkins et al. (1981) demonstrated that infusion of PGE2 into
afferent vessels caused an 84% reduction in cell flow that began minutes following
treatment and remained reduced for six hours. Similar to the effects of treatment
with complement, infusion with PGE2 caused a complete disappearance of B cells.
To determine if PGE2 was a specific mediator causing a 'shut down' in cell
trafficking, inhibitors of prostaglandin synthesis were infused prior to treatment with
PGE2. The researchers demonstrated that aspirin and indomethacin prevented cell
flow shut down, while imidazole, a selective inhibitor of thromboxane A2, had no
effect. This suggests that prostaglandins rather than thromboxanes influence cell
trafficking.
The direct effect of cytokines on cell trafficking has not been extensively
. studied. The cytokine IFN-a, however, has been tested in sheep and both
intravenous and intradermal injections of IFN-a induce a marked reduction in cell
numbers within efferent lymph. For example, injection of nanogram quantities of
IFN-a will- cause a 10-fold reduction of cell traffic into efferent lymph that lasts for
approximately 30 hours. This drop in cell numbers correlates with only a transient
increase in numbers of lymphocytes extracted from blood. This observation
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supports the conclusion that lymphocytes are retained within the LN over this period
(Kalaaji et al., 1988).
Bradykinin is a potent vasoactive compound and a strong mediator of pain
impulses. The kinetics and magnitude of cell trafficking responses induced by
bradykinin differs significantly from cell trafficking responses following PGE2
treatment. Infusion of bradykinin caused a 35%) reduction in cell flow within the first
20 minutes after treatment. And then cell output increased to 200% above baseline
levels for approximately 80 minutes (Moore, 1984). The initial decrease in cell flow
was not a consistent finding, as only one-third of the sheep demonstrated reduced
cell trafficking.
Treatment with vasoactive intestinal peptide (VIP) illustrated the ability of
short-acting molecules to produce a prolonged reduction in cell traffic.
Administration of VIP induced a 7-fold decrease in cell output within the first 60
minutes with a return to baseline levels 22 hours post-treatment. Even in the
presence of reduced cell trafficking, not all lymphocyte subpopulations were reduced
in number. Moore et al. (1988) demonstrated that VIP caused a significant reduction
in CD8 T cells and B cells but a moderate increase in CD4 T cells.
As mentioned, not all vasoactive compounds cause an initial 'shut down' in
cell trafficking after injection. The vasoactive neurotransmitter Substance P for
instance, caused a prompt and marked increased in cell migration. Infusion of 50 Jlg
of Substance P into afferent lymphatics causes an increase in cell trafficking 2 hours
post-treatment with cell-output peaking by the third and fourth day. At peak periods,
cell output was 8 fold greater than pre-stimulation levels (Moore et al., 1989). In a
subsequent experiment, Moore et al. (1990) demonstrated that increased cell output
was associated with elevated numbers of CD4 T cells and a comparable reduction in
CD8 T cells and B cells.
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Other peptides including bombensin, (met)enkephalin and serotonin caused
a rapid increase in cell traffic as well. Moore (1984), demonstrated that bombensin
was a potent peptide capable of increasing cell trafficking. The administration of
bombensin caused a 2-fold and 6-fold increase in Iymphoblasts and small
lymphocytes' in collected lymph respectively. The increased cell output was rapid
with the numbers of Iymphoblasts peaking 30 minutes after treatment.
Stimulation of peripheral nerves also causes a short-lived increase in cell
traffic that is mediated through the release of catecholamines. Stimulation of the
splanchnic nerve will cause an 80% elevation in fluid flow and a 200% increase in
cell migration, that return to baseline levels 5 minutes post-treatment. Infusion with
norepinephrine produced a similar pattern in cell flow, and this increased flow could
be abrogated with an a-adrenergic antagonist. This observation suggested that a-
adrenergic stimulation and the subsequent release of norepinephrine enhanced cell
trafficking (McGeown, 1993).
It is believed that the effects of several vasoactive peptides are mediated
through the release of second messengers. Indirect in vitro evidence suggests that
vasoactive peptides can increase the levels of cyclic nucleotide compounds in cells.
To determine whether cyclic nucleotides can alter cell trafficking, Moore &
. Lachmann (1982) infused cAMP and cGMP into afferent lymphatic vessels.
Treatment with cAMP produced a rapid decrease in cell trafficking that persisted for
eight hours. There was also a decrease in the number of small lymphocytes and
Iymphoblasts and the volume of lymph flow. In contrast, cGMP caused a rapid
eight-hour increase in fluid flow and the release of small lymphocytes and
Iymphoblasts into efferent lymph.
The effects of various mediators on cell movement have been examined in
non-cannulated tissue such as skin. Colditz & Watson (1992) demonstrated that
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various cytokines and proteins have distinct effects on cell movement through the
dermis. They demonstrated that intradermal injections of IFN-y, TNF-a, IL-B and
, zymosan-activated plasma caused a significant influx of lymphocytes into skin that
persisted for a 9-hour period. In contrast, treatment with IL-12, leukotriene 84
(LT84), platelet activating factor and phytohemagglutinin did not enhance cell
movement. Immunohistochemical analysis of the treated skin demonstrated marked
dermal infiltrates of predominately CD4 T cell, with fewer COB T cells and rare y8 T
cells.
1.5.5 Movement of Fluid between Tissue and the Vasculature
Extracellular fluid accumulates in the interstitium by a net movement of fluid
from blood vessels. Protein rich interstitial fluid flows either into lymphatics through
clefts between endothelial cells or via transcellular migration across plasmalemmal
vesicles (Dobbins & Rollins, 1970; Leak, 1971). The movement of fluid through the
interstitium is dependent both on the hydrostatic pressure of blood and external
forces (Aukland & Reed, 1993). The movement of extracellular fluid across blood
vessel endothelium occurs by 3 distinct mechanisms: the intrinsic, extrinsic and
retrograde lymph pumps. The intrinsic lymph pump consists of oscillatory
constriction of smooth muscle around lymphatic vessels. Fluid moves in an
.anterograde fashion during periods of relaxation allowing, for vessel filling (Schmid-
Schonbein, 1990). The extrinsic pump differs from the intrinsic lymph pump in that
periodic compression and expansion of the vessel is dependent on surrounding
tissue. This mechanism is particularly important for lymph movement in skeletal
muscle (Schmid-Schonbein, 1990). Movement of lymph by the retrograde pump
occurs as lymph travels along the lymphatic and develops a 'suction' between an
open upstream valve and the closed downstream valve. This causes a pressure
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gradient across the vessel and surrounding tissue to form and thereby allows
extracellular fluid to flow across the lymphatic endothelium (Reddy et al., 1975).
This mechanism is believed to facilitate the movement of extracellular fluid into
mesenteric vessels.
Transcellular migration of extracellular fluid into endothelial cells plays an
important role in uptake of large solutes including ferritin and particulate matter.
Transport of fluid occurs in vesicles and this form of transport may playa role in
receptor-mediated processes. It is postulated however, that the transcellular
movement of extracellular fluid likely does not involve large quantities of fluid moving
across the vessel wall into the lumen (Rippe & Haraldsson, 1994) and therefore is of
minor importance in lymph flow after antigen challenge.
1.5.6 Conclusion for the Cell Trafficking Section
The movement of lymph between various compartments is a dynamic
process. Treatment with antigens, mitogens and other biologically active
compounds can cause significant changes in the both the number and phenotype of
cells migrating between the afferent lymph, LN and efferent lymph. As the effects of
different antigens and other products on cell trafficking have been extensively
. studied in sheep, the use of the sheep model is ideal for studying the effects of
plasmid DNA and immunostimulatory oligodeoxyribonucleotides on cell trafficking in
a localized area.
1.6 Summary of the Literature Review
A review of literature in the area of DNA vaccination has shown that plasmid
DNA encoding antigen can induce effective and protective immune responses.
These responses are affected by route of administration and the presence of
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immune modulating products such as encoded cytokines and immunostimulatory
CpG motifs within the plasmid. CpG motifs in particular are quite effective at
inducing immune responses as small CpG sequences in the form of CON can
protect against disease following challenge with different bacteria. It is well
established that products such as antigen and mitogen can alter immune
surveillance by changing cell trafficking and altering lymph node structure. These
changes are likely important for the dissemination of 'immunological information' and
generation of robust immune responses. It is of interest therefore, to determine
whether plasmid DNA and immunostimulatory CpG motifs also influence immune
surveillance, and thereby help to elucidate mechanisms that may be involved in
immune modulation by bacterial DNA products.
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CHAPTER 2
THE RESEARCH HYPOTHESIS
Within the last decade, it has become apparent the bacterial DNA has a
remarkable capacity to stimulate cells involved in immune induction. The presence
of hexameric CpG motifs within bacterial DNA is considered essential for immune
activation and indeed it is well documented that CpG motifs are capable of
stimulating both innate and adaptive immune responses. As examples, CpG motifs
with synthetic oligodeoxyribonucleotides (DON) can induce the release of cytokines
and increase the expression of chemokines and costimulatory molecules (Krieg et
al., 1995; Ballas et al., 1996; Yi et al., 1998, Takeshita et al., 2000). These motifs
can also enhance humoral and cell-mediated immunity and protect against disease
following a challenge with a variety of pathogens. CpG motifs are believed to
stimulate immune system by acting as a pathogen-associated molecular pattern
(PAMP) and binding to pattern recognition receptors (PRR) present on or within
many cells.
Lymphocytes have the unique ability to migrate from blood to tissue and back
to blood. This recirculation of cells allows for continuous communication between
different immune compartments, facilitating immune surveillance and the
dissemination of immunological information throughout the body. Although PAMP
can influence the migration of inflammatory cells in tissue, the effects of PAMP cell
trafficking are not fully understood. At present, only one PAMP, LPS, has been
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shown to affect cell trafficking, and like antigen it causes a shut down of cell flow in
efferent lymph.
I hypothesized that immunostimulatory CpG motifs, either in the form of
synthetic ODN or encoded within plasmid DNA, function as a PAMP that can alter
immune surveillance. Changes in immunosurveillance were monitored by
measuring cell trafficking in the efferent lymph of the prescapular lymph node and
assessing cellular and structural changes within this lymph node following a single
intradermal injection of either plasmid DNA or an immunostimulatory OON.
The research objectives therefore were divided into three main areas:
1) A long-term lymph node study (30 days) to determine if induced a
prolonged change in lymph node size and architecture.
2) A lymphatic cannulation study to measure cell migration through a lymph
node following a single intradermal injection of either plasmid DNA or an
immunostimulatory OON.
3) A short-term study (4 days) to determine whether a single intradermal
injection of either plasmid DNA or an immunostimulatory ODN induced detectable
changes in lymph node architecture and cellular composition. This analysis of lymph
node structural changes provided insight into the mechanisms by which CpG motifs
might alter cell trafficking
These research objectives were designed to test the hypothesis that a
specific PAMP, immunostimulatory CpG motifs present in bacterial DNA, could
indeed affect immune surveillance within a sheep lymph node.
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CHAPTER 3
PLASMID DESIGN AND IN VITRO TRANSFECTION STUDIES
3.1 Introduction
DNA vaccination is a plasmid-based technology developed to induce
antigen-specific immunity. To achieve this goal, the first priority was to develop
plasmids that induced protective immune responses. Plasmids were designed to
enhance gene expression and to improve vaccine adjuvanticity. Strategies aimed at
improving gene expression included: the addition of a strong eukaryotic promoter
(Boshart et a/., 1985); the insertion of intron A (Chapman et a/., 1991); and the
presence of poly A adenylation sequences (poly [A] tail) (Pfarr et a/., 1986). Vaccine
adjuvanticity has also been enhanced by incorporating immunostimulatory CpG
motifs into plasmids (Sato et a/., 1996; Roman et a/., 1997). These motifs were
added to some plasmids either by inserting tandem repeats of a known
immunostimulatory DNA sequence or by using ~-Iactamase to select plasmids in
culture.
One of the objectives of the cannulation experiment (chapter 5) was to
determine whether cells migrating from the site of DNA injection expressed protein.
To test this, several plasmids were created that expressed reporter genes, namely
the wild type green fluorescent protein of jellyfish (GFP) and a variant form of the
jellyfish protein, eGFP. Any cells transfected by plasmid and expressing the
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encoded GFP protein could then be detected by fluorescence. This would therefore
aid in the detection of individual cells that were transfected by plasmid DNA and
expressed GFP in collected lymph.
This chapter will describe the creation of the following plasmids: pCAN1,
pCAN1-GFP, pCAN1-eGFP, pBISIA and pBISIA-88 and examine the expression
efficiency of pCAN1-GFP and pCAN1-eGFP plasmids following transfection of COS
7 cells.
3.2 Methods and Materials
3.2.1 Plasmid Construction and Purification
The plasmid pCAN1 was generated by ligating a fragment of plasmid from
pUC19 (Yanisch-Perron et al., 1985) with a fragment from the pSLlA plasmid (Braun
etal., 1997). An 1814 base pair fragment containing the origin of replication and~­
lactamase was digested from pUC19 with the restriction enzymes Aatll and AfllIl. A
2244 base pair fragment encoding the human cytomegalovirus (HCMV) promoter,
intron A and the bovine growth hormone poly (A) region was cut from pSLlA with
EcoRI and Hindlli. These two fragments were blunted with T4 DNA polymerase and
ligated with T4 DNA ligase. The resulting plasmid pCAN1 incorporates 17
hexameric CpG sequences that potentially display immune stimulating properties.
The plasmid pCAN1-eGFP was created by excising the eGFP gene from
peGFP with Xbal sites (Clonetec Laboratories Inc., CA, USA) and ligating this
fragment into pCAN1 at the Xbal site. Linear DNA with 1752 and 3069 bp fragments
were created by digesting 2000 Jlg pCAN1-eGFP with 2500u Pstl and 2000u SspI
for 6 hours at 37 °C. The oligodeoxynucleotide (DON 2135), 5'-TCGTCGTTTG-
TCGTTTTGTCGTT-3' with a nuclease-resistant phosphorothioate backbone induced
in vitro B cell proliferation and IFN-y production by sheep blood lymphocytes
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(Pontarollo at al., 2001) and hence was used in future experiments either alone or as
an insert into plasmids. To insert ODN 2135 into plasmids, two copies of ODN 2135
were joined to form 5'-ACTCGTCGTTTGTCGTTTTGTCGTTTCGTCGTTT-
GTCGTTTTGTCGTTG-3' and this construct (dimer) along with its complementary
strand were annealed and inserted into the Avail site of the pMAS plasmid (Krieg at
al., 1998)(pMAS was a gift from H.L. Davis, Loeb Research Institute, ON, Canada).
The resulting construct, pBIS-88; contained 22 inserts of ODN 2135, which is
equivalent to 88 CpG motifs~ To create pMASIA and pBISIA-88, the HCMV intron A
was isolated from pCAN1 by digestion with Eagl and Pst! and then ligated into
pMAS and pBIS-88 cut with Eagl and EcoRV. Plasmid pMASIA has 18 potentially
immunostimulatory hexameric sequences. To ensure these plasmids were created
correctly and contained proper inserts, all plasmids were digested with restriction
enzymes and run on 1% agarose gel. Purified plasmids were grown in E. coli strain
DH5a (New England Biolabs, ON, Canada) and production and purification of
plasmid DNA were performed according to manufacturer's specifications (Giga Kits,
Qiagen Inc., On, Canada). All enzymes used for ligations were purchased from
Pharmacia Biotech (Baie-Urefe, QB, Canada) and plasmids were resuspended in
saline (1 IJg/lJl) and stored at -20°C.
.3.2.2 Endotoxin Assay
Endotoxin contamination of plasmid preparations was assessed using the
QCL-1000 Limulus Amebocyte Lysate Kit (BioWhittaker Inc., Walkersville, USA)
according to manufacturer's specifications. Plasmid preparations containing 400 IJg
of DNA had endotoxin levels that varied from 2 pg to 500 pg.
3.2.3 Transfection of COS 7 Fibroblasts with Plasmid Expressing GFP and
eGFP.
The COS 7 fibroblast cell line was used in transfection experiments and
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these cells were grown to confluence in 6 well plates with growth medium (Iscove's
Modified Dulbecco's Media, Gibco-BRL, ON, Canada) containing 2.5 % fetal bovine
serum (FBS, Gibco-BRL, ON, Canada) and penicillin and streptomycin (Gibco-BRL,
ON, Canada). Plasmid DNA was prepared for transfection by adding Jipofectamine
(Lipofectin Reagent, Gibco-BRL, Canada) to plasmid DNA in Optimem (Opti-MEM,
Gibco-BRL, ON, Canada) at a 5:1 ratio (vol/wt), and then incubating for 15 minutes
at room temperature. During this incubation period, COS7 cells were washed twice
with Optimem at 37°C. The Iipofectamine treated plasmids were added to confluent
COS 7 cells and incubated at 37°C in 5% C02 for 2 hours. The cells were then
washed with growth medium and incubated at 37°C in 5 % C02 for the duration of
the experiment. Measurements of cell fluorescence were achieved with a
FACSscan flow cytometer (Becton Dickinson, CA, USA) and the Cell Quest (Becton
Dickinson, CA, USA) program was used for data acquisition and analysis.
Photographs of green fluorescing COS 7 fibroblasts were taken with 100 ASA color
film (Kodak Eastman, ON. Canada) exposed to ultraviolet light for 30 seconds.
3.2.4 Data Analysis
Comparisons of the values for fluorescence of cells transfected with either
pCAN1-GFP or pCAN1-eGFP were performed with a paired Student's t-test. Levels
. of significance were measured and any P values less than 0.05 were considered
significant. All numerical values are expressed as mean ± standard error of the
mean (SEM).
3.3 Results
3.3.1 Enzymatic Digestion of Plasmid DNA
To ensure that plasmids isolated from bacterial culture were the appropriate
constructs, plasmids were digested with various restriction enzymes and run on 1%
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agarose gels. This analysis would verify the molecular weight and confirm the
presence of either the reporter gene or ODN 2135 inserts. All plasmids were cut at
a single restriction site and the size of the plasmid was determined. The molecular
weights of pCAN1, PCAN1-GFP, pCAN1-eGFP, pMASIA and pBISIA-88 were 4058,
4731,4821,4232 and 4833 base pairs (bp), respectively (Fig. 3.1: Lanes 1,2,4,
7and 9). All plasmids except for pCAN1 were cut with two enzymes to confirm that
these plasmids contained the appropriate insert. The digests of plasmids pCAN1-
GFP and pCAN1-eGFP generated 724 and 4007 and 763 and 4058 bp DNA
fragments, respectively (Fig. 3.1: Lanes 3 and 5). The reporter proteins GFP and
eGFP correlate to the 724 and 763 bp segments. Similarly, digests of pMASIA and
pBISIA-88 produced 1221 and 3011 and 1221 and 3612 bp DNA fragments,
respectively (Fig. 3.1: Lanes 8 and 10). The ODN 2135 tandem repeat segment
(600 bp) is located within the 3612 DNA fragment of pBISIA-88. Diagrams of the
five plasmids are found in the appendix (Appendix: Fig. 1).
3.3.2 Transfection of COS 7 Cells with Plasmid DNA
The results from the plasmid digests suggested that both GFP and eGFP
were successfully cloned into the plasmid pCAN1. Gene insertion within the plasmid
does not necessarily ensure biological activity, however, as orientation of the insert
. could be inverted. To assess biological activity, plasmids were transfected into COS
7 cells and protein fluorescence was assessed. The results verified that both GFP
(Fig 3.2 and 3.3) and eGFP (Fig 3.3) were ligated with proper orientation into the
plasmid pCAN1 as COS 7 cells fluoresced following transfection with both plasmids.
Figure 3.3 demonstrates that the amount of fluorescence differed in cells transfected
with the two GFP inserts. It also shows that fluorescence was influenced by both the
concentration of plasmid and the duration of incubation following transfection. Cells
transfected with 2 J.1g of plasmid pCAN1-GFP and incubated for 48 hours had the
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Figure 3.3. The percentage of COS7 cells that fluoresce following transfection
with pCAN1-GFP or pCAN1-eGFP. The bar represents mean ± SEM and all
samples were run in triplicate.
a Significant difference in fluorescence of COS 7 cells transfected with 2 J.lg of
pCAN1-GFP and 2 J.1g pCAN1-eGFP (P < 0.05).
highest level of fluorescence. These results were similar to cells treated with 4 J.lg
of the same plasmid and incubated over 48 hour period. This suggests that gene
expression does not improve following transfection with more than 2 J.lg of plasmid.
Cultured COS 7 cells developed moderate levels of fluorescence following
transfection with pCAN1-eGFP. In this experiment, transfection was only examined
in cells treated with 2 J.lg of plasmid and incubated for 24 hours (Fig. 3.3). The
number of fluorescent cells following pCAN1-eGFP was approximately 48% of that
observed following pCAN1-GFP transfection (P < 0.05).
To determine whether the amount of GFP and eGFP expression differed in
transfected cells, the mean fluorescence intensity (MFI) was measured in COS 7
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cells following transfection. Table 3.1 demonstrates that cells transfected with either
2 Ilg of pCAN1-GFP or 2 Ilg of pCAN1-eGFP and incubated for 24 hours had similar
MFI. This indicates that transfected cells expressed both proteins with comparable
efficiencies. An increase in the MFI of transfected cells was also seen following
transfection with increased concentrations of plasmid as well as an increased
expression time post-transfection (Table 3.1). Interestingly, there was no variation in
the MFI of cells transfected with either 2 Ilg or 4 Ilg of pCAN1-GFP when analyzed
48 hours post transfection. This supports the finding that GFP expression is not
improved in cells transfected with concentrations of plasmid greater than 2 IlQ.
Table 3.1 Mean fluorescence intensity of COS 7 cells transfected with pCAN1-GFP
or pCAN1-eGFP.
Post-Transfection (hours)
Treatment 6 12 24 48
1 IlQ pCAN1-GFP 306 548.7 961.7 1720.0
± ± ± ±
19.0 14.7 108.0 55.2
2 Ilg pCAN1-GFP 481.6 1189 2217.6 2894.3
± ± ± ±
9.4 32.9 71.1 61.7
4 Ilg pCAN1-GFP 590.7 1220.7 1972.3 3081.0
± ± ± ±
30.5 109.4 48.2 159.6
2 J.1Q pCAN1-eGFP NO NO 2406.7 NO
±
119.0
Values represent the mean ± SEM for the fluorescence intensity of C07 cells
transfected with pCAN1-GFP and pCAN1-eGFP (n=3). NO indicates that the data
was not determined.
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3.4 Discussion
Development of plasmids with both strong immunostimulatory properties and
the potential to express high amounts of antigen is important in the development of
an effective DNA vaccine. Using this rationale, plasmids were designed that could
effectively express antigen and these plasmids were further supplemented with
strong immunostimulatory DNA sequences to improve adjuvanticity. Several
methods were employed to further improve antigen expression, including the
addition of the human cytomegalovirus (HMCV) promoter, intron A and poly [A] tail
sequences and the use of ampicillin resistance for plasmid selection. As an
example, the HMCV promoter has induced strong antibody responses in vivo.
Braun et al. (1997) compared antibody production in mice after treatment with
plasmids containing either Rous sarcoma virus or HMCV promoters. These
researchers showed that mice injected either intradermally or intramuscularly with a
plasmid containing HCMV promoter, induced rapid production of antigen-specific
antibodies that remained elevated for the duration of the experiment. In comparison,
mice injected with plasmid containing the Rous sarcoma virus promoter, produced
antibody titers that peaked weeks later than mice treated with plasmid incorporating
the HCMV promoter.
Plasmids with an intron A sequence also expressed higher levels of antigen
when compared to plasmids lacking the intron (Chapman et al., 1991). Expression
of a bacterial surface protein was absent in cells treated with plasmids missing intron
A. This differed from cells transfected with plasmids containing the intron, as these
cells had marked protein expression (Chapman et al., 1991). To further improve
gene expression, a poly [A] tail from bovine growth hormone was added to plasmids.
Poly [A] tails present at the 3' end of mRNA have been shown to improve mRNA
stability and gene expression (Pfarr et al., 1986). Finally, adjuvanticity can be
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improved by adding the ampicillin resistance gene to plasmids, as in vivo studies
showed improvement in immune responses following immunization with plasmids
expressing ~-Iactamase. Sato et al. (1996) for example, demonstrated a 9-fold
increase in antibody titers in mice injected with plasmids encoding ~-Iactamase
when compared to plasmids encoding kanamycin resistance. It is believed that the
presence of two additional immunostimulatory CpG motifs within the ampicillin
resistance gene is responsible for the enhanced adjuvanticity.
All plasmids generated have an origin of replication site derived from the self
replicating plasmid CoL E1, a plasmid that can generate large copy number in
bacterial culture (Clewell, 1972). Incorporating the origin of replication into plasmids
ensures the production of large quantities of plasmid.
The gene sequence encoding for the green fluorescent protein of jellyfish
(GFP) was added to the plasmid pCAN1 to facilitate the detection of cells
transfected with plasmid DNA during cell trafficking studies. The transfection
experiments demonstrated that both pCAN1-GFP and pCAN1-eGFP express
adequate levels of protein. Interestingly, pCAN1-eGFP transfection was
approximately one-half as efficient as pCAN1-GFP transfection (Figure 3.3). It is
difficult to explain the transfection differences between the two plasmids. The
. pCAN1-GFP did not express protein with greater efficacy than pCAN1-eGFP, as the
MFI of transfected cells were similar (Table 3.1). Furthermore, the protein
sequences of GFP and eGFP are quite similar and eGFP has been engineered to
have improved gene expression. The eGFP protein has modified translational
initiation sites (Kozak, 1987) and fluorescence is enhanced 100-fold by shifting the
light emission spectrum (Cormack et al., 1996). One possible cause for differences
in the amount of fluorescence was the potential for variations in test conditions.
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Cells were transfected with the two plasmids at different times and changes in test
conditions could alter transfection efficiency. Another possible explanation is that
pCAN1-GFP is incorporated into cells with greater efficiency than pCAN1-eGFP and
this transfection efficiency may be dose-dependent. This possibility is unlikely,
however, as both plasmids are similar in size and structure. Nevertheless, a dose-
response study with pCAN1-eGFP was not carried out to determine whether
transfection of cells with a higher concentration (4f.lg) of pCAN1-eGFP would have
improved transfection efficiency. The transfection experiments, however, verified
that both plasmids had adequate gene expression to detect transfected cells and
either plasmid could be used in the lymph node or cell trafficking studies.
The plasmid pMASIA was created from pMAS (Krieg at al., 1998) and pMAS
was generated from the plasmid pUk21-A2 by removing 36 CpG motifs from at least
15 immunoneutralizing DNA sequences. The plasmid pMAS was shown to generate
strong humoral and cell-mediated responses in vivo. Mice treated with pMAS for
example, demonstrated a 100/0 and 300% increase in CTL responses and hepatitis B
antigen antibody titers respectively, when compared to pUK21-A2 treated mice
(Krieg at al., '1998). The plasmid pBISIA-88 was created by inserting 11 tandem
repeats of the ODN 2135 dimer into pMASIA. For DNA sequences to be
immunostimulatory they must maintain a proper CpG orientation. If these
sequences are reversed and have a GpC orientation, the DNA segments are no
longer immunostimulatory. Proper orientation of the ODN 2135 insertion into
pMASIA was accomplished by cutting both the plasmid and oligodeoxyribo-
nucleotides (ODN) with restriction enzymes to form sticky ends. After annealing
ODN 2135 to its complementary strand, ODN 2135 was cut with the restriction
enzyme Avail to form sticky ends. The resulting duplex was joined end to end with
another Avail cut ODN 2135 to form a single large ODN containing 11 tandem
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repeats of the CDN 2135 dimer. The plasmid pBIS was also cut with Avail to form
sticky ends, and the tandem CDN was ligated into pBIS to create the plasmid pBIS-
88. The rationale for inserting tandem repeats of CDN 2135 into plasmid was based
on studies that demonstrated improved adjuvanticity in DNA vaccines containing
immunostimulatory CpG motifs (Sato et al., 1996; Roman et al., 1997). Plasmids
containing known immunostimulatory CDN provided an effective tool to address the
role of CpG motifs in modulating cell trafficking through a draining lymph node.
3.5 Summary
To study the effects of plasmid (bacterial) DNA on lymph node morphology
and cell trafficking, various plasmids were created. These plasmids included two null
vectors lacking inserts (pCAN1 and pMASIA), a plasmid with enhanced
immunostimulatory CpG motifs (pBISIA-88) and plasmids containing functional
eukaryotic reporter genes (pCAN1-GFP and pCAN1-eGFP).
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CHAPTER 4
LONG-TERM EFFECTS OF INTRADERMALLY INJECTED PLASMID DNA ON
THE DRAINING LYMPH NODE MORPHOLOGY
4.1 Introduction
Deoxyribonucleic acid (DNA) immunization is a recent innovation in vaccine
delivery. Bacterial DNA, usually in the form of double stranded circular plasmids,
has been extensively studied and used for DNA immunization. The relative ease
and low expense of large scale plasmid production and the simplicity of inserting
genes that encode antigens or modulate immune function makes plasmid DNA an
ideal candidate for immunization or gene therapy. Plasmid DNA has been
administered intramuscularly (Braun et al., 1997; van Drunen Littel-van den Hurk et
al., 1998), intravascularly (Kawabata et al., 1995; Lew et al., 1995; Isner et al., 1996)
and intradermally (Lew et al., 1995; Braun et al., 1997; van Drunen Littel-van den
Hurk et al., 1998) using techniques that varied from syringe and needle to ballistic
. delivery (Braun et al., 1997; van Drunen Littel-van den Hurk et al., 1998). The
method of delivery, location of injection and amount of plasmid DNA administered
can influence the immune response to an encoded antigen.
Initially, bacterial plasmid DNA was considered inert and an ideal vehicle for
immunization. Within the past decade, however, plasmid DNA has been shown to
induce B lymphocyte proliferation (Krieg et al., 1995) activate natural killer cells
(Yamamoto et al., 1992; Ballas et al., 1996; Cowdery et al., 1996) and enhance
production of cytokines that influence both cell-mediated (Corr et al., 1996; Klinman
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et al., 1996; Sato et al., 1996; Roman et al., 1997) and humoral (Klinman et al.,
1996; van Drunen Littel-van den Hurk et al., 1998) immune responses. It is believed
that bacterial DNA has inherent immunostimulatory properties. Unmethylated
cytosine and guanine dimers (CpG), flanked by two purines upstream and two
pyrimidines downstream to form a hexameric sequence may be responsible for this
phenomenon (Klinman et al., 1997). These CpG motifs occur approximately 16
times more frequently in bacterial DNA than in vertebrate DNA (Krieg et al., 1995). It
is postulated that these differences between bacterial and vertebrate DNA aid in the
recognition of microbial invasion and influence the capacity of the vertebrate immune
system to mount an appropriate response.
To date, the long-term effects of administering plasmid DNA on draining
lymph node size or morphology have not been investigated. As DNA vaccines may
be widely used in people and food producing animals in the future, the effects of
plasmid administration on lymph node size and morphology should be addressed.
The objective of this study was to use ultrasonography to follow changes in ovine
popliteal lymph nodes following plasmid DNA administration and then to examine
lymph nodes for macroscopic and histological changes.
4.2 Materials and Methods
. 4.2.1 Experimental Design and Lymph Node measurements
Five, 20-week-old male or female Suffolk sheep (Department of Poultry and
Animal Science, University of Saskatchewan, Canada), were injected intradermally
two centimeters distal to the lateral prominence of the head of the fibula with 400 IJg
(11Jg/lJl) of purified pCAN1 plasmid. An equal volume of saline was injected at the
same location on the contralateral leg. Ultrasound imagery of lymph nodes was
done every seven days for 28 days using a B-mode ultrasound scanner equipped
with a 7.5 MHz linear-array transducer (Aloka SSD-500 Instruments, Science and
104
Medicine Inc., Vancouver, Canada). The wool was shaved and measurements were
done transcutaneously over the caudo-Iateral aspect of the femorotibial joint in the
region of the popliteal fossa. Mineral oil was used as a coupling medium. The
transducer was maneuvered to obtain the most complete medial section of the
lymph node. The image was frozen and lymph node height and width were
measured using the integrated electronic calipers of the ultrasound machine. Area
measurements were estimated with the formula of an ellipse (~ height x ~ width x
1t). Sheep were euthanized 30 days after plasmid DNA injection and popliteal lymph
nodes were removed. Adipose tissue was stripped from the capsular surface and
lymph node volume and weight were assessed by water displacement and
gravimetric measurements, respectively. A midline section through the long axis of
each lymph node was fixed in 100k buffered formalin, processed routinely and
embedded in paraffin. Histological sections used for morphologic evaluation were
stained with hematoxylin and eosin (HE). Tissue sections were also stained with
Gordon and Sweet's silver stain for reticular fibers to delineate germinal centers and
help visualize changes within the medulla.
Total cortical and medullary areas of the lymph node were determined by
image analysis (Northern Eclipse, Empix Imaging Inc., Mississauga, Ont.). The
.diameter of germinal centers, thickness of medullary cords and distance spanning
medullary sinuses were measured with a micrometer at 100x and 400x
magnification. The total number of germinal centers was determined by counting all
germinal centers per histological section. To ensure an accurate measurement of
germinal centers, the radius of each germinal center was taken as the average of
two radii measurements. It was assumed that germinal centers were spherical and
the area of each germinal center was calculated (area =1t~). The total germinal
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center area was a calculated summation of all germinal center areas per histological
section. Measurements for medullary cords and sinuses were taken as the average
of measurements of five random locations within the medulla in histological section.
4.22 Data Analysis
Comparisons of the values for plasmid and saline-treated popliteal lymph
nodes were performed with a paired Student's t-test. Levels of significance were
measured and any P values less than 0.05 were considered significant. All
numerical values are expressed as mean ± standard error of the mean (SEM).
4.3 Results
4.3.1 Analysis of Popliteal Lymph with Ultrasound and Gravimetric and
Volumetric Measurements
Following plasmid injection, lymph node size was measured weekly.
Ultrasound measurements demonstrated a progressive increase in lymph node size
for both saline and plasmid DNA treatment (Fig.4.1). Lymph nodes were collected
on day 30 post-treatment and gravimetric analysis demonstrated a significant
increase (P < 0.05) in plasmid treated lymph nodes (Table 4.1).
4.3.2 Histological Measurements of Popliteal Lymph Nodes
Histological examination of control and plasmid-exposed lymph nodes
. revealed no statistically significant changes in total, medullary or cortical lymph node
area (Table 4.2). It is noteworthy, that a 400/0 increase in medullary area was not
statistically significant (P < 0.13); however, such a large change could have
biological. importance.
The most prominent histological changes in plasmid-exposed lymph nodes
were increased germinal center number and germinal center area, with marked
enlargement of medullary cords and sinuses. Figures 4.2a and 4.2b show that both
the number (71.4 ± 17.7) and total area (4.0 ± 1.3 mm2) of germinal centers within
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Figure 4.1 Ultrasound measurements of the area of popliteal lymph nodes
exposed to 400 IJg of plasmid (11Jg/lJl) or 400 IJI of saline over a 28-day period.
Bars represent mean ± SEM of values for 5 sheep.
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Lymph Node Plasmid DNA1 Saline2 Percentage
Change3Measurements
Weight (g) 2.8 ± 0.1 2.0 ±0.6
Volume (ml) 2.2 ± 0.8 1.6 ± 0.6
Density (g/ml) 1.5 ± 0.3 1.4 ± 0.1
Table 4.1. Gravimetric and volumetric measurements at 30 days post-exposure of
popliteal lymph nodes exposed to plasmid DNA.
Data represents the mean ± SEM for 5 sheep treated with plasmid or saline.
1400 J.11 (1 J.1g/J.1l) of plasmid DNA injected intradermally.
2Contralaterallymph node was exposed to 400 J.l1 of saline injected intradermally.
3percentage change represents the mean value of plasmid DNA treated lymph
nodes divided by the mean value for saline treated lymph nodes.
* Significant difference between plasmid and saline treated lymph nodes (P < 0.05).
107
a
,
D Sheep 1 ! L. C 7 bi.e: 100 0
- ~ 02co. • A Sheep2 E Q.u 6 I
'EEc L. _ ~;~~ 75 v v Sheep3 ~N '" 5
" E~~u o Sheep4 II- ~
... ~~ o 'a400. -0
~fIJ~ 50 0 o Sheep5 • ",z~ L. 3~~'a
_A_ D L. ~.e: f.Q~o « .... 0.EcZ i i E 2:J~ 25ZU D .... U)r, D0 ~ .J10 00 pCAN1 0Saline Saline pCAN1
_c
)r,.e:
•
E02 d
~ tc 150 c .. ~~ 75.. "(J)o ~
'a.Jo ~ " ~~ ~- U :J 'a~ ~1S T «coSO't5 Q.~ 100
•
~-c
'E'(J) u(J)
.. -
c )r,.e:
.. ::1'a .~Q.
--0 .... • Ec rnZ 50 D .!=)r,25':':'a 8 C -5.J
.Y S a ~~FU ~&
0 0Saline pCAN1
o
T
Saline
8
pCAN1
Figure 4.2 Histologc measurements of popliteal I~ph nodes 30 days post eXposLre.
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Table 4.2. Histological measurements at 30 days post-exposure of popliteal lymph
nodes exposed to plasmid DNA.
Lymph Node Plasmid DNA1
Measurements
Saline2 Percentage
Change3
Total Lymph Node Area
(mm2)
Cortical Area (mm2)
Medullar Area (mm2)
Percentage of Cortical
Area to Total Lymph
Node Area
Percentage of Medullary
Area to Total Lymph
Node Area
183.0 ± 43.0
56.4 ± 9.1
126.7 ± 36.4
34.4 ± 5.1
65.6 ± 5.1
141.0 ± 36.1
50.5 ± 8.6
90.5 ± 27.2
38.7 ± 8.5
47.3 ± 6.0
30
12
40
-11
38
Data represents the mean ± SEM for 5 sheep treated with plasmid or saline.
1400 JlI (1 Jlg/JlI) of plasmid DNA injected intradermally.
2Contralaterallymph node was exposed to 400 J.l1 of saline injected intradermally.
3Represents a percentage change of the mean values of plasmid DNA treated lymph
nodes relative to the mean values of saline treated lymph nodes.
the tissue section were increased significantly (P <0.05) in plasmid-exposed lymph
nodes when compared to control lymph node (40.4 ± 11.4 and 1.6 ± 1.2 mm2,
respectively). Figures 4.2c and 4.2d indicate that medullary cords were thickened
and medullary sinuses were wider in plasmid-exposed lymph nodes. Medullary
cords were significantly thicker (P < 0.01) in plasmid-exposed lymph nodes (114.2 ±
25.2 fJm) than in control lymph nodes (62.7 ± 14.9 jJm) and medullary sinuses of
plasmid treated lymph nodes (64.4 ± 2.5 fJm) were significantly more distended (P <
0.01) when compared to control lymph nodes (36.5 ± 1.0 fJm). Typical histological
changes within lymph nodes are presented with tissue from Sheep 4 (Fig. 4.3).
Plasmid treated lymph node from this animal displayed an approximately, two fold
increase in germinal center number. The plasmid-exposed lymph node (Fig. 4.3a)
had numerous clusters of germinal centers that extended to the deep aspect of the
cortex. These germinal centers were packed with round cells with open-faced nuclei
and abundant pale finely vacuolated eosinophilic cytoplasm (Iymphoblasts). The
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number of mitotic figures present varied (0-10 per germinal center) and several
macrophages containing phagocytized cell debris (tingible-body macrophages) were
apparent. Germinal centers in the control lymph node (Fig. 4.3b) were smaller,
seldom extended into the deep aspect of the cortex and had fewer mitotic figures (0-
2 per germinal center). Medullary cords in plasmid-exposed lymph node (Fig. 4.3c)
as compared to control lymph node (Fig. 4.3d) were markedly thicker, often tortuous,
and contained a cell population rich in small lymphocytes and plasma cells with
fewer Iymphoblasts and macrophages. Within plasmid-exposed lymph nodes,
sinuses separating medullary cords were dilated, often free of cells and occasionally
had reticular fibers that spanned the sinusoidal space (Fig. 4.3e). In contrast,
sinuses in control lymph nodes were narrow, with little separation of reticular fibers
(Fig.4.3f). These sinuses were populated primarily with macrophages and fewer
lymphocytes were evident.
4.4 Discussion
This investigation is the first report to demonstrate that bacterial DNA can
cause long-term changes in draining lymph node weight and morphology (Uwiera et
al., 2001). Morphometric and histological measurements of lymph nodes 30 days
post-injection, revealed changes in lymph node weight and architecture that were
. unique to the plasmid treated lymph node. The increased weight of plasmid treated
lymph nodes could be caused by either an accumulation of lymph, cells, or a
combination of the two. Our results suggested that these lymph node changes
correlated with an enlargement of the medulla as total cortical area remained
relatively constant (Table 4.2). Histological examination of the lymph nodes
revealed that plasmid DNA induced an increase in medullary size that was
associated with both increased cellularity and an accumulation of lymph (Fig. 4.3).
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Medullary cords are structures that extend into the medulla and are filled with
B-Iymphocytes, proplasmacytes and plasma cells (Straus, 1981; Wheater, 1987). In
plasmid-exposed lymph nodes, medullary cords were thickened and rich in lymphoid
cells and medullary sinuses were distended, with reticular fibers being widely
separated. Several studies have demonstrated that enlargement of medullary cords
can occur after administration of protozoal organisms (Masake, 1980), bacteria
(Sato et al., 1990; Spalding & Heath, 1991) and dextran (Spalding & Heath, 1991).
The injection of these antigens was associated with large distorted medullary cords
filled with plasma cells and Iymphoblasts. The sinuses were also dilated, displayed
fewer reticular fibers and displayed a prominent orientation towards the hilus. These
previous observations suggest that bacterial DNA either induced an active immune
response, or activated cellular events that mimic morphologic events induced by
foreign antigens.
Histological evaluation of plasmid-exposed lymph nodes also demonstrated a
marked enlargement of germinal centers. Germinal centers are composed
predominantly of B Iymphoblasts and follicular dendritic cells (Morrison, 1986).
Enlargement of germinal centers may have been the result of increased B cell
proliferation or a reduction in the death of Iymphoblasts. In the present experiment,
. germinal centers of plasmid-exposed lymph nodes were enlarged and rich in
Iymphoblasts with variable mitotic activity. These observations suggest an
enhanced generation of cells within germinal centers. Expansion of germinal
centers has been identified in animals challenged with endotoxin (Fujino et al.,
1996), protozoa (Masake, 1980), or bacteria (Sato et al., 1990). These researchers
have shown that following an insult, germinal centers can respond with increased
number, size and lymphoblast proliferation.
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Clonal expansion of B-Iymphocytes can be caused by the addition of B
lymphocyte mitogens such as endotoxin (Hadden, 1990). Endotoxin contamination,
therefore, is always a concern in plasmid prepared for DNA immunization. In our
experiments, less than 2 pg of endotoxin were detected in each plasmid injection.
Most studies have examined the effects of endotoxin on indicators of acute
inflammation (Boosman et al., 1989; Conner et al., 1989; Adams et al., 1990). One
study in mice, however, demonstrated enlargement of germinal centers and
medullary cords after endotoxin administration. The study did not extend beyond 10
days and therefore the long-term effect of endotoxin on germinal centers was not
assessed (Fujino et al., 1996). The amount of endotoxin used in these experiments
ranged from microgram to milligram quantities and greatly exceeded the quantity of
endotoxin delivered in our experiment. It is unlikely, therefore, that the lymph node
changes were caused by administering endotoxin. We cannot dismiss, however, the
possibility that a low level of endotoxin may interact synergistically with plasmid DNA
and accentuate changes seen within the cortex or medulla. Cowdery at al. (1996)
described that mice pre-treated with bacterial DNA produced large quantities of
interferon-y and interleukin-6 after endotoxin challenge. If bacterial DNA influences
cytokine profiles following endotoxin exposure, then it is possible that endotoxin
. exposure could influence changes in lymph node morphology following the
administration of bacterial DNA.
4.5 Summary
Our study demonstrated that purified bacterial plasmid DNA can elicit marked
long-term changes in lymph node weight and morphology in sheep. As plasmid
DNA is the primary vehicle used in DNA immunization, understanding the effect of
plasmid DNA on draining lymph nodes and thereby regional immunity is essential.
Further work is needed though, to determine the extent of both low levels of
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endotoxin and of immunostimulatory CpG plasmid motifs on draining lymph node
morphology. It is not feasible to construct a plasmid devoid of CpG sequences as
these sequences are found in areas essential for plasmid replication (Hashimoto-
Gotoh & Inselburg, 1979; Naito & Uchida, 1980). In the future, therefore,
construction of a plasmid with added numbers of immunostimulatory CpG motifs and
the further removal of endotoxin from plasmid preparations would help address
these questions.
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CHAPTER 5
EFFECTS OF INTRADERMALLY INJECTED PLASMID DNA AND ODN ON CELL
TRAFFICKING FROM THE DRAINING LYMPH NODE
5.1 Introduction
The role lymphocytes play in the development and maintenance of an
adaptive immune response has been extensively investigated. Many of the cellular
and molecular events that regulate the induction of humoral and cell-mediated
immunity have been well characterized. It has become evident, however, that the
induction and regulation of adaptive immunity is greatly influenced by the response
of the innate immune system to infection or inflammation (Fearon & Locksley, 1996;
Medzhitov & Janeway, 1997).
The innate immune system utilizes a variety of receptors, known as pattern
recognition receptors (PRR), to recognize pathogen-associated molecular patterns
(PAMP) that are unique to microorganisms (Fearon & Locksley, 1996). CpG motifs
. present within bacterial DNA act as PAMP (Krieg & Wagner, 2000) and can activate
a variety of cells involved in the induction of an adaptive immune response.
Unmethylated CpG motifs present in bacterial DNA or synthetic
oligodeoxyribonucleotides (ODN), for example can enhance B cell survival, influence
dendritic cell differentiation and induce cytokine secretion by B cells, monocytes,
natural killer cells and dendritic cells (Krieg et al., 1995; Ballas et al., 1996; Yi et al.,
1998). Further, the presence of immunostimulatory CpG motifs in plasmid DNA
vaccines (Roman et al., 1997; Klinman et al., 1997) or immunostimulatory ODN can
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substantially enhance antigen-specific humoral and cell-mediated immune
responses (Davis et al., 1998). Finally, treatment with ODN containing CpG motifs
can protect mice against challenge by a variety of bacterial pathogens (Klinman et
al., 1999; Weighardt et al., 2000). Collectively these observations implicate CpG
motifs as potent PAMP that effectively activate the innate immune system and
modulate the adaptive immune response.
Lymphocytes have the unique ability to migrate continuously from blood to
tissue and back to blood. The movement of lymphocytes between different immune
compartments is non-random (Abernethy et al., 1991; McKay et al., 1996) and
specific mechanisms have evolved to regulate lymphocyte trafficking. The
recirculation and homing of lymphocytes allows for continual communication
between different immune compartments, facilitates immunosurveillance and the
dispersion of 'immunological information' throughout the body (Young, 1999).
Although PAMP can induce the migration of inflammatory cells into tissues
(Schwartz et al., 1997; Deng et al., 1999), the effect of PAMP on lymphocyte
recirculation and, in particular, cell trafficking through draining lymph nodes has not
been fully investigated. Only one study has examined the effects of another PAMP,
LPS, on lymphocyte movement through a lymph node. The changes in cell
. trafficking induced by lipopolysaccharide were similar to those reported following
antigen treatment (Cahill et al., 1976). Factors that alter lymphocyte trafficking may
have a significant effect on the development and dissemination of an adaptive
immune response. We therefore, investigated the effects of bacterial DNA on
immune surveillance by measuring cell movement through the draining lymph node
and determined whether immunostimulatory CpG motifs were responsible for the
observed changes.
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5.2 Methods and Materials
5.2.1 Animals and Surgery
Suffolk ewes, one to five years of age, were used in all experiments
(Department of Animal and Poultry Science, University of Saskatchewan, SK,
Canada). The efferent lymphatic vessel of the prescapular lymph node was
cannulated as described by Glover & Hall (1976). The method was modified slightly,
by forming a loop with the tubing and suturing the loop to the subcutaneous tissue.
The tubing then exited the skin at a location ventral to the incision. Clot resistant
polyurethane tubing with a 0.95mm outer diameter was used for cannulation (Micro-
Renathane implantation tubing, Braintree Scientific Inc., MA, USA).
5.2.2 Plasmid Injection, Lymph Collection and Cell Preparation.
For the construction and preparation of the various plasmids used in cell
trafficking experiments, refer to Chapter 3. Lymph was collected in 250 ml
polyethylene bottles containing 100 U.S.P. of heparin (Hepalean, Organon, ON,
Canada) and 20 mg of sodium ampicillin (Penbritin-2000, Ayerst, QB, Canada) in 1
ml of sterile saline. Depending on the experimental protocol, lymph collection bottles
were changed every 30 minutes to twelve hours. Total cell numbers were measured
with either a hemacytometer or a particle counter with a 100 Jlm aperture tube
(Coulter Model 21, Coulter Electronics of Canada, ON, Canada). Animals were
rested 48 to 72 hours post-operatively to allow surgery-related changes in lymph
flow to subside. FollOWing this rest period, plasmids, linear DNA, calf thymus DNA
or ODN 2135 were injected intradermally 10-cm anterior to the tuber scapulae.
Lymph was collected over a 4-day post-treatment period and the number and
phenotype of lymph cells were analyzed. Cells were washed three times with
phosphate buffered saline (PBS) and then resuspended in PBS prior to phenotype
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analysis. Dendritic cells were isolated using the method described by Knight et al.
(1983). Briefly, lymph cells were layered on a 14.5% (wtIvol) metrizamide gradient
made with medium (Iscove's modified Dulbecco's media, Gibco-BRL, ON, Canada)
containing 10% FBS (Gibco-BRL, ON Canada). These lymph cells were centrifuged
for 10 min at 600 x 9 and cells at the interface were collected.
5.2.3 Flow Cytometry.
For both single and dual staining immunofluorescence, 2 x 106 lymph cells
were labeled with primary monoclonal antibody (mAb) in a total volume of 100 Jll.
Isotype-specific goat anti-mouse Ig (CalTag Laboratories, CA, USA), conjugated
with either fluorescein isothiocyanate or phycoerythrin were diluted at 1:100 (v/v) in
FAcola (0.1 M PBS, 0.20/0 gelatin, 0.030/0 NaH3) was then used to detect mAb in dual
and single labeled cell preparations. An isotype matched mouse monoclonal
antibody was used as a control for non-specific mAb binding to cells. Labeled cells
were fixed in 2% paraformaldehyde in PBS and stored in the dark at 4 °C until
analyzed with a FACSscan flow cytometer (Becton Dickinson, CA, USA). The Cell
Quest (Becton Dickinson, CA, USA) program was used for data acquisition and
analysis.
5.2.4 Monoclonal Antibodies.
The following mAb were used for flow cytometric analysis. The mAbs for
ovine slgM (Plg45A), MHC Class II (TH81A5), CD25 (CACT116A) and monocytesl
granulocytes (DH59B) were purchased from VMRD (Pullman, WA USA). The mAbs
for ovine CD1 b (VPM5) and mouse control IgG1 were purchased from Serotec
(Raleigh, NC, USA), Boehringer Mannheim (Laval, QB, Canada) and Novocastra
Laboratories LTD, (Newcastle, UK), respectively. Dr. W. Hein (Agriculture Research,
Wallaceville, NZ) generously provided hybridomas from which the mAb specific for
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sheep CD5 (ST1a), CD45R (20-96), CD4 (17D-13), CD8 (E95), y8TCR (86D) and
LFA1 (F1 0-150) were produced.
5.2.5 Data Presentation and Statistical Analysis.
In Figs. 5.1, 5.2, and 5.4 to 5.14, the cell number in lymph is expressed as
the mean ± standard error of the mean (SEM) for values from 3-6 sheep. Post-
treatment values are expressed as a percentage change from the pre-treatment
value, which is expressed as 100°,10. Figure 5.3 presents changes in cell number
(cell/hour) for each lymphocyte sub-population identified. Comparison of values
between treatment groups was performed with a Kruskal-Wallis analysis and a
Dunns comparison (GraphPad Prism, CA, USA). P values less than 0.05 were
considered significant.
5.3 Results
5.3.1 Plasmid DNA Increases Cell Number in Efferent Lymph.
Purified plasmid DNA was used as a source of bacterial DNA with a known
nucleic acid sequence. To determine whether plasmid DNA altered cell trafficking
and to monitor possible DNA transfection and expression, the pCAN1 vector,
containing the eGFP reporter gene (pCAN1-eGFP), was injected intradermally.
Efferent lymph was collected over a 4-day post-treatment period to measure cell
. traffic (cell/hour) following a single intradermal injection of 4 /-1g, 40 /-1g and 400 /-1g
plasmid DNA. An significant increase (P <0.05) in cell trafficking was observed with
as little as 4 /-1g of plasmid and this increase was evident as early as 6 hours post-
treatment (Fig. 5.1 a). At 24 hours post-treatment, the increase in cell traffic ranged
from a 150 to 6500/0 increase relative to cell number in lymph collected in sheep
following the injection of 400 f.Lg calf thymus DNA (CT DNA). There were no
significant differences in the cell trafficking response induced by the three
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Figure 5.1. Intradermal injection of plasmid DNA increases cell numbers in the
efferent lymph of the draining prescapular lymph node. a A comparison. of cell
trafficking following the injection of different doses of pCAN1-eGFP plasmid (eGFP)
and calf thymus DNA (CT DNA). b A comparison of cell trafficking following the
injection of restriction enzyme digested pCAN1-eGFP plasmid (Linear DNA), intact
PCAN1 plasmid (pCAN1), and calf thymus DNA (CT DNA). Data are presented as a
percentage change in cell number (cells/hour) relative to lymph collected 24 hour
prior to injecting DNA. Data are presented as the mean ± SEM of values from each
treatment group (n = 6 for CT DNA and n = 3 for all other groups).
* Significant difference between plasmid DNA and CT DNA controls (P <0.05).
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concentrations of plasmid. Nonetheless, it did appear that increased cell trafficking
persisted longer and was more consistent following treatment with 40 Jlg and 400 Jlg
plasmid DNA than with 4 Jlg plasmid DNA (Fig. 5.1 a). Flow cytometric analyses did
not detect any fluorescent cells expressing eGFP in samples of total lymph cells.
While flow cytometric analysis detected very low numbers of potential CD1 b+ cells
and DH59B+ cells following centrifugation on a density gradient, there were no
significant differences among treatment groups (Table 5.1 and 5.2).
These observations suggested that plasmid DNA might directly increase cell
traffic through a lymph node. To determine whether the expression of a foreign
protein (GFP) contributed to the observed increase cell trafficking, we injected 400
Jlg of the pCAN1 vector lacking the eGFP gene insert. The pCAN1 plasmid by itself
induced a rapid and prolonged rise in cell traffic that was statistically significant (P <
0.05) on days 1 and 2 post-treatment (Fig. 5.1 b). The increased cell flow varied
between 150-225% of the pre-treatment values and was not statistically different
from cell flow rates observed following the injection of 400 Jlg of pCAN1-eGFP
plasmid. Therefore, these two independent experiments clearly demonstrated that
intradermal injection of plasmid DNA, with or without an encoded eukaryotic reporter
gene, induced a significant and prolonged increase in cell trafficking through the
draining lymph node.
5.3.2 Circular Plasmid is Required to Induce Increased Cell Flow.
As plasmid DNA is a circular form of bacterial DNA, we investigated the
possibility that the circular form of plasmid DNA was required to induce a cell traffic
response. The pCAN1-eGFP plasmid was digested into two linear segments and
400 Jlg of digested plasmid DNA was injected intradermal/y. This linear plasmid DNA
did not induce a significant increase in cell trafficking (Fig. 5.1 b). Therefore, we
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Table 5.1. The number of CD1 bhighp220- cells collected from gradient-enriched
efferent lymph cells following treatment with calf thymus DNA, plasmid, linear DNA
or oligodeoxyribonucleotides.
Number of CD1 b+P220- cells collected from Efferent LymphB
(x104 cell/hour)
Time Post-Treatment (days)
Treatmentb 0 1 2 3 4
CT DNA 0 0.66 ± 0.78 0 0 0
4 ,...g eGFP 0 0 0 0 2.2 ± 1.2
40,...g eGFP 0 0 1.2 ± 1.0 0.33 ± 0.3 0
400 ,...g eGFP 0 0 0 3.4 ± 2.0 3.2 ± 1.0
400 ,...g Linear DNA 0 3.3 ± 2.0 2.3 ± 2.3 2.6 ± 1.7 0
11.7,...g CON 2135 0 0 0.66 ± 0.58 0 0
585 ,...g CON 2135 0 0 2.6 ± 1.5 1.6 ± 1.6 0
400,...g pCAN1 3.0 ± 1.3 0.5 ± 0.5 0.5 ± 0.5 0.7 ± 0.5 0.5 ± 0.5
40 Jlg pMASIA 0 0 1.0 ± 0.3 1.0 ± 0.1 1.0 ± 0.1
40 Jlg pBISIA-88 0 0 0 0 1.3 ± 1.3
400 ,...9 pBISIA-88 1.3 ± 1.3 0 0 1.0 ± 1.0 1.3 ± 0.2
Abbreviations: CT DNA calf thymus DNA; eGFP pCAN1-eGFP; Linear DNA digested
pCAN1-eGFP; CON 2135 oligodeoxyribonucleotides.
Data is presented as mean ±SEM of values for each treatment group (CT DNA: n=6,
pCAN1: n=4; and for all other treatment groups: n=3).
B Cells were collected from gradient enriched lymph and the frequency of
CD1 bhighp220- cells were quantified with flow cytometry. Total CD1 bhighp220- cell
number represents the frequency of CD1 b+P200- cells multiplied by the total number
of cells collected in lymph per hour.
b All treatments were diluted in saline and delivered intradermally in a total 400JlI
volume.
concluded that circular plasmid DNA was required to induce a significant increase in
cell trafficking.
5.3.3 CpG motifs in Plasmid DNA Induce Increased Cell Trafficking.
Since unmethylated CpG motifs in bacterial DNA have been associated with
potent immunostimulatory activities, we investigated the possibility that such
immunostimulatory CpG motifs were required to induce a cell trafficking response to
plasmid DNA. The effect of CpG motifs on cell trafficking was investigated by using
both linear immunostimulatory CON and the same immunostimulatory CpG motifs
inserted into plasmid DNA. To facilitate a comparison with previous experiments,
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Table 5.2. The number of DH59ShighCD1 b·cells collected from efferent lymph
following treatment with calf thymus DNA, plasmid, linear DNA or
oligodeoxyribonucleotides.
Number of DH59B+highCD1 b-cells Collected from Efferent Lympha
(x104 cell/hour)
Time Post-Treatment (days)
Treatmentb 0 1 2 3 4
CT DNA 4.0 ± 0.8 0 0.3 ± 0.4 0 0
. 4 J.Lg eGFP 0.26 ± 0.27 0 0 0 0.6 ± 0.7
40J.LgeGFP 1.0±1.0 0 3.0±1.0 2.0±1.7 0
400 J.Lg eGFP 7.5 ± 4.0 5.3 ± 5.0 4.0 ± 1.0 0.3 ± 0.3 0
Linear DNA 0 0.3 ± 0.3 2.0 ± 2.0 3.4 ± 1.7 0
11.7 J.Lg ODN 0 0 0.66 ±0.58 0 0
400 J.Lg ODN 0 0 1.6 ± 1.6 0 0
400 J.Lg pCAN1 1.3 ± 1.3 1.3 ± 1.3 0 0.5 ± 0.5 0.5 ± 0.5
40 J.Lg pMASIA 0 0 0 0 0
40 J.Lg pBISIA-88 0 0 0 0 0
400 J.Lg pBISIA-88 2.0 ± 1.7 0 4.7 ± 0.5 1.3 ± 1.3 1.3 ± 1.3
Abbreviations: CT DNA calf thymus DNA; eGFP pCAN1-eGFP; Linear DNA digested
pCAN1-eGFP; ODN 2135 oligodeoxyribonucleotides.
Data is presented as mean ±SEM of values for each treatment group (CT DNA: n=6,
pCAN1: n=4; and for all other treatment groups: n=3)
a Cells were collected from lymph and the frequency of DH59BhighCD1 b-cells were
quantified with flow c~ometry. Total DH59BhighCD1 b- cell number represents the
frequency of DH59B+h,ghCD1 b- cells multiplied by the total number of cells collected
in lymph per hour.
b All treatments were diluted in saline and delivered intradermally in a totaI400J.L1
volume.
the molarity of CpG dinucleotide delivered was calculated. On this basis, the low
dose of ODN 2135 (11.7 J.Lg) had a CpG dinucleotide content equivalent to 400 J.Lg of
.pCAN1 and the high dose of ODN 2135 (585IJ.g) had a CpG dinucleotide content
equivalent to 20 mg of pCAN1. Cell trafficking was not significantly changed by the
intradermal injection of either a low or a high dose of linear ODN 2135 (Fig. 5.2 a).
These observations indicated that either CpG motifs were not involved in the cell
trafficking response or, as suggested by the previous experiment, that linear
bacterial DNA is poor at effectively inducing this biological response.
To address the question whether the form of immunostimulatory CpG motifs
influences cell trafficking, it was necessary to first identify a DNA plasmid that, by
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Figure 5.2. CpG motifs, in the context of plasmid DNA, increased cell numbers
in the efferent lymph of the draining prescapular lymph node. a A comparison of
cell trafficking following the injection of 11.7 ug (Low CON 2135) or 585 ug (High
CON 2135) of immunostimulatory CON and calf thymus DNA (CT DNA). b A
·comparison of cell trafficking following the injection of 40 ug or 400 ug of either
pMASIA plasmid (pMASJA) or pMASIA plasmid containing tandem repeats of the
immunostimulatory CON 2135 sequence (pBISIA-88) and calf thymus DNA (CT
DNA). Data are presented as a percentage change in cell number (cells/hour)
relative to lymph collected 24 hour prior to injecting DNA. Data are presented as
the mean ± SEM of values from each treatment group (CT DNA: n = 6; pCAN1: n
=4; CON 2135, pMASIA and pBISIA-88: n =3).
* Significant difference between plasmid DNA and CT DNA controls (P <0.05).
:t: Significant difference between 40 ug pBISIA-88 and 400 ug pBISIA-88
(P<0.05).
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itself, did not induce a significant change in cell trafficking. The pMASIA plasmid
was selected, as it is similar in size to pCAN1 and both plasmids contain similar
numbers of CpG dinucleotides. The pCAN1 plasmid however, does contain a
leading 5'-TCGT-CGTT-3' motif located 2 bases upstream from a known
immunostimulatory CpG motif. This leading sequence is essential for OON induced
cell activation of blood mononuclear cells of cattle (Pontarollo et al., 2001). The
pMASIA plasmid also differs from pCAN1 by incorporating one more known
immunoneutralizing CpG motifs. The intradermal injection of either 40 or 400 .ug of
pMASIA did not induce a significant increase in cell traffic (Fig. 5.2 b). On this basis
the pMASIA plasmid, therefore, was deemed suitable and subsequently modified
through the insertion of 11 tandem repeats of the immunostimulatory OON 2135
sequence (pBISIA-88) (Refer to Chapter 3).
Intradermal injection of 40 ~g of pBISIA-88 induced a rapid increase in cell
trafficking (6 hours) that was significantly different (P <0.05) from CT DNA at 24
hours post-treatment (Fig. 5.2 b). In contrast, injecting 400 ~g pBISIA-88 did not
induce a significant change in cell trafficking throughout the 4 day post-treatment
period (Fig 5.2b). Furthermore, there was a significant difference (P <0.05) between
the level of cell trafficking induced by 40 ~g and 400 ~g of pBISIA-88 at 6 hour and
24 hours post-treatment. These results clearly indicated that CpG motifs, in the
context of circular plasmid, could induce an increase in cell traffic through a lymph
node. It was apparent also that the induction of increased cell trafficking by
immunostimulatory CpG motifs was dose-dependent with a high dose of CpG having
no apparent effect on cell trafficking.
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5.3.4 Kinetics of Cell Trafficking Response Following Plasmid Treatment.
The kinetics of a biological response can reveal significant information
regarding cell signaling mechanisms, the need for gene expression and for de novo
protein synthesis. Previous experiments indicated that a significant increase in cell
trafficking occurred within 6 hours after injecting pCAN1-eFGP plasmid (Fig. 5.1 a).
The kinetics of this response was examined further by injecting 400 J.lg of pCAN1
plasmid intradermally and then collecting lymph 30 min later and at hourly intervals
for the next 6 hours. Although not statistically different from pre-treatment values,
there was a 50% increase in cell number that was observed within 30 minutes and
this gradually increased throughout the 6 hour post-treatment period (Fig. 5.3). This
experiment revealed a very rapid onset in the cell traffic response to plasmid DNA
but, when viewed collectively with previous observations (Fig. 5.1 and 5.2), it is
clearly evident that the maximum cell traffic response observed in this study required
at least 24 hours to develop. Thus, while plasmid DNA may have a direct or
immediate effect on cell recruitment or cell retention within the lymph node, the
gradual increase in cell traffic over a 24 hour period, however, suggests that plasmid
DNA induces the production of factors that influence cell recruitment and traffic
through a lymph node.
5.3.5 Lymphocyte Populations Involved in the Response to Plasmid DNA.
Cell trafficking responses frequently involve specific cell populations or
lymphocyte subsets. The characterization of the specific cell populations present in
lymph can provide insight into the nature or specificity of the signals involved in cell
recruitment to, and trafficking through, a lymph node. Throughout each of the
previous experiments, the phenotype of cells present in lymph was analyzed by flow
cytometry. Efferent lymph contained only lymphocytes: while the majority were T
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Figure 5.3. The kinetics of lymphocyte trafficking into the efferent lymph of
the prescapular lymph node following intradermal injection of 400 ~ pCAN1
plasmid. Data are presented as a percentage change in cell number
(cells/hour) relative to lymph collected 24 hour prior to injecting DNA. Data
are presented as the mean ± SEM of values from four sheep.
cells (Fig. 5.4 a-5.14 a) all T cell and 8 cell subpopulations analyzed contributed to
the increased cell trafficking induced by plasmid DNA (Fig. 5.4 b,c-5.14 b,c).
Furthermore, an analysis of CD25 (lL-2R<l) expression on the total T cell
(CD5+) population and of MHC Class II expression on CD4+ T cells did not reveal a
significant change in the number of activated T cells leaving the lymph node (Fig. 5.4
. d-5.14 d). Thus, the phenotypic analyses indicated that plasmid DNA induced a
non-selective trafficking of lymphocytes through the lymph node.
The phenotypic analysis also revealed the presence of extremely small
numbers of CD1 b+cells and DH59B+ cells in efferent lymph (Table 5.1 and 5.2).
This finding was inconsistent and statistical analyses revealed no significant
differences between the various treatment groups. The CD1 b cluster determinant is
expressed on dendritic cells, 8 cells, macrophages and monocytes and in this
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experiment, almost all CD1b+ corresponded to CD45R+ cells (B cells). Therefore,
the presence of CD1 b+ cells was not a definitive indicator of dendritic cells.
5.4 Discussion
The innate immune system is a phylogenetically old system that is found in
all multicellular organisms and uses receptors encoded in germline DNA (Medzhitov
& Janeway, 1997). In vertebrates, cells associated with innate immunity utilize PRR
to recognize conserved PAMP and PRR binding then to activate cells involved with
acquired immunity (Fearon & Locksley, 1996; Medzhitov & Janeway, 1997). Indeed,
it has become apparent that the innate immune system controls both the activation
and differentiation of cells involved in the adaptive immune response that arises
following exposure to a pathogen (Fearon & Locksley, 1996; Medzhitov & Janeway,
1997). Our hypothesis was that immunostimulatory CpG motifs, a known PAMP,
may also influence adaptive immune responses by altering the movement of cells
through a lymph node. Increased lymphocyte trafficking through a regional lymph
node is one of the hallmarks of an adaptive immune response and provides a
mechanism to optimize screening of the available immune repertoire (Smith et al.,
1970b; Cahill et al., 1976). The experiments were designed, therefore, to determine
whether bacterial DNA could alter lymphocyte trafficking through a regional lymph
node. Indeed, the data that immunostimulatory CpG motifs can increase lymphocyte
recruitment provides further evidence that recognition of PAMP by the innate
immune system can influence adaptive immune responses.
The present investigation identified some factors that might influence the
capacity of immunostimulatory CpG motifs to signal an increase in lymphocyte
trafficking. A dose-dependent facet to this signal was clearly evident as
demonstrated by changes in cell flow following treatment with the CpG enhanced
pBISIA-88 plasmid (Fig. 5.2 b). Furthermore, circular plasmid DNA was also
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required to induce a significant increase in lymphocyte trafficking (Fig. 5.1 b). It is
difficult to interpret the biological significance of these observations without a
complete understanding of the mechanism by which CpG motifs bind to and activate
cells and without knowing the mechanism by which CpG motifs alter lymphocyte
trafficking. Several investigations indicate that cell surface receptors that bind DNA
do not activate cells directly and that CpG motifs must be endocytosed for activation
to occur (Hacker et al., 1998; Macfarlane & Manzel, 1998). It has also been shown
that CpG induced cell activation is dependent on the presence of Toll-like receptor-9
within cells and that this protein could be an intracellular receptor for CpG DNA
(Hemmi et al., 2000). It remains to be determined, however, whether DNA binding
to cell surface receptors, a process which is not sequence specific (Kimura et al.,
1994), facilitates the subsequent uptake of CpG motifs into cells involved in cell
trafficking,
The present observations might have relevance for understanding the
mechanisms by which DNA vaccines activate the immune system. A dose-
dependent effect of CpG motifs on lymphocyte trafficking is consistent with previous
reports that the adjuvanticity of CpG motifs is also dose-dependent. As an example,
injection of plasmid containing moderate numbers of CpG motifs elicits strong
.antibody responses, while treatment with plasmids containing high numbers of CpG
motifs induced a lower level of antibody production (Krieg et al., 1998). It is
apparent that excessive amounts of CpG can suppress biological responses in a
variety of systems. It is tempting to speculate that the CpG content of bacterial DNA
may regulate physiological processes namely cell trafficking, and antibody
production, in a dose-dependent manner. It is possible that by generating vastly
different cell trafficking responses to small changes in the amount of CpG motifs
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present in bacterial DNA, a sophisticated mechanism has evolved to monitor
bacterial insult.
The lack of activity observed with linear DNA may not be explained solely by
rapid degradation by nucleases present in skin (Anai et al., 1981) and lymph nodes
(Lacks, 1981). It has been shown that both plasmid DNA and digested plasmid DNA
induced strong activation of bovine mononuclear cells (Pontarollo et al., 2001).
Alternatively, DNA retention and uptake may be greater for plasmid than linear DNA
as indicated by transfection studies in vitro and in vivo. Cultured cells transfected
with plasmid DNA for example, had a 10-fold increase in gene expression when
compared to cells transfected with linear DNA (Upcroft, 1987). Similarly, in
comparison to circular plasmid, there was a markedly lower level of gene expression
in muscle following the injection of linear DNA (Danko & Wolff, 1994). Thus, the
biological relevance of a cell trafficking response being dependent upon intact
plasmid is intriguing. One explanation may be that the circular form of bacterial DNA
acts as a signal that alerts the immune system to microbial invasion. It is known that
bacteria can release both chromosomal DNA as welt as large pJasmids into the
surrounding area during periods of either bacterial cell growth or lysis (Muto & Goto,
1986). Therefore, the injection of circular plasmid may mimic a physiological
condition that occurs during bacterial infection and that is important for regulating
cell traffic to the draining lymph node.
The differences observed in cell trafficking responses following treatment
with plasmids of similar size and number of CpG motifs suggest that other factors
within plasmids might influence these responses. It is interesting that pMASIA
plasmid failed to induce an increase in cell trafficking, while pCAN1 evoked marked
and prolonged enhancement in cell trafficking (Fig. 5.1 band 5.2 b). One possible
explanation for these differences in plasmid activity may be the presence of a
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leading 5'-TCGTCGTT-3' motif situated 2 bases upstream from a known
immunostimulatory CpG motif. Although only weakly immunostimulatory on its own,
this sequence is essential for cell activation by immunostimulatory CpG motifs in
bovine mononuclear cells (Pontarollo et al., 2001). As an illustration, in CpG motifs
with only moderate immunostimulatory activity, such activity will be markedly
improved if this leading sequence is added upstream (Pontarollo et al., 2001). A
second possibility is that the presence of an extra immunoneutralizing CpG motif
within pMASIA may have dampened the immunostimulatory effects of CpG motifs
present within the plasmid. It has been shown that the addition of synthetic
immunoneutralizing CpG motifs can substantially impair the induction of immune
responses following DNA vaccination (Krieg et al., 1998). These studies and the
present observation support the conclusion that cell proliferative responses and cell
trafficking responses can be affected by the number of immunostimulatory CpG
motifs present within a plasmid, and these activities can be further modulated by
other DNA sequences as well.
The kinetics of lymphocyte trafficking following treatment with plasmid DNA
revealed a very acute response (30 min) that gradually increased in amplitude over
a 24 hour period (Fig. 5.3). This temporal pattern is consistent with more than one
.cell signaling pathway and/or multiple soluble mediators being involved in the
regulation this response. High endothelial venules (HEV) may be one site of a
lymph node that is affected by plasmid treatment. The release of cell mediators,
namely cytokines and chemokines, that either quickly disperse to HEV or HEV
glycocalyx or use the fibroblastic reticular conduit system, could rapidly alter cell
migration. Within the last decade, a variety of chemokines that modulate
lymphocyte binding to endothelium and movement throughout lymph nodes have
been identified (Baggiolini, 1998). Indeed, chemokines can induce the adherence of
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lymphocytes to cell adhesion molecules (Gunn et al., 1998) and within minutes
cause cells to migrate from blood vessels into the paracortex of the lymph node
(Larsen et al., 1989). Immunostimulatory CpG motifs can induce the secretion of
numerous chemokines, including MIP-1 a, MIP-1~, MIP-2 and RANTES, which are
associated with the migration of different lymphocyte populations within lymph nodes
(Takeshita et al., 2000). Treatment with immunostimulatory CpG motifs will increase
the rapid and prolonged production of these chemokine mRNA in lymph node
macrophages (Takeshita et aI., 2000). Immunostimulatory CpG motifs will also
increase secretion of cytokines such as TNF-a, IFN-a, IFNy, IL-6 and IL-12 (Ballas
etal., 1996; Sato etal., 1996; Yi etal., 1998). Of these only IFN-a has been
evaluated in vivo in sheep and it has been shown to promote lymphocyte migration
into, but not out, of lymph nodes (Kalaaji et al., 1988). Further investigations are
required to determine if increases in chemokine or cytokine levels are responsible
for the acute and sustained increase in lymphocyte trafficking following plasmid DNA
treatment. The likelihood of DNA acting directly on HEV to enhance cell flow is
remote since the large net electronegative charge present on both plasmid DNA and
the glycoproteins within the endothelial glycocalyx would likely prevent this
interaction (Van Damme et al., 1994).
The lymphocyte trafficking response to plasmid DNA is distinct from the
response observed following the injection of either antigen or LPS, a known PAMP.
The most immediate consequence of antigenic challenge is an abrupt shut down or
decrease in emigration of lymphocytes followed first by a significant increase in cell
number in efferent lymph and thereby the appearance of blast and activated
lymphocytes (Smith et al., 1970b; Hay et al., 1972; Cahill et al., 1976). Depending
upon the antigenic stimulus, the cellular composition of lymph may be significantly
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altered. In contrast to antigen treatment, the injection of plasmid DNA did not induce
a 'shut down' in cell traffic or detectable changes in the cellular composition of
efferent lymph or the number of activated lymphocytes (Fig. 5.4-5.14). The results
of these phenotypic analyses were consistent with non-selective recruitment of
lymphocytes from blood to efferent lymph. One possible explanation for a non-
selective increase in cell trafficking is a simple increase in blood flow to the lymph
node (Hay & Hobbs, 1977). Hyperemia is a cardinal sign of inflammation and
several studies in mice have indicated that CpG motifs can induce an inflammatory
response (Schwartz et al., 1997; Deng et al., 1999). It is tempting to speculate that
during a bacterial infection, bacterial DNA may serve to enhance cell recruitment
from blood while bacterial antigens promote cell retention and cell activation within
the lymph node. A coordinated interaction between these two biological responses
might ensure the rapid and efficient induction of an adaptive immune response.
As mentioned previously, the effects of LPS and of bacterial DNA on cell
trafficking kinetics are markedly different. Exposure to LPS in sheep causes a rapid
and prolonged shut down in cell traffic followed by a marked increase in cell flow
(Cahill et al., 1976). In contrast, bacterial DNA (plasmid), caused a rapid and
prolonged increase in cell trafficking. It is intriguing that two different PAMP (LPS
. and CpG in bacterial DNA) display such distinct and different effects on lymphocyte
trafficking. It is possible that the opposing responses induced by LPS and bacterial
DNA may ensure that appropriate numbers of cells enter and leave the lymph node
to disseminate information to other immune compartments. These very different
responses to PAMP may provide a mechanism to modulate the magnitude and type
of host response to individual pathogens.
Previous studies have shown that immunostimulatory CpG motifs can
enhance the recruitment of effector cells, such as neutrophils and NK cells, to the
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lung (Schwartz et a/., 1997). This cell recruitment has obvious implications for
immune surveillance, but the recruitment of lymphocytes to a lymph node identifies a
novel mechanism by which a known PAMP might serve to integrate innate and
adaptive immune responses. It remains to be determined whether changes in cell
trafficking have a direct affect the induction and duration of an acquired immune
response.
5.5 Summary
Bacterial DNA acts as a PAMP that, primarily through immunostimulatory
CpG motifs, induces the secretion of numerous chemokines and cytokines and
activates a variety of effector cells (Ballas et a/., 1996; Sato et a/., 1996; Yi et a/.,
1998; Takeshita et a/., 2000). The possibility that either plasmid DNA or CON
containing CpG motifs might modulate immunosurveillance by altering cell traffic
through a regional lymph node was investigated. This is the first study to
demonstrate that plasmid DNA and CON do indeed affect cell trafficking (Uwiera et
a/., 2002). The intradermal injection of plasmid DNA induced rapid and prolonged
increases in the number of lymphocytes present in efferent lymph. This effect on
cell trafficking was not dependent on the expression of an encoded reporter gene
but varied with plasmid construct and required circular plasmid DNA. The possibility
. that CpG motifs were responsible for inducing the increase in cell trafficking was
further examined. CON containing immunostimulatory CpG motifs were injected
intradermally, either alone or as tandem repeats within a plasmid insert. CON alone
did not alter lymphocyte trafficking but CpG enhanced plasmid induced a dose-
dependent increase in cell trafficking. Phenotypic analyses of lymphocytes collected
in the efferent lymph revealed that the increase in cell trafficking involved all
lymphocyte subpopulations and represented a non-selective movement of cells.
These observations reveal that plasmid (bacterial DNA), through immunostimulatory
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CpG motifs, can alter immunosurveillance nonspecifically by increasing cell
recruitment to a regional lymph node.
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CHAPTER 6
SHORT-TERM EFFECTS OF INTRADERMALLY INJECTED PLASMID DNA AND
ODN ON DRAINING LYMPH NODE SIZE, MORPHOLOGY AND RESIDENT CELL
POPULATIONS
6.1 Introduction
It is well documented that plasmid DNA activates cells involved in the
induction and maintenance of an immune response to proliferate and release
cytokines (Krieg at al., 1995; Klinman at al., 1996; Sparwasser at al., 1997).
Plasmid DNA can also encode antigen and once administered, can generate
protective antigen-specific humoral and cell-mediated immunity. It has become
apparent that immunostimulatory CpG motifs present within plasmid DNA can
influence the induction of these cellular responses in vivo and might act as an
adjuvant for DNA vaccines.
We have previously shown that injection of plasmid DNA causes long-term
changes in the size and architecture of draining lymph nodes (Uwiera at al., 2001).
Following plasmid treatment, lymph nodes increased in weight, germinal centers
were both larger and more abundant, medullary cords were thicker and medullary
sinuses expanded. Injection of plasmid DNA also caused marked changes in cell
trafficking through a draining lymph node with a rapid and prolonged (2-4 days)
increase in the numbers of cells that migrated into efferent lymph (Uwiera at al.,
2002). The presence of tandem repeats of CpG motifs within plasmid DNA
influenced cell trafficking. Cell migration through a lymph node increased when a
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low amount of plasmid (40 ~g pBISIA-88) containing tandem repeats of CpG motif
were administered to sheep. In contrast, high amounts (400 p,g) of the same
plasmid did not enhance cell traffic, suggesting that the presence of CpG motifs
affected cell migration in a dose-dependent manner (Uwiera et ~/., 2002).
To investigate whether changes in cell trafficking were associated with
functional or structural changes within a draining lymph node, the short-term effects
of plasmid DNA and CON on the size and morphology of sheep lymph nodes were
examined in this study. We analyzed changes in different resident lymph node
populations, measured the frequency of antigen-specific antibody cells and
assessed lymphocyte responses to cytokines. These measurements will determine
whether plasmid DNA or CON activated lymph node cells and if these changes were
indeed associated with cell trafficking responses.
6.2 Methods and Materials
Many of the materials and procedures employed in this study have been
already described in Chapters 4 and 5. This section will only deal with methods and
materials unique to the present experiment.
6.2.1 Animals and Experimental Design
Female Suffolk sheep ranging from eight months to five years of age
. (Department of Poultry and Animal Science, University of Saskatchewan, Canada)
were used in the experiments. All sheep were injected intradermally with either
plasmid DNA, CON 2135 or calf thymus DNA at a site that was approximately 10 cm
anterior to the tuber scapulae. Initially, sheep were injected at the same site with
150 ~g and 50 ~g of hen egg lysozyme (HEL) at 10 days and 4 days prior to
treatment, respectively. Sheep were then injected with 400 ~g (1 ~g/~1) of either
plasmid DNA, calf thymus DNA or CON 2135. Four hundred microliters of saline
148
were injected intradermally on the opposite shoulder and this contralateral lymph
node was used as an internal negative control. Sheep were euthanized 4 days post
DNA treatment and both prescapular lymph nodes were removed.
6.2.2 Lymph Node Collection, Cell Preparation and Flow Cytometry
For lymph node collection and histological assessment of the lymph nodes,
refer to Chapter 4. For cell preparation, flow cytometry and antibody staining, refer
to Chapter 5. Following lymph node removal, lymph nodes were cut longitudinally in
a medial plane. One half of the lymph node was used for histological measurements
while the other half was used to analyze the phenotype and function of different cell
populations residing within the lymph node and to quantify the frequency of HEL
specific antibody secreting cells. Single cell suspensions were prepared by gently
scraping the cut surface of the lymph node while it was immersed in PBS containing
0.1 % ethylenediaminetetraacetic acid (EDTA). Lymph node cells were filtered
through a 40 fJ.m nylon filter and washed three times with Dulbecco's minimal
essential medium (DMEM, Gibo-BRL, ON, Canada) and then resuspended in either
PBS for phenotype analysis or AIM-V medium (Gibco-BRL, ON, Canada) with 2%
FBS to measure cell proliferative responses and the frequency of antigen-specific
antibody secreting cells. Cells numbers were determined 'with a hemacytometer
.using trypan blue exclusion for assessing cell viability.
6.2.3 Measurement of Antibody Secreting Cells and Cell Proliferations
For the Enzyme-linked immunospot assay (ELISPOT), nitrocellulose plates
(Multiscreen nitrocellulose plates, Millipore, Molshem, France) were coated with HEL
(200 ng/well) in coating buffer (O.05M NaC03-, 0.05MNaHC03, O.003M NaH3, pH
9.6) at 4 °C for 12 hours. Some wells were treated with coating buffer without HEL
to provide controls for the specificity of antibody binding. Plates were washed 3
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times with PBST (0.05%) Tween 20 in PBS; vol/vol) and then washed 3 times with
PBS. Cells were then added to plates at a concentration of 1 x106 cells/well and
incubated at 37°C for 18 hours. Plates were washed 6 times with distilled water and
then washed 4 more times with PBST. Rabbit anti-sheep IgG (light and heavy
chain) polyclonal antibodies conjugated to alkaline phosphatase (Kirkegaard and
Perry Laboratories, MO, USA) were diluted in PBST (1/2000 ratio; vol/vol) and 100 fJ.1
were added per well. Rabbit anti-sheep IgG was incubated in the wells for 2 hours
at room temperature and then the plates were washed 6 times with PBST to remove
unbound rabbit anti-sheep polyclonal antibody. The alkaline phosphatase substrate,
5-bromo-4-chloro-3 indolyl phosphate/nitro blue terazolium (Sigma Chemical Co.,
MO, USA) was added to plates and the reaction was allowed to proceed for 15-30
minutes at room temperature. The reaction was stopped by washing the plates with
distilled water. Using a stereoscopic microscope, antigen-specific antibody secreting
cells were quantified by counting the number of purple circular spots in each well
coated with HEL and subtracting spots identified in control wells. For the ELISPOT,
all sample were run in triplicate for each individual sheep.
In the cell proliferation assay, sample were run in triplicate, and 2 x 105 viable
lymph node cells were added to microtiter wells that contained either medium alone
. (AIM-V Media) or medium containing 50 ng of cytokines. Cells were then incubated
for 72 hours at 37°C in a humidified atmosphere with 5% CO2 and 950/0 O2 and then
pulsed for 8 hours with 0.04 fJ.Ci/well of 3[H]-thymidine (50-60 mCi/mmol; Amersham
Canada Ltd., ON, Canada). Cells were harvested on to filter mats (Skatron Inc., VA,
USA) and each sample was placed in a vial with scintillant (Ready Safe, Beckman,
ON, Canada) and counted by a ~-scintillation counter (Beckman Instruments, ON,
Canada). All cytokines used in the proliferation assays were recombinant human
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cytokines purchased from Peprotech (London, UK).
6.2.4 Data Presentation and Analysis
All measurements are expressed as the mean ± standard error of the mean
(SEM) for values from 3-6 sheep. Comparison of values betwe~n different treatment
groups and between treated lymph nodes and contralateral control lymph nodes
were performed with a Kruskal-Wallis analysis and a Dunns comparison (GraphPad
Prism, CA, USA.). P values less than 0.05 were considered significant. The
stimulation index was calculated as the proliferative responses (counts per minute)
of cytokine stimulated cells divided by the proliferative responses of cells cultured in
AIM-V medium.
6.3 Results
6.3.1 Gravimetric and Volumetric Measurements of Treated Lymph Nodes
The biological activity of plasmid DNA and CON was examined by measuring
macroscopic changes in lymph nodes following treatment. Lymph nodes were
removed from sheep on the fourth day post-treatment, and gravimetric and
volumetric measurements were made. Table 6.1 demonstrates that no significant
change in lymph node size, volume or density was observed either between
treatment groups, or between the treated lymph node and the contralateral control
lymph node.
6.3.2 Histological Measurements of Treated Lymph Nodes
Histological measurements were used to examine lymph node architecture.
Morphometric analysis of total lymph node, cortical and medullary area did not
reveal any significant differences between the different treatment groups nor
between the treated lymph node and the contralateral control lymph node (Table
6.2). Similarly, no changes were seen in the ratio of either cortical or medullary area
per total area following the different treatments (Table 6.3). There was, however, an
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Table 6.1. Gravimetric and volumetric measurements of prescapular lymph nodes
following treatment with calf thymus DNA, plasmid or oligodeoxyribonucleotides.
Gravimetric and Volumetric Measurements of Treated Lymph Nodes]
Treatment Weight Volume Density (g/ml)
(g) (ml)
CT DNA* 9.2 ± 0.75 10.0 ± 2.0
Saline:1: 10.0 ± 2.0 10.0 ± 1.1
pMASIA* 10.2 ± 1.6 11.0 ± 1.5
Saline:1: 11.4 ± 2.5 11.7 ±2.1
pBISIA-88* 8.2 ± 1.1 7.2 ± 1.3
Saline:1: 9.6 ± 0.3 9.5 ± 0.3
CDN 2135* 7.6 ± 1.5 7.9 ± 1.:3
Saline:1: 6.9 ± 1.2 6.3 ± 0.1
0.84 ± 0.06
1.04 ± 0.03
0.92±0.04
0.97 ± 0.04
0.98±0.08
1.00 ± 0.00
0.98±0.03
1.03 ±0.08
Data is represented as mean ± SEM of 3 sheep.
f Lymph nodes were removed from sheep 4 days post-treatment and gravimetric
and volumetric measurements were performed.
* 400 Jlg (1 JlgIJlI) of either calf thymus DNA (CT DNA), plasmid (pMASIA, pSISIA-
88) or oligodeoxyribonucleotides (ODN 2135) were injected intradermally.
:1: Contralateral lymph node was exposed to 400 JlI of saline injected intradermally.
Table 6.2. Histological measurements of prescapular lymph nodes following
treatment with calf thymus DNA, plasmid or oligodeoxyribonucleotides.
Histological Measurements of Treated Lymph Nodes]
Treatment Total Lymph Cortical Medullary Percentage
Node Area Area Area of Cortex
(mm2) (mm2) (mm2) per
Total Lymph
Node Area
Percentage
of Medulla
per
Total Lymph
Node Area
CT DNA* 609.2 ± 43.5 148.1 ± 2.7 461.0 ± 44.1
Saline:1: 630.7 ± 146.5 132.8 ± 5.7 497.7 ± 151.7
pMASIA* 766.6 ± 184.5 261.7 ± 84.7 616.1 ± 68.8
Saline:1: 766.5 ± 125.8 187 ± 43.5 560.0 ± 65.7
pBISIA-88* 683.7 ± 35.2 165.7 ± 41.5 518.3 ± 11.7
Saline:1: 804.6 ± 73.5 188.4 ± 31.7 602.2 ± 80.5
CDN 2135* 589.3 ± 63.7 148.3 ± 39.4 440.9 ± 35.2
Saline:1:· 486.5 ± 33.0 127.7 ± 6.4 358.8 ± 28.2
24.4 ± 1.7
27.4 ± 5.2
27.4 ± 3.7
23.2 ± 2.0
23.7±4.6
23.4 ±4.0
24.2±4.7
26.2 ± 1.1
75.4±1.7
76.5 ±5.2
69.7 ± 6.1
74.0 ± 3.6
76.2±4.6
74.6 ± 5.8
75.5 ±4.7
73.6 ± 1.2
Data is represented as mean ± SEM of 3 sheep.
f Lymph nodes were removed from sheep 4 days post-treatment and lymph nodes
were fixed and sectioned and histologic measurements were performed
* 400 Jlg (1 Jl911l1) of either calf thymus DNA (CT DNA), plasmid (pMASIA, pSISIA-
88) or oligodeoxyribonucleotides (ODN 2135) were injected intradermally.
:j: Contralateral lymph node was exposed to 400 III of saline injected intradermally.
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prescapular lymph nodes following treatment with calf thymus DNA,
oligodeoxyribonucleotides.
Table 6.3. Measurement of germinal center, medullary cord and medullary sinus in
plasmid or
Histological Measurements of Treated Lymph Nodesl
CT DNA* 1.9 ± 1.0 58.0 ± 23.4
Saline~ 3.4 ± 2.7 66.0 ± 20.0
Treatment Total Germinal Total Germinal Thickness of
Center Area Center Number Medullary Cords
(mm2) (J,lm)
53.0 ± 17.0
74.0 ± 17.0
Distance
Across
Medullary
Sinuses
(J,lm)
59.0 ± 15.0
65.0 ± 14.0
pMASIA* 17.6 ± 9.5 240.3 ± 61.7 T
Saline~ 12.6 ± 6.7 153.0 ± 41.7
pSISIA-88* 3.1 ± 1.1 79.7 ± 18.5
Saline~ 5.2 ± 0.9 111.3 ± 7.6
ODN 2135* 7.7 ± 6.7 106.7 ± 54.1
Saline~ 8.6 ± 4.5 99.0 ± 37.6
93.0 ±32.0
89.0± 23.0
44.0±5.0
60.0 ±22.0
80.0 ± 13.0
57.0±11.0
44.0 ± 3.0
46.0 ± 3.0
52.0 ±4.0
44.0±5.0
61.0 ± 9.0
49.0 ±4.0
Data is represented as mean ± SEM of 3 sheep.
f Lymph nodes were removed from sheep 4 days post-treatment and lymph nodes
were fixed and sectioned and histologic measurements were performed
* 400 J.Lg (1 J.1g/J.1I) of either calf thymus DNA (CT DNA), plasmid (pMASIA, pBISIA-
88) or oligodeoxyribonucJeotides (CDN 2135) were injected intradermally.
; Contralateral lymph node was exposed to 400 J.11 of saline injected intradermally.
t Significant difference between pMASIA and CT DNA (P <0.05).
80% increase in cortex area in pMASIA treatment group as compared to CT DNA
treatment. While not statistically different, however, this difference may have
biological importance. Similarly, while not statistically different, there was an
approximate 9-fold increase in the total area of germinal centers in pMASIA treated
sheep. Treatment with pMASIA also caused a significant 5-fold increase in the
numbers of germinal centers when compared to treatment with CT DNA. (Table 6.3;
P < 0.05).
6.3.3 Phenotypic Analysis of Isolated Lymph Node Cells
Examining cell populations in lymph nodes can provide insight into the cell
populations that might be recruited or retained within a lymph node following
different treatments. The percentages of different cell populations present in
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prescapular lymph nodes were analyzed and data are presented in Table 6.4. None
of the various treatments caused significant changes in B or T cells, macrophages
(OH59Bhi9h) or dendritic cells (C01b+P220-). Although treatment with CON 2135
caused an increased frequency in B cells, this increase was not significantly different
from CT DNA treatment (Table 6.4). A few differences were observed in the
frequency of various lymphocyte sub-populations isolated from lymph (Tables 6.5,
6.6).
In general, treatment with pMASIA and CON 2135 did not cause significant
changes in B cell sub-populations when compared to CT DNA treated lymph nodes.
There was, nonetheless, a 52°,/0 and 119% increase in C072+C021 +B cells following
pMASIA and CON 2135 treatment respectively, and this may have biological
importance (Table 6.6). Notably, there was a significant 4-fold increase in the ratio
of C021+ versus C021- B following injection with pMASIA (P <0.05; Table 6.6).
Furthermore, a 350/0 and 49% increase in B cells expressing surface IgM (slgM) was
detected in lymph nodes isolated from sheep treated with CON 2135 and pMASIA,
respectively. These findings suggest that treatment with bacterial DNA markedly
altered B cell populations but not T cell populations. It is noteworthy that although
activation of B cells by CpG motifs is well known (Krieg et al., 1995; Klinman et al.,
. 1996), the effects of CpG motifs on specific B cell sub-population has not been
reported.
Analyzing the expression of surface markers provides information on the
state of cellular activation or differentiation. Data presented in Table 6.7 shows no
significant difference in T cell expression of either MHC II or CD25 between either
treatment groups or treated lymph nodes and contralateral controls. The one
notable exception was a 48% increase in C05+CD25+ T cells detected in lymph
nodes treated with CDN 2135 when compared to lymph nodes treated with CT DNA.
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Percentage of Cell Populations Isolated from Treated Lymph Nodes]
Table 6.4. The percentage of cell populations isolated from prescapular lymph
nodes following treatment with calf thymus DNA, plasmid or
oligodeoxyribonucleotides.
Treatment B-cells T-cells DH59BliiQIi+ CD1 b+P220·
cells cells
CT DNA* 33.8 ± 4.5 63.1 ± 3.1 2.3 ± 0.8 2.5 ± 1.4
Salinet 30.6 ± 4.4 62.5 ± 3.6 2.9 ± 0.7 2.4 ± 1.0
pMASIA* 30.7 ± 8.7 60.0 ± 3.7 4.6 ± 1.4 3.2 ± 2.1
Salinet 33.3 ± 2.1 58.7 ± 1.5 4.5 ± 1.8 2.6 ± 0.8
pBISIA-88* 27.2±4.7 59.1 ±4.4 2.3±0.6 2.7±0.4
Salinet 35.6 ± 4.4 58.1 ± 1.1 3.2 ± 1.5 2.6 ± 0.5
CON 2135* 43.1 ±8.3 56.0 ± 2.1 1.3 ± 0.3 5.3 ± 1.9
Salinet 38.8 ± 4.6 58.1 ± 1.1 1.3 ± 0.3 7.2 ± 1.5
Data is represented as mean ± SEM of 3 sheep treated with
oligodeoxyribonucleotide (ODN 2135) and plasmid (pMASIA, pSISIA-BB) and 6
sheep treated with calf thymus DNA (CT DNA).
f Cells were isolated from excised sheep lymph nodes 4 days post-treatment. The
percentage of S-cel/s, T-cel/s, DH59Bhigh+ cells and CD1 b·P220· cel/s isolated from
lymph nodes was determined with flow cytometry.
* 400 J.1g (1 J.19/J.11) of either calf thymus DNA (CT DNA), plasmid (pMASIA, pSISIA-
BB) or oligodeoxyribonucleotides (ODN 2135) were injected intradermally.
t Contralateral lymph node was exposed to 400 J.11 of saline injected intradermal/y.
Table 6.5. The percentage of T cell sub-populations isolated from prescapular
lymph nodes following treatment with calf thymus DNA, plasmid or
oligodeoxyribonucleo-tides.
Percentage ofT-ceil Sub-populations Isolated from Treated Lymph Nodes!
Treatment CD4+ T-cells CD8+ T-cell ylo TCR+ T-cell
CT DNA* 46.4 ± 3.0 12.1 ± 0.7 4.6 ± 0.7
Salinet 46.2 ± 4.2 11.7 ± 1.0 4.6 ± 0.8
pMASIA* 45.7 ± 1.7 10.8 ± 2.2 3.7 ± 1.9
Salinet 47.8 ± 1.9 11.9 ± 0.9 2.9 ± 1.2
pBISIA-88* 45.6 ± 3.0 10.3 ± 1.3 3.2 ± 0.7
Salinet 41.0 ± 2.6 9.0 ± 1.7 2.8 ± 0.4
ODN2135* 40.4±1.8 11.8±0.6 3.9±0.2
Salinet 41.0 ± 1.5 13.8 ± 0.6 3.3 ± 0.3
Data is represented as mean ± SEM for 3 sheep treated with
oligodeoxyribonucleotide (ODN 2135) and plasmid (pMASIA, pSISIA-BB) and 6
sheep treated with calf thymus DNA (CT DNA).
f Cells were isolated from excised sheep lymph nodes 4 days post-treatment. The
percentage of CD4+, CDB+ and ylo TCR+ T-cells isolated from lymph nodes was
determined with flow cytometry
* 400 J.1g (1 J.1g/J.1l) of either CT DNA, plasmid (pMASIA, pSISIA-BB) or ODN 2135
was injected intradermally.
t Contralateral lymph node was exposed to 400 J.11 of saline injected intradermally.
155
Table 6.6. The percentage of B cell sub-populations and percentage of slgM
expressing B cells isolated from prescapular lymph nodes following treatment with
calf thymus DNA, plasmid or oligodeoxyribonucleotides.
Percentage of B-cell Sub-populations Isolated from Treated Lymph Nodes]
Treatment slgM CD21-CD72+ CD21+CD72+ Ratio of
B-cells B-cells CD21 +CD72+
CD21-CD72+
B-cells
CT DNA* 13.5 ± 2.1 9.7 ± 1.1 13.7 ± 5.2
Salinet 10.3 ± 2.5 9.1 ± 1.3 11.9 ± 4.6
pMASIA* 20.1 ± 1.9 4.9 ± 1.4 20.9 ± 2.4
Salinet 23.6 ± 3.2 7.6 ± 1.0 22.5 ± 1.2
pBISIA-88* 17.4 ± 2.2 5.5 ± 1.3 17.4 ± 4.3
Salinet 19.3 ± 1.6 8.5 ± 1.2 22.0 ± 3.7
CDN 2135* 18.3 ± 1.7 14.1 ± 1.4 30.1 ± 5.6
Salinet 17.0 ± 1.2 10.6 ± 1.3 14.5 ± 4.9
1.2±0.3
1.0±0.3
4.9 ± 1.5T
3.0 ± O.4t
3.7 ± 1.3
2.7±0.8
2.2±0.5
1.6 ± 0.5
Data is represented as mean ± SEM for 3 sheep treated with
oligodeoxyribonucleotide (ODN 2135) and plasmid (pMASIA, pBISIA-88) and 6
sheep treated with calf thymus DNA (CT DNA).
f Cells were isolated from excised sheep lymph nodes 4 days post-treatment. The
percentage of CD21-CD72+ and CD21 +CD72+ B-cells as well as slgM+ B-cells
isolated from lymph nodes was determined with flow cytometry. The change in
frequency of CD21 +B-cells following treatment is demonstrated by CD21 +CD72+ B-
cells divided by CD21-CD72+ B cells.
* 400 Jlg (1 JlgIJlI) of either calf thymus DNA (CT DNA), plasmid (pMASIA, pBISIA-
88) or oligodeoxyribonucleotides (ODN 2135) were injected intradermally.
t Contralateral lymph node was exposed to 400 JlI of saline injected intradermally.
tSignificant difference between both CT DNA and pMASIA and CT DNA the contra-
,lateral lymph node (saline) of pMASIA treated sheep (P<O.05).
6.3.4 Quantifying the Frequency of Antigen-specific Antibody Producing Cells
Isolated from Treated Lymph Nodes
It has been shown that CpG motifs either alone or present within plasmid can
enhance antibody production by B cells (Krieg et al., 1995: Klinman et al., 1997).
We therefore investigated the possibility that treatment with either plasmid or ODN
2135 altered the frequency of B cells producing antibody to a specific antigen.
Sheep were immunized with HEL and then injected with pMASIA, pBISIA-88 or ODN
2135. Quantitative measurements of cells secreting antibody to HEL did not detect
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Table 6.7. The percentage of T cells expressing activation markers following
isolation from prescapular lymph nodes treated with calf thymus DNA, plasmid or
oligodeoxy-ribonucleotides.
Percentage of T-cell sub-populations Expressing Activation Markers Isolated from
Treated Lymph Nodes!
Treatment CD4+MHCII+ CD5+CD25+ CD5+LFA1+ CD8+CD25+
T-cells T-cells T-cells T-cells
CT DNA 23.0 ± 4.5 20.2 ± 1.6 29.9 ± 3.5 3.2 ± 0.5
Saline 23.6 ± 2.9 21.7 ± 4.6 32.6 ± 2.7 3.4 ± 0.4
pMASIA 18.4 ± 2.5 18.4 ± 1.3 29.7 ± 5.8 2.4 ± 0.8
Saline 21.2 ± 3.1 14.9 ± 2.0 39.6 ± 3.9 2.1 ± 0.2
pBISIA-88 14.1 ± 2.9 17.1 ± 2.3 4'1.6 ± 8.8 2.2 ± 0.3
Saline 18.1 ± 1.9 13.7 ± 2.1 28.9 ± 2.3 1.6 ± 0.5
ODN2135 13.1±2.6 30.1±6.4 30.1±6.4 2.1±0.5
Saline 18.4 ± 0.2 26.7 ± 2.6 26.7 ± 2.6 2.3 ± 0.3
Data is represented as mean ± SEM for 3 sheep treated with
oligodeoxyribonucleotide (ODN 2135) and plasmid (pMASIA, pBISIA-88) and 6
sheep treated with calf thymus DNA (CT DNA).
f Cells were isolated from excised sheep lymph nodes 4 days post-treatment. The
percentage of CD4+MHCII+-, CD5+CD25+, CD5+LFA1+ and CD8+CD25+ T-cells isolated
from lymph nodes was determined with flow cytometry.
* 400 ~g (1 ~g/~l) of either calf thymus DNA (CT DNA), plasmid (pMASIA, pBISIA-
88) or oligodeoxyribonucleotides (ODN 2135) were injected intradermally.
:j: Contralateral lymph node was exposed to 400 J.!I of saline injected intradermally.
any significant differences among the various treatment groups or the treated lymph
node and the contralateral control lymph node (Table 6.8). The ODN 2135 treated
lymph nodes had an approximate 4.4 fold increase in the frequency of B cells
producing HEL specific antibody when compared to CT DNA treated lymph node.
Treatment with ODN 2135 may be the only treatment group that has any biological
significant results, as this group had the smallest variability between individual
sheep.
6.3.5 Proliferation of Cells Following Cytokine Treatment
Lymphocyte activation is frequently associated with the expression of
cytokine receptors and exposure to the appropriate cytokine can then induce a
proliferative response. Thus, measuring cytokine-induced proliferative responses
can provide information on cell activation and the expression of functional cytokine
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Table 6.8. The number of hen egg lysozyme (HEL) antibody-secreting cells isolated
from prescapular lymph nodes following treatment with calf thymus DNA, plasmid or
oligodeoxyribonucleotides.
Number of HEL Specific Antibody Secreting Cells Isolated from Treated Lymph
Nodes!
Treatment HEL Antibodies Secreting Cells
(positive cells per 106 cells)
CT DNA* 1.6 ± 0.8
Saline; 2.2 ± 0.8
pMASIA* 12.5 ± 11.0
Saline; 4.1 ± 1.7
pBISIA-88* 18.5 ± 9.0
Saline; 12.5 ± 10.7
ODN 2135* 7.1 ± 1.2
Saline; 6.3 ± 5.2
Data is represented as mean ± SEM for 3 sheep treated with
oligodeoxyribonucleotide (ODN 2135) and plasmid (pMASIA, pBISIA-88) and 6
sheep treated with calf thymus DNA (CT DNA).
! Cells were isolated from excised sheep lymph nodes 4 days post-treatment. The
numbers of HEL specific antibody secreting cells were quantified by subtracting the
number of positive cells (purple spots) from negative controls.
* 400 Jlg (1 ).1g/JlI) of either CT DNA, plasmid (pMASIA, pBISIA-88) or ODN 2135
was injected intradermally.
; Contralateral lymph node was exposed to 400 ).11 of saline injected intradermally.
receptors (Goldsmith & Greene, 1994). Isolated lymph node cells were exposed to
IL-2, IL-4, IL-7 and IL-15, a group of cytokines that bind to y chain common subunit
receptors and are important for lymphocyte development. No significant differences
in the cytokine-induced stimulation indexes between either treatment groups or
. treated lymph nodes versus contralateral control lymph nodes were observed (Fig.
6.1). Though not statistically significant, the proliferative responses of cells isolated
from lymph nodes treated with bacterial DNA were consistently greater than the
responses of cells isolated from CT DNA treated lymph nodes. Cells isolated from
pBISIA-88 treated lymph nodes demonstrated a 730/0, 104% , 320/0 and 880/0 increase
in the stimulation index in response to IL-2, IL-4, IL-7 and IL-15, respectively. Lymph
node cells isolated from sheep injected with ODN 2135 showed a 77%, 1160/0 and
158
250 a 30 b
I 200 I
.5 Jii 20
S 150 cQ
~ 100 ie10
i 50 i
0 0
+ + + + + + - + +
« I() $ i « I() g; ~z ('/) ~ z
('/) ~""' ~ ""' ~C N C N
I- Z ~ (/) I- Z ~ (/)
u c a. m (.) c a. m
0 a. 0 a.
TreatnEllt Groups TreatlTBt Gro~s
75 400 d
I Ii'C 300
Jii 50 .5
c SQ
i i 200
,§ 25 i
U; i 100
0 0
+ + + - ++ + + + -
< I() < ~ « I() « i('/) ~ z ('/) ~z ""' ~ ""' ~C N C N
I- Z ~ ~ I- Z ~ 00
u c a. 00 u c a. m
0 a. 0 a.
TreatllEd Gro~s Treatrrent Gro~s
Figure 6.1 The stimulation indexes for cyokine-induced proliferative responses of cells
isolated from sheep following a 4-day treatment with plasmid (pMASIA, pBISIA-88),
oligodeoxyribonucleotides (ODN 2135) and calf thymus DNA (CT DNA). a Cells exposed
to 50 ng of IL-2. b Cells exposed to 50 ng of IL-4. c Celfs exposed to 50 ng of IL-7. d
Cells exposed to 50 ng of IL-15. Treated lymph nodes are shown as (+) and
contralateral saline treated lymph nodes are represented by (-) and are placed to the
right of data for each treatment group. The bar represents the mean ± SEM and all
samples were run in quadruplicate. Six sheep were treated with CT DNA and all other
treatments had 3 sheep per group.
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41%) increase in the stimulation index with IL-2, IL-4 and IL-15, respectively. Cells
from pMASIA treated lymph nodes also had a 540/0 increase in the IL-7 induced
stimulation index.
The stimulation index is a ratio between cytokine treated and medium treated
cells, therefore any large variations in background levels of medium treated cells
could affect stimulation index values. Background proliferation values in all groups
were similar (Figure 6.2) suggesting that the stimulation index (Figure 6.1) of
cytokine treated cells did not reflect differences in spontaneous background
proliferative responses between treatment groups.
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Figure 6.2. Background proliferation of cells isolated from the lymph nodes of
sheep following a 4-day treatment with plasmid (pMASIA, pBISIA-SS),
oligodeoxyribonucleotides (ODN 2135) and calf thymus DNA (CT DNA). Treated
lymph nodes are shown as (+) and contralateral saline treated lymph nodes are
represented by (-) and are placed to the right of data for each treatment group.
The bar represents the mean ± SEM and all samples were run in quadruplicate.
Six sheep were treated with CT DNA and all other treatments had 3 sheep per
arouo.
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6.4 Discussion
This study was conducted to determine whether the previously observed
changes in cell trafficking could be related to structural or functional changes
occurring within the lymph node. Sheep were treated with immunostimulatory OON
or plasmid with added immunostimulatory CpG motifs and then the architecture and
cellular composition of collected lymph nodes were examined. These
measurements included assessing the changes in lymph node size and morphology
as well as changes in the resident cell populations. Measurements of cell
proliferative responses and the numbers of antigen-specific antibody producing cells
present in lymph nodes were also determined.
One of the most consistent findings in this study was that regardless of
treatment, changes that occurred within the treated lymph nodes were very similar to
changes observed in the contralateral control lymph nodes. This observation
supports the conclusion that plasmid and ODN treatment effects were not localized
to the draining lymph node but also affected lymphoid tissue at distant sites. This
conclusion, however, is not supported by observations ma.de by Lipford et al. (2000),
when examining the effects of OON on mouse lymph nodes. Their experiment
differed from our study as they delivered both a smaller amount (30 Jlg) of OON and
used a subcutaneous route of delivery. Nevertheless, they showed that treatment
with ODN increased the total cell number present in the draining lymph nodes while
saline-treated contralateral lymph nodes remained relatively quiescent. They
demonstrated that at Day 2 post-treatment, there was an approximate 5-fold
increase in total cell number, which was followed by a gradual increase in all cell
populations that generally peaked at Day 10 post-treatment and then rapidly
declined by Day 14. The discrepancy between our findings and the work by Lipford
et al. (2000) suggests that quantitative histological assessment of lymph nodes may
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not be sufficiently sensitive to identify early changes in lymphocyte cell number
following treatment with ODN. Isolating and counting all cells from a single lymph
node may be a be.tter method for evaluating lymph node cellularity. This method,
however, may be impractical in sheep, as sheep lymph nodes are considerably
larger than mouse lymph nodes. Similarly, isolating cells from a large fragment of
lymph node may also not be ideal method either. Although this method could
provide a large number of cells, it may not provide an accurate assessment of
resident cell populations, as the distribution of cell populations varies within the
lymph node. Furthermore, a disadvantage of isolating cells to evaluate lymph node
change is the inability to assess lymph node morphology.
Lipford et 81. (2000) also demonstrated marked short-term increases in 8 cell
number following ODN treatment. They did not determine, however, whether these
cells were found in medullary cords or in germinal centers, an assessment that could
give insight into the type of 8 cell present and its stage of maturation. 80th immature
and mature 8 cells are present in germinal centers for example, but only mature 8
cells and plasma cells are found in medullary cords (Junqueira, 1986; Wheater,
1987). Our experimental design did reveal that pMASIA and ODN 2135 treatment
caused an enlargement of germinal centers, and there was a significant increase in
. CD72+CD21 + 8 cells following treatment with pMASIA. This increase in na'ive 8
cells was reflected in an increased ratio of CD72+CD21+ 8 cells to CD72+CD21- 8
cells (Table 6.6). The CD72 cell marker is expressed on all developing 8 cells,
some populations of macrophages, follicular dendritic cells and T cells, but is not
expressed on plasma cells (Gordon, 1994; Parnes & Pan, 2000). The CD72 surface
protein assists in 8-T cell interactions by binding to CD5 on T cells and is also
believed to playa role in 8 cell maturation (Gordon, 1994)" The CD21 molecule is a
complement receptor that has been identified on 8 cells, immature T cells and
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follicular dendritic cells (Tsoukas & Lambris, 1993). This surface protein may be
involved in B-cell regulation as CD21 is down regulated following B cell activation
and differentiation (Tsoukas & Lambris, 1993). The expre~ssion of CD21 on B cells
has been used to identify a stable population of recirculating B cells that often
expresses L-selectin (Young et al., 1997). Cell trafficking studies have revealed that
CD21+B cells represent either a population of recirculatin~~non-memory B cells, or of
B cells that were recently activated by antigen (Young et (~/., 1997). The increase in
CD72+CD21 + 8 cells following treatment with CDN 2135 or pMASIA indicates that
non-memory and possibly immature B cells could be the B cell population that
responds to the immunostimulatory effect at CpG motifs. It is possible hat
CD72+CD21 + B cells may have been either recruited from blood into the lymph node
by L-selectin binding to high endothelial venules or have been generated in germinal
centers. Currently, it is unknown whether CpG motifs or plasmid DNA preferentially
stimulate specific B cell sub-populations.
The slgM expressed by mature B cells can signal differentiation and
activation of B cells (Haseman & Capra, 1989) and an increased level of slgM
expression may indicate 8 cell activation. Enhanced secretion of slgM has been
reported in mice treated with CDN (Klinman et al., 1996) and the secretion of other
. isotypes is also increased following injection with CDN (Krieg et al., 1995) and
plasmid (Klinman et al., 1997). These observations indicate that CDN and plasmid
DNA can activate 8 cells that produce different antibody isotypes. In our
experiment, an increased frequency of slgM+ 8 cells was observed for all treatment
groups, with the highest frequency of slgM+ B cells present in lymph nodes collected
from pMASIA treated sheep. The correlation between CD21, CD72 and slgM
expression was not analyzed. Thus, we can not determine whether the increase in
CD72+CD21 + B cells was a direct consequence of an increased frequency of slgM+
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B cells.
Injection of CDN 2135 into sheep caused an approximately 50% rise in the
frequency of T cells (CD5+) expressing a detectable level of IL-2 receptor (IL-2Ra.)
relative to CT DNA lymph node controls. The specific sub-population or sub-
populations of T cells expressing IL-2Ra. was not determined, but it was clear that
these CD25+T cells did not express CD8+ (Table 6.7). OJigodeoxyribonucleotides are
not thought to activate T cells directly, but instead to induce dendritic cells to release
IL-12 and IFN-y and these cytokines are believed to then activate Th1 cells
(Chattergoon et al., 1997; Krieg & Wagner, 2000). To determine whether dendritic
cells did indeed induce T cell activation, it would be necessary to measure the
cytokines produced by dendritic cells and assay the capacity of isolated dendritic
cells to activate T cells. This analysis was not carried out in our experiment and
further work is therefore needed to determine the mechanism by which bacterial
DNA or CpG increased IL-2Ra. expression on T cells.
Changes in cell phenotype can assist in determining whether a specific
treatment has had a biological effect. Phenotypic analysis of cells, however, does
not always provide information regarding cell function. As an example, the IL-2Ra.
by itself is a non-functional receptor and is unable to transmit a signal from the cell
surface (He & Malek, 1998). Therefore, increased expression of IL-2Ra. on
lymphocytes does not necessarily ensure that a lymphocyte will respond to IL-2.
Measuring cell proliferation following exposure to exogenous cytokines, however,
provides information on both cell activation and cell function. To determine whether
treatments with plasmid or OON 2135 altered cell function, isolated lymph node cells
were stimulated with cytokines and cell proliferative responses were measured.
Although not statistically significant, treatment with OON 2135 and pBISIA-88
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resulted in increased cell proliferative responses following stimulation with IL-2, IL-4,
IL-7 and IL-15. Thus, the in"creased proliferative responses of cell exposed to IL-2
confirmed that increased expression of CD25 (IL-2Ra) on T cells reflected an
increased capacity to respond to cytokines.
It is interesting that cells isolated from lymph nodes exposed to ODN 2135
and pBISIA-88 displayed a responsiveness to y chain common cytokines relative to
lymph nodes exposed to CT DNA. This general increase in cytokine-induced cell
proliferative responses may be related to the structural similarities of the above
mentioned cytokines. The four cytokines used are members of a cytokine family that
bind to receptors with a y chain common subunit and all these cytokines playa role
in lymphopoiesis (Giri et al., 1994; Kondo et al., 1994; Kimura et al., 1995;). These
receptors are present on virtually all hematopoietic cells and when bound by a
cytokine will induce cell activation using the JAKISTATS signaling pathway (O'Shea,
1997). The intracellular signals generated by y chain common subunit receptors
demonstrate a redundancy in receptor function, as members of this cytokine family
produce many similar cellular responses (Girl et al., 1994; Kondo et al., 1994;
Kimura et al., 1995; He & Malek, 1998). The relatively uniform increase in cell
proliferative responses following pBISIA-88 and ODN 2135 treatment suggested that
either these treatments induced e?Cpression of all four y chain common subunit
receptors on the cell surface or that the recombinant cytokines cross-reacted with
two or more cytokine receptors. Further work is needed to determine whether IL-4,
IL-7 and IL-15 cytokine receptors were increased on cell surfaces and to identify the
specific cell populations that had increased expression levels of these receptors
following bacterial DNA treatment.
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As mentioned, this experiment was carried out in part to determine whether
changes in cell trafficking could be related to structural and functional changes
occurring within the lymph node following plasmid treatment. In Chapter 5, it was
demonstrated that increased cell trafficking involved a non-selective movement of
lymphocytes through the lymph node (Uwiera et al., 2002). The observations in this
study indicated that non-memory, immature CD72+CD21 +B cells were increased in
frequency following plasmid DNA or ODN treatment. A minor increase in
CD72+CD21 +B cells, however, could not account for the increased numbers of cells
present in efferent lymph and there was not a selective increase in B cell trafficking.
Therefore, increased ceJl trafficking was likely not related to either de novo
generation of cells or decreased retention of cells within the lymph node. Thus, the
cells collected from efferent lymph most likely migrated directly from blood into
efferent lymph. This interpretation is supported by a study in sheep that showed that
less than 4% of cells that migrate into efferent lymph originated from within the
lymph node (Hall & Morris, 1965).
The Increased frequency of CD72+CD21+ B cells a.nd CD25+ T cells within
the lymph node and the enhanced proliferative responses of lymph node cells
indicated that bacterial DNA and ODN had a biological effect within the draining
. lymph node. These responses did not correlate with an increase in cell trafficking
suggesting that plasmid DNA and CpG motifs can affect cells within the lymph node
and yet not alter cell trafficking. CpG motifs may directly activate mechanisms
involved in inflammation that mediate an increase in blood flow and thereby increase
cell trafficking. Alternatively, CpG motifs may activate lymphocytes, macrophage or
dendritic cells to release mediators that influence cell traffic. Thus, it is difficult to
relate the increased B cell populations or the activation of T cells within lymph nodes
to increased cell trafficking following plasmid treatment. It is documented, however,
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that CpG motifs can induce resident lymph node macrophages to increase
production of mediators involved in lymphocyte migration (Takeshita et al., 2000). It
is possible, therefore, bacterial DNA could indirectly influence lymphocyte trafficking
by inducing the release of mediators from cells closely involved in regulating cell
flow.
6.5 Summary
In Chapter 5, we demonstrated that intradermal injection of plasmid DNA
induced significant changes in cell trafficking. This cell trafficking response was
related to both the form of DNA and the quantity of immunostimulatory CpG motifs
present within plasmids. To determine whether changes in cell trafficking were
related to short-term changes in the draining lymph node, sheep were injected with
plasmid (pMASIA and pBISIA-88) and CON 2135 and lymph nodes were then
removed and analyzed. Treated prescapular lymph nodes were collected and
gravimetric, volumetric and histologic measurements of lymph nodes were made.
Cells were isolated from lymph nodes and the frequency of various cell populations
and the levels of cell activation and cytokine responsiveness were assessed.
Treatment with pMASIA was associated with an increased number of germinal
centers, suggesting that 8 cells and possibly recirculating, non-memory B cells were
. affected by treatment. The increased expression of IL-2Ru, as well as increased
cytokine-induced proliferative responses, suggested that ODN 2135 and possibly
pBISIA-88 treatment were associated with an increased expression of y chain
common subunit receptors on cells, which possibly reflected enhanced cell
activation
Several experiments generated results that seemed to be potentially
biologically significant though not statistically significant. Increasing the numbers of
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animals in treatment groups, using animals of similar age as well as reducing
exposure to bacteria present within the environment may reduce the variations in
results. The increased number of animals needed to address these variations,
however, may not be feasible in out-bred animals such as sheep. For example, the
data from CT DNA treated animals (6 sheep) were in many instances as variable as
data from the other treatments groups (3 sheep). Therefore, to reduce inter-group
variation, sheep in treatments groups should be age-matched and have minimal
exposure to environmental bacteria or products that induce immune stimulation.
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CHAPTER 7
GENERAL DISCUSSION
In 1798, Jenner published the first clinical study showing that an inoculation
(vaccination) with cowpox could cross protect individuals from lethal infections with
smallpox. Since then, vaccines have nearly eradicated many infectious diseases,
such as smallpox and polio, and consequently have saved countless lives through
induction of immunity against infectious agents. Vaccines have also improved
animal health bolstering livestock production and increasing revenue for livestock
producers. Indeed, it is argued that the development of vaccines has been one of
most beneficial health related technologies created to improve the well being of both
people and animals. One of the latest innovations in vaccine development is the use
of plasmid DNA to deliver vaccine antigens to induce protective humoral and cell-
mediated immunity. The relative ease and low expense of large-scale plasmid
production and the simplicity of inserting genes encoding antigen or immune
modulating proteins makes plasmid DNA a good candidate for use in vaccination
programs. Although initially bacterial DNA was considered inert, it has become
apparent that CpG motifs present within plasmids are responsible for the activation
of cells involved in adaptive immune responses and CpG motifs can act as
adjuvants to enhance immune responses to DNA vaccines. Small linear segments
of immunostimulatory CpG motifs (ODN) can also activate cells involved in innate
immunity and promote protection against disease. Indeed, researchers have shown
169
that these ODN can protect animals against challenge by a variety of infectious
microorganisms (Klinman at a/., 1999; Weighardt at a/., 2000).
To date, research examining the effects of DNA vaccines and
immunostimulatory ODN on the induction of immune responses and disease
protection has taken place predominantly in mice. Both the low cost of these animals
and an extensive knowledge of mouse genetics and immune function have
facilitated their use as the primary animal model for testing DNA vaccines and ODN.
New product testing should also be done within the target species to ensure that the
products are immunologically active within the proper species. Great potential exists
for implementing DNA vaccines and immunostimulatory CON in the livestock
industry to improve animal health. It is necessary, therefore, to study the effects of
plasmid DNA and immunostimulatory ODN in food producing animals.
The primary objective of this work was to investigate the effects of plasmid
DNA and ODN on ruminant immune function. This investigation was focused on
three main research areas. 1) The first objective was to examine the long-term
effects of plasmid DNA on lymph node architecture, using the draining lymph node
as a model system. 2) The second objective was to determine whether bacterial
DNA might alter immune surveillance by changing the migration of cells involved in
. the induction and maintenance of an immune response through a draining lymph
node. This was carried out by examining whether the structure of DNA, the
presence of known immunostimulatory CpG motifs and expression of foreign protein
influenced cell trafficking following treatment with plasmid DNA. A lymphatic
cannulation model was used to investigate these short-term changes in cell
trafficking. Furthermore, it was hoped that understanding the interaction between
bacterial DNA and the mammalian immune system might provide further insight into
the host response to bacterial infection. Using the sheep cannulation model, short-
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term changes in cell trafficking were measured following treatment with plasmid DNA
and DON. 3) Finally, we wanted to determine whether changes in cell trafficking
following treatment with bacterial DNA were associated with functional and structural
changes within the draining lymph node. Such associations might provide further
insight into the mechanisms by which bacterial DNA altered cell migration into or
through the lymph node and into efferent lymph.
Sheep were chosen as the animal model for these investigations for several
reasons. Firstly, cell trafficking during the induction and maintenance of an immune
response has been well characterized in sheep. Secondly, mouse monoclonal
antibodies specific for a variety of sheep leukocyte antigens were available and this
facilitated a phenotypic analysis of cells present in lymph and lymph nodes. Thirdly,
synthetic CpG motifs with known immunostimulatory activity in sheep had been
identified and were commercially available. Finally, surgical techniques used in cell
trafficking studies are well established in sheep (Glover &Hall, 1976).
Plasmids used in the experiments were designed to have both enhanced
adjuvanticity and support optimal gene expression. Chapter 3 describes the creation
of these plasmids and the evaluation of protein expression in plasmids that encoded
GFP and eGFP reporter genes. These reporter genes were inserted to facilitate the
. detection of cells transfected with plasmid in cell trafficking studies. To assess gene
expression and protein synthesis, plasmids were transfected into COS? fibroblasts
and production of the green fluorescence of protein was measured. Cells
transfected with pCAN1-GFP and pCAN1-eGFP expressed sufficient protein to
generate a fluorescent signal that was readily detected by flow cytometry. These in
vitro experiments suggested that cell transfection in vivo could produce sufficient
amounts of GFP to be detectable with flow cytometry. Since dendritic cells can also
express GFP following transfection with plasmid encoding GFP (Paglia et al., 1998;
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Strobel et a/., 2000), we assumed that our in vitro transfection of fibroblasts (COS?
cells) provided an indication that in vivo transfection of dendritic cells should also be
detectable with flow cytometry.
To investigate whether bacterial DNA altered immune surveillance in the
draining lymph node, the long-term effects of plasmid (bacterial) DNA on popliteal
lymph node size and morphology were first examined. The popliteal lymph node
was examined as its size, shape and subcutaneous location made it readily
accessible to measure with ultrasound equipment. In Chapter 4, ultrasound was
used to follow changes in lymph node size over a 28-day period. At 30 days post-
treatment, all lymph nodes were then removed and assessed both macroscopically
and histologically. Ultrasound was selected for this experiment to facilitate the
monitoring of changes in lymph node size over time and allowed for repeated lymph
node measurements within an individual animal. This approach also reduced the
numbers of sheep used by 4-fold, as otherwise it would have been necessary to
perform euthanasia on sheep at weekly intervals to measure progressive changes in
lymph node size.
There was a relatively equal and gradual increase in the size of both the
lymph node exposed to plasmid and the contralateral lymph node exposed to saline.
. Ultrasound measurements demonstrated an approximately 66 and 75 percent
increase in lymph node size in plasmid and saline-treated lymph nodes, respectively.
The lack of difference between the lymph nodes suggested that either plasmid
treatment did not have a significant effect on lymph nodes or that the effect was not
localized to the lymph node draining the site of DNA injection. Macroscopic and
histological measurements, however, revealed that plasmid DNA treatment did
indeed significantly alter the structure of the lymph node draining the DNA injection
site. Relative to saline-treated lymph nodes, plasmid treated lymph nodes weighed
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more, had an increased medullary area and demonstrated an approximately 2-fold
increase in germinal center number and area. Furthermore, medullary cord
thickness and medullary sinus width was significantly increased following exposure
to plasmid DNA. Medullary expansion as well as increased medullary cord
thickness and increased width of medullary sinuses suggested that the increased
lymph node weight was caused by both an accumulation of lymph and an increase
in cell number. These changes in lymph node morphology were similar to changes
that occur following exposure to antigen and mitogens, known activators of humoral
immunity. These observations suggested, therefore, that plasmid DNA was also a
potent and long-term activator of cells involved in humoral immune responses.
Long-term (30 days) changes in lymph node structure following plasmid
treatment have implications for the use of DNA vaccines within the livestock
industry. As mentioned, plasmid treated lymph nodes were heavier and had distinct
architectural changes compared to saline-treated lymph nodes. Alterations in lymph
node size and structure following DNA vaccination might be interpreted by food
inspection personnel as indicators of a response to infectious disease or injury.
Thus, the induction of lymph node enlargement by a DNA vaccine might lead to
unnecessary carcass trimming or whole animal condemnation.
Changes in lymph node function following plasmid treatment could have an
impact on concurrent immune responses. The enlargement of germinal centers
associated with plasmid injection may increase the population of 8 cells that
produces.antibodies to the antigens or infectious organisms. This may have a
beneficial effect by improving the amplitude of immune responses as suggested by
the modest increase in numbers of antigen-specific antibody secreting cells (Table
6.8). Conversely, expansion of 8 cells without stringent antigen selection may result
in the production of autoantibodies. Therefore, lymph node changes following
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plasmid treatment may lead to changes in immune function and potentially adversely
affect animal health.
The acute effects of plasmid DNA and immunostimulatory DDN were then
examined by monitoring cell trafficking through a lymph node (Chapter 5). In this
study, the efferent lymphatic vessel of the prescapular lymph nodes was cannulated
and cells were collected following the intradermal injections of plasmid DNA or DON.
Although the popliteal lymph node was used in the long-term lymph node study, the
prescapular lymph node was used for cell trafficking studies, since it was much
easier to consistently cannulate the efferent lymphatic vessels of this lymph node.
Intradermal injections of as little as 4 Ilg of plasmid DNA caused a marked
increase in cell trafficking through the prescapular lymph node. A dose-dependent
facet existed for this response, although significant differences were not observed
with a 100-fold increase in dose of plasmid (400 1l9), the increased cell trafficking
response persisted longer with 40 Ilg and 400 Ilg of plasmid than with 4 Ilg. As
mentioned, the eGFP gene was inserted into pCAN1 to facilitate the possible
detection of DNA transfected cells. Flow cytometric analysis failed to detect any
cells expressing eGFP in efferent lymph even when using techniques to enrich for
dendritic cells. This suggests that either cells expressing eGFP did not enter lymph
or the frequency of cells expressing eGFP was below the level of detection (0.01 %)
with flow cytometry. To ensure that increased cell trafficking was not caused by the
expression of a foreign protein (eGFP), pCAN1 without the eGFP gene insert was
injected into sheep and the cell trafficking response was again measured. The
increased cell trafficking in efferent lymph was similar following treatment with either
pCAN1-eGFP or pCAN1. This observation indicated that the increase in cell traffic
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was not dependent upon expression of a foreign protein but was probably a direct
response to plasmid DNA.
Increased cell traffic induced by bacterial DNA was then further characterized
by determining whether the form of bacterial DNA was critical for this response.
Treatment with plasmid (circular) DNA induced the greatest increase in cell traffic.
In contrast, when plasmid DNA was digested into linear fragments of DNA, cell
trafficking was not significantly increased. The apparent lack of activity observed in
response to linear DNA, could not be explained simply by rapid nuclease digestion
since nuclease-resistant CDN failed to alter cell trafficking. An alternative
explanation might be greater DNA retention and uptake for plasmid than linear DNA.
The latter possibility is supported by in vitro and in vivo transfection studies. Another
intriguing possibility is that the immune system may have developed receptors that
recognize circular DNA as an indicator of bacterial infection. It has been shown that
bacteria can release both chromosomal DNA as well as large plasmids into the
surrounding area during either periods of growth or bacterial cell lysis (Muto & Goto,
1986). Therefore, the injection of circular plasmid may mimic a bacterial infection
and the increase in cell trafficking induced by intact plasmid may reveal a relevant
limitation to the host response to bacterial DNA.
Numerous studies have shown that immunostimulatory CpG motifs present
in plasmid or synthesized as CDN can activate cells in vitro and can improve
protective immune responses in vivo. Chapter 5 addressed the question of whether
immunostimulatory CpG motifs were required to alter cell migration through a lymph
node. The results of these experiments clearly showed that the addition of
immunostimulatory CpG motifs to a plasmid could indeed increase cell trafficking in
a dose-dependent manner. The injection of 40 Ilg of pBISIA-88 plasmid induced a
marked increase in cell trafficking while treatment with 400 Ilg of pBISIA-88 failed to
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significantly increase the level of cell traffic in efferent lymph. These changes in cell
trafficking are consistent with previous reports that excessive levels of many CpG
motifs in plasmid DNA can reduce immunological responses. A plasmid containing
50 CpG sequences for example, induced a lower immune response than a plasmid
construct containing only 16 CpG motifs (Krieg et al., 1998). Thus, an excessive
amount of CpGs can suppress both the amplitude of cell trafficking response and
the induction of a humoral immune response. It is tempting to speculate that the
CpG content in bacterial DNA might also regulate other physiological processes,
such as cell trafficking, in a dose-dependent manner. It could be hypothesized that
by modulating cell trafficking responses to the amount of CpG motifs present in
bacterial DNA, vertebrates may have evolved a mechanism to monitor the level of
bacterial infection. Another interesting observation was that although plasmid with
tandem repeats of CON 2135 induced increased cell trafficking, linear CON 2135
failed to produce any significant alterations in cell traffic. Similar to observations
following treatment with linear fragments of plasmid DNA, the lack of activity
observed with linear CON 2135 might be related to less retention and uptake of
linear OON by cells relative to CON present in circular plasmid DNA. From the
present study, it is apparent that CpG motifs present within a plasmid, but not in
. excessive numbers, can induce increased cell trafficking through a draining lymph
node.
Another interesting observation was that, regardless of plasmid treatment,
there were no specific changes in the ceflular composition of efferent lymph,
indicating that plasmid treatment induced a nonselective increase in lymphocyte
traffic. Plasmid treatment also caused a rapid (30 minutes) increase in cell traffic
that reached maximal levels by 24 hours. This pattern of cell trafficking is unique to
treatment with plasmid (bacterial) DNA. Exposure to antigen or mitogen (LPS) for
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example, induced an initial shutdown in cell traffic within the first 24 hours, followed
by a selective release of Iymphoblasts and activated lymphocytes into efferent
lymph. The differences in responses following plasmid and antigen treatment
suggest that different mechanisms are influencing cell trafficking responses to
immunostimulatory CpG motifs and antigen. Plasmid DNA specifically enhances cell
recruitment without altering cell retention in the lymph node. This indicates that
bacterial DNA likely does not activate specific mediators involved in cell retention. It
is possible therefore, that a coordinated interaction between antigen and bacterial
DNA with CpG motifs might ensure the rapid and effective induction of an adaptive
immune response.
In Chapter 6 we investigated the effects of bacterial DNA on lymph node
architecture and cellular composition. The objective was to characterize events
occurring within the lymph node and determine whether these changes could
elucidate the mechanisms involved in altered cell flow. Previous studies in mice
have shown that five days after CDN injection, lymph nodes were increased in size
and cellularity. In contrast, our study demonstrated no such changes four days after
intradermal injection. Although there were differences in the amount, composition
and method of CDN delivery in the mouse study, the discrepancy between our study
and the mouse study, suggests that total cell counts may be a more sensitive
method for measuring lymph node cellularity in vivo. Analysis of cells isolated from
lymph nodes, however, does not provide information regarding lymph node
morphology. While assessment of total cell counts is currently impractical in sheep,
future studies including both total cell counts and assessment of lymph node
morphology would provide the most complete and useful information.
The short-term lymph node study identified several significant changes in
lymph node architecture and cellular composition. It also identified however, some
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other changes that may have biological significance. Treatment with CDN 2135 and
pMASIA was associated with an increased number of germinal centers and a
possible expansion in naive, or recently activated B cells (CD72+CD21+ B-cells).
Although not statistically significant, treatment with CDN 2135 and pBISIA-88 may
have also induced an increased expression of y chain common receptors on T cells
and enhanced cytokine induced proliferative responses. These receptors are found
on many lymphocytes and are essential for the development, maturation and
activation of lymphoid cells (He & Malek, 1998). It appears, therefore, that CDN and
pBISIA-88 induced activation of lymph node cells following treatment.
The short-term lymph node experiment demonstrated that treatment with
plasmid DNA or CDN induced multiple cellular effects within a lymph node. These
effects, however, did not appear to correlate with increased cell trafficking,
suggesting that bacterial DNA may have separate effects on cells involved in cell
trafficking and on resident lymph node cells.
In summary, the effects of plasmid (bacterial) DNA and immunostimulatory
CpG motifs on immunosurveillance were investigated using the lymph node as a
model system. Immunosurveillance was monitored by analyzing the dynamics of
cell migration through a lymph node and then determining whether changes in cell
. trafficking were associated with changes within the lymph node. This research was
divided into three groups of experiments. 1) A long-term lymph node study that
provided the first evidence that exposure to plasmid DNA induced prolonged
changes in lymph node size and architecture. 2) A cell trafficking study that
examined the kinetics of cells migrating through a lymph node and provided clear
evidence that exposure to CpG motifs within plasmid DNA could enhance cell traffic
through a lymph node. These are the first observations to determine that bacterial
DNA can alter immune surveillance. 3) A short-term study of lymph node
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architecture and cellular composition demonstrated that although CpG motifs caused
several cellular changes within a lymph node, these changes could not be directly
correlated with the increase in cell trafficking. Taken together these observations
support the conclusion that bacterial DNA can significantly enhance cell recruitment
and movement through a lymph node and the increased cell number in efferent
lymph is likely not directly related to changes in resident lymph node cell
populations. In the future, DNA vaccines and immunostimulatory CDN may be used
to both protect against and treat diseases that affect both man and domestic
animals. It is therefore essential to develop a fuJI understanding of the mechanisms
whereby these products affect the function of the immune system. This work has
provided substantial information on both the short and long-term effects of plasmid
DNA and immunostimulatory CpG motifs on immune surveillance and a basis for
future studies.
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Appendix 1. Plasmid constructs of pCAN1; pCAN1-GFP; pCAN1-eGFP; pMASIA; pBISIA-
88. All plasmids contain five regions: multiple cloning site (MCS), intron A, bovine growth
hormone poly A [BGH p(A)], origin of replication (ORI), and human cytomegalovirus
promoter/enhancer (HCMV IE1). For plasmid selection in culture, the plasmids pCAN1,
pCAN1-GFP and pCAN1-eGFP encoded J3-lactamase (Amp) while the plasmids pMASIA
and pBISIA-88 encoded kanamyacin resistance factors. Plasmids pCAN1-GFP and
pCAN1-eGFP encode the GFP and eGFP reporter genes, respectively. pBISIA-88 contains
an 11 tandem repeat insert of ODN 2135 [2135(11)]. Enzyme restriction sites used to
digest plasmids (Fig. 3.1) are displayed on the plasmids.
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